

Inhaltsverzeichnis

POLARIX	2
Datenschnitt: 28 Juni 2021.....	2
Charakterisierung der Studienpopulationen	2
Mortalität	20
Gesamtüberleben.....	20
Morbidität.....	22
Krankheitsfreies Überleben.....	22
Ereignisfreies Überleben.....	32
Progressionsfreies Überleben.....	35
Patienten-berichtete Endpunkte.....	41
EORTC QLQ-C30	41
FACT GOG/NTX.....	116
EQ-5D VAS	121
FACT-LymS	126
Verträglichkeit.....	131
Generelle Verträglichkeit.....	131
Spezifische Verträglichkeit	407
Datenschnitt: 25 Februar 2022.....	429
Mortalität	429
Gesamtüberleben.....	429

POPULATION: Intent-To-Treat Population, Global Enrollment Phase Subpopulation

ENDPOINT: --

MODEL: descriptive

STUDY: GO39942

Demographic and Baseline Characteristics per Arm

	Polatuzumab Vedotin + R-CHP (N=440)	R-CHOP (N=439)	Total (N=879)
Age (years)			
n	440	439	879
Mean (SD)	63.11 (11.36)	63.01 (11.87)	63.06 (11.61)
Median	65	66	65
25% and 75%-ile	58.00 - 71.00	59.00 - 71.00	58.00 - 71.00
Min - Max	19.0 - 80.0	19.0 - 80.0	19.0 - 80.0
18 - 64	209 (47.5%)	203 (46.2%)	412 (46.9%)
>=65	231 (52.5%)	236 (53.8%)	467 (53.1%)
18 - 60	140 (31.8%)	131 (29.8%)	271 (30.8%)
>60	300 (68.2%)	308 (70.2%)	608 (69.2%)
Sex			
n	440	439	879
Male	239 (54.3%)	234 (53.3%)	473 (53.8%)
Female	201 (45.7%)	205 (46.7%)	406 (46.2%)
Race			
n	440	439	879
American Indian or Alaska Native	1 (0.2%)	2 (0.5%)	3 (0.3%)
Asian	85 (19.3%)	84 (19.1%)	169 (19.2%)
Black or African American	8 (1.8%)	8 (1.8%)	16 (1.8%)
Native Hawaiian or other Pacific Islander	0	3 (0.7%)	3 (0.3%)
White	235 (53.4%)	236 (53.8%)	471 (53.6%)
Other	6 (1.4%)	6 (1.4%)	12 (1.4%)
Unknown	105 (23.9%)	100 (22.8%)	205 (23.3%)
Ethnicity			
n	440	439	879

Hispanic or Latino	18 (4.1%)	30 (6.8%)	48 (5.5%)
Not Hispanic or Latino	317 (72.0%)	306 (69.7%)	623 (70.9%)
Not Stated	66 (15.0%)	49 (11.2%)	115 (13.1%)
Unknown	39 (8.9%)	54 (12.3%)	93 (10.6%)
Weight (kg) at Baseline			
n	437	436	873
Mean (SD)	75.92 (20.07)	76.12 (18.68)	76.02 (19.38)
Median	74.4	75	74.5
25% and 75%-ile	61.60 - 87.00	63.00 - 85.00	62.50 - 86.36
Min - Max	38.4 - 227.9	39.8 - 191.1	38.4 - 227.9
Height (cm) at Baseline			
n	438	436	874
Mean (SD)	168.18 (10.16)	167.73 (10.34)	167.95 (10.25)
Median	167.75	168	168
25% and 75%-ile	161.00 - 175.30	160.00 - 175.00	160.02 - 175.00
Min - Max	144.3 - 200.0	141.3 - 200.0	141.3 - 200.0
ECOG Performance Status at Baseline			
n	440	439	879
0	175 (39.8%)	173 (39.4%)	348 (39.6%)
1	199 (45.2%)	190 (43.3%)	389 (44.3%)
2	66 (15.0%)	75 (17.1%)	141 (16.0%)
Missing	0	1 (0.2%)	1 (0.1%)
Ann Arbor Stage			
n	440	439	879
I	2 (0.5%)	9 (2.1%)	11 (1.3%)
II	45 (10.2%)	43 (9.8%)	88 (10.0%)
III	124 (28.2%)	108 (24.6%)	232 (26.4%)
IV	269 (61.1%)	279 (63.6%)	548 (62.3%)
Stratification - IPI Score (IxRS)			
n	440	439	879
IPI 2	167 (38.0%)	167 (38.0%)	334 (38.0%)
IPI 3-5	273 (62.0%)	272 (62.0%)	545 (62.0%)
IPI at Screening (eCRF)			
n	440	439	879
1	1 (0.2%)	0	1 (0.1%)

2	164 (37.3%)	165 (37.6%)	329 (37.4%)
3	174 (39.5%)	156 (35.5%)	330 (37.5%)
4	76 (17.3%)	96 (21.9%)	172 (19.6%)
5	25 (5.7%)	22 (5.0%)	47 (5.3%)
Stratification - Bulky Disease (IxRS)			
n	440	439	879
ABSENT	247 (56.1%)	247 (56.3%)	494 (56.2%)
PRESENT	193 (43.9%)	192 (43.7%)	385 (43.8%)
Baseline Bulky Disease (eCRF)			
n	440	439	879
Present	193 (43.9%)	195 (44.4%)	388 (44.1%)
Absent	247 (56.1%)	244 (55.6%)	491 (55.9%)
Stratification - Geographic Region (IxRS)			
n	440	439	879
Western Europe/United States/Canada/Australia	302 (68.6%)	301 (68.6%)	603 (68.6%)
Asia	81 (18.4%)	79 (18.0%)	160 (18.2%)
Rest of World	57 (13.0%)	59 (13.4%)	116 (13.2%)
Baseline LDH			
n	440	439	879
<= 1xULN	146 (33.2%)	154 (35.1%)	300 (34.1%)
> 1xULN	291 (66.1%)	284 (64.7%)	575 (65.4%)
Missing	3 (0.7%)	1 (0.2%)	4 (0.5%)
Bone Marrow Involvement at Diagnosis			
n	440	439	879
INDETERMINATE	11 (2.5%)	11 (2.5%)	22 (2.5%)
NEGATIVE	342 (77.7%)	349 (79.5%)	691 (78.6%)
POSITIVE	76 (17.3%)	72 (16.4%)	148 (16.8%)
Missing	11 (2.5%)	7 (1.6%)	18 (2.0%)
No. of Extranodal Sites			
n	440	439	879
0-1	227 (51.6%)	226 (51.5%)	453 (51.5%)
>=2	213 (48.4%)	213 (48.5%)	426 (48.5%)
Time from Diagnosis to Study Dose			
n	436	437	873

Mean (SD)	29.99 (21.46)	33.02 (35.74)	31.51 (29.51)
Median	26	27	27
25% and 75%-ile	16.00 - 37.50	19.00 - 41.00	17.00 - 39.00
Min - Max	1.0 - 195.0	1.0 - 621.0	1.0 - 621.0
<= 30 days	265 (60.2%)	261 (59.5%)	526 (59.8%)
> 30 days	171 (38.9%)	176 (40.1%)	347 (39.5%)
Missing	4 (0.9%)	2 (0.5%)	6 (0.7%)
NHL Histologic Diagnosis (eCRF)			
n	440	439	879
DLBCL NOS, ABC, GCB	373 (84.8%)	367 (83.6%)	740 (84.2%)
HGBL, NOS, DHL/THL	43 (9.8%)	50 (11.4%)	93 (10.6%)
Other Large B-cell	24 (5.5%)	22 (5.0%)	46 (5.2%)
COO (Central Review)			
n	440	439	879
ABC	102 (23.2%)	119 (27.1%)	221 (25.1%)
GCB	184 (41.8%)	168 (38.3%)	352 (40.0%)
UNCLASSIFIED	44 (10.0%)	51 (11.6%)	95 (10.8%)
UNKNOWN	110 (25.0%)	101 (23.0%)	211 (24.0%)
Double-Expressor Lymphoma by IHC (Central Review)			
n	440	439	879
DEL	139 (31.6%)	151 (34.4%)	290 (33.0%)
NON DEL	223 (50.7%)	215 (49.0%)	438 (49.8%)
UNKNOWN	78 (17.7%)	73 (16.6%)	151 (17.2%)
Double/Triple-Hit Lymphoma (Central Review)			
n	440	439	879
DH/TH+	26 (5.9%)	19 (4.3%)	45 (5.1%)
DH/TH-	305 (69.3%)	315 (71.8%)	620 (70.5%)
UNKNOWN	109 (24.8%)	105 (23.9%)	214 (24.3%)

Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_dm.sas

Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output/t_dm_GLOBAL_IT_28JUN2021_39942.xls
01DEC2021 11:52

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: --
MODEL: descriptive
STUDY: GO39942
Randomization Stratification Factors per Arm

Stratification Factor: Bulky disease

	Polatuzumab Vedotin + R-CHP (N=440)			R-CHOP (N=439)		
	eCRF data			eCRF data		
	Absent	Present	Total	Absent	Present	Total
IxRS data						
Absent	240 (54.5%)	7 (1.6%)	247 (56.1%)	241 (54.9%)	6 (1.4%)	247 (56.3%)
Present	7 (1.6%)	186 (42.3%)	193 (43.9%)	3 (0.7%)	189 (43.1%)	192 (43.7%)
Total	247 (56.1%)	193 (43.9%)	440 (100%)	244 (55.6%)	195 (44.4%)	439 (100%)

Percentages are based on N in the column headings.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_dm_stratconc.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_dm_stratconc_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:48

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: --
MODEL: descriptive
STUDY: GO39942
Randomization Stratification Factors per Arm

Stratification Factor: Geographical region

	Polatuzumab Vedotin + R-CHP (N=440)				R-CHOP (N=439)			
	eCRF data				eCRF data			
	Asia	Rest of World	Western Europe/United States/Canada/Australia	Total	Asia	Rest of World	Western Europe/United States/Canada/Australia	Total
IxRS data								
Asia	81 (18.4%)	0	0	81 (18.4%)	79 (18.0%)	0	0	79 (18.0%)
Rest of World	0	57 (13.0%)	0	57 (13.0%)	0	59 (13.4%)	0	59 (13.4%)
Western Europe/United States/Canada/Australia	0	0	302 (68.6%)	302 (68.6%)	0	0	301 (68.6%)	301 (68.6%)
Total	81 (18.4%)	57 (13.0%)	302 (68.6%)	440 (100%)	79 (18.0%)	59 (13.4%)	301 (68.6%)	439 (100%)

Percentages are based on N in the column headings.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_dm_stratconc.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_dm_stratconc_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:48

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: --
MODEL: descriptive
STUDY: GO39942
Randomization Stratification Factors per Arm

Stratification Factor: IPI score											
	Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)				
	eCRF data						eCRF data				
	1	2	3	4	5	Total	2	3	4	5	Total
IxRS data											
2	1 (0.2%)	158 (35.9%)	7 (1.6%)	1 (0.2%)	0	167 (38.0%)	162 (36.9%)	4 (0.9%)	1 (0.2%)	0	167 (38.0%)
3-5	0	6 (1.4%)	167 (38.0%)	75 (17.0%)	25 (5.7%)	273 (62.0%)	3 (0.7%)	152 (34.6%)	95 (21.6%)	22 (5.0%)	272 (62.0%)
Total	1 (0.2%)	164 (37.3%)	174 (39.5%)	76 (17.3%)	25 (5.7%)	440 (100%)	165 (37.6%)	156 (35.5%)	96 (21.9%)	22 (5.0%)	439 (100%)

Percentages are based on N in the column headings.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_dm_stratconc.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_dm_stratconc_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:48

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)

ENDPOINT: --

MODEL: descriptive

STUDY: GO39942

Demographic and Baseline Characteristics per Arm

	Polatuzumab Vedotin + R-CHP (N=381)	R-CHOP (N=363)	Total (N=744)
Age (years)			
n	381	363	744
Mean (SD)	63.23 (11.50)	63.36 (11.66)	63.29 (11.57)
Median	65	66	66
25% and 75%-ile	59.00 - 71.00	59.00 - 71.00	59.00 - 71.00
Min - Max	19.0 - 80.0	19.0 - 80.0	19.0 - 80.0
18 - 64	177 (46.5%)	164 (45.2%)	341 (45.8%)
>=65	204 (53.5%)	199 (54.8%)	403 (54.2%)
18 - 60	115 (30.2%)	104 (28.7%)	219 (29.4%)
>60	266 (69.8%)	259 (71.3%)	525 (70.6%)
Sex			
n	381	363	744
Male	206 (54.1%)	183 (50.4%)	389 (52.3%)
Female	175 (45.9%)	180 (49.6%)	355 (47.7%)
Race			
n	381	363	744
American Indian or Alaska Native	1 (0.3%)	2 (0.6%)	3 (0.4%)
Asian	76 (19.9%)	68 (18.7%)	144 (19.4%)
Black or African American	8 (2.1%)	5 (1.4%)	13 (1.7%)
Native Hawaiian or other Pacific Islander	0	3 (0.8%)	3 (0.4%)
White	197 (51.7%)	194 (53.4%)	391 (52.6%)
Other	5 (1.3%)	3 (0.8%)	8 (1.1%)
Unknown	94 (24.7%)	88 (24.2%)	182 (24.5%)
Ethnicity			
n	381	363	744
Hispanic or Latino	13 (3.4%)	22 (6.1%)	35 (4.7%)
Not Hispanic or Latino	274 (71.9%)	250 (68.9%)	524 (70.4%)
Not Stated	59 (15.5%)	44 (12.1%)	103 (13.8%)

Unknown	35 (9.2%)	47 (12.9%)	82 (11.0%)
Weight (kg) at Baseline			
n	378	360	738
Mean (SD)	75.69 (20.12)	75.62 (19.28)	75.65 (19.70)
Median	74.1	73.65	74
25% and 75%-ile	61.40 – 87.00	62.50 – 84.95	62.10 – 86.00
Min – Max	38.4 – 227.9	39.8 – 191.1	38.4 – 227.9
Height (cm) at Baseline			
n	379	360	739
Mean (SD)	168.13 (10.04)	167.33 (10.67)	167.74 (10.35)
Median	167.8	167.35	167.6
25% and 75%-ile	161.00 – 175.00	160.00 – 175.00	160.00 – 175.00
Min – Max	144.3 – 200.0	141.3 – 200.0	141.3 – 200.0
ECOG Performance Status at Baseline			
n	381	363	744
0	155 (40.7%)	144 (39.7%)	299 (40.2%)
1	173 (45.4%)	163 (44.9%)	336 (45.2%)
2	53 (13.9%)	55 (15.2%)	108 (14.5%)
Missing	0	1 (0.3%)	1 (0.1%)
Ann Arbor Stage			
n	381	363	744
I	2 (0.5%)	9 (2.5%)	11 (1.5%)
II	42 (11.0%)	38 (10.5%)	80 (10.8%)
III	108 (28.3%)	92 (25.3%)	200 (26.9%)
IV	229 (60.1%)	224 (61.7%)	453 (60.9%)
Stratification - IPI Score (IxRS)			
n	381	363	744
IPI 2	146 (38.3%)	148 (40.8%)	294 (39.5%)
IPI 3-5	235 (61.7%)	215 (59.2%)	450 (60.5%)
IPI at Screening (eCRF)			
n	381	363	744
1	1 (0.3%)	0	1 (0.1%)
2	143 (37.5%)	148 (40.8%)	291 (39.1%)
3	155 (40.7%)	127 (35.0%)	282 (37.9%)
4	63 (16.5%)	75 (20.7%)	138 (18.5%)
5	19 (5.0%)	13 (3.6%)	32 (4.3%)
Stratification - Bulky Disease (IxRS)			
n	381	363	744

ABSENT	225 (59.1%)	220 (60.6%)	445 (59.8%)
PRESENT	156 (40.9%)	143 (39.4%)	299 (40.2%)
Baseline Bulky Disease (eCRF)			
n	381	363	744
Present	156 (40.9%)	146 (40.2%)	302 (40.6%)
Absent	225 (59.1%)	217 (59.8%)	442 (59.4%)
Stratification - Geographic Region (IxRS)			
n	381	363	744
Western Europe/United States/Canada/Australia	260 (68.2%)	251 (69.1%)	511 (68.7%)
Asia	72 (18.9%)	63 (17.4%)	135 (18.1%)
Rest of World	49 (12.9%)	49 (13.5%)	98 (13.2%)
Baseline LDH			
n	381	363	744
<= 1xULN	133 (34.9%)	139 (38.3%)	272 (36.6%)
> 1xULN	245 (64.3%)	224 (61.7%)	469 (63.0%)
Missing	3 (0.8%)	0	3 (0.4%)
Bone Marrow Involvement at Diagnosis			
n	381	363	744
INDETERMINATE	10 (2.6%)	9 (2.5%)	19 (2.6%)
NEGATIVE	296 (77.7%)	292 (80.4%)	588 (79.0%)
POSITIVE	68 (17.8%)	59 (16.3%)	127 (17.1%)
Missing	7 (1.8%)	3 (0.8%)	10 (1.3%)
No. of Extranodal Sites			
n	381	363	744
0-1	198 (52.0%)	197 (54.3%)	395 (53.1%)
>=2	183 (48.0%)	166 (45.7%)	349 (46.9%)
Time from Diagnosis to Study Dose			
n	381	363	744
Mean (SD)	30.12 (22.12)	34.23 (38.24)	32.12 (31.10)
Median	26	28	27
25% and 75%-ile	16.00 - 38.00	20.00 - 41.00	17.50 - 40.00
Min - Max	1.0 - 195.0	1.0 - 621.0	1.0 - 621.0
<= 30 days	232 (60.9%)	210 (57.9%)	442 (59.4%)
> 30 days	149 (39.1%)	153 (42.1%)	302 (40.6%)
NHL Histologic Diagnosis (eCRF)			
n	381	363	744
DLBCL NOS, ABC, GCB	324 (85.0%)	307 (84.6%)	631 (84.8%)

HGBL, NOS, DHL/THL	37 (9.7%)	38 (10.5%)	75 (10.1%)
Other Large B-cell	20 (5.2%)	18 (5.0%)	38 (5.1%)
COO (Central Review)			
n	381	363	744
ABC	95 (24.9%)	104 (28.7%)	199 (26.7%)
GCB	159 (41.7%)	135 (37.2%)	294 (39.5%)
UNCLASSIFIED	37 (9.7%)	46 (12.7%)	83 (11.2%)
UNKNOWN	90 (23.6%)	78 (21.5%)	168 (22.6%)
Double-Expressor Lymphoma by IHC (Central Review)			
n	381	363	744
DEL	116 (30.4%)	127 (35.0%)	243 (32.7%)
NON DEL	200 (52.5%)	179 (49.3%)	379 (50.9%)
UNKNOWN	65 (17.1%)	57 (15.7%)	122 (16.4%)
Double/Triple-Hit Lymphoma (Central Review)			
n	381	363	744
DH/TH+	21 (5.5%)	17 (4.7%)	38 (5.1%)
DH/TH-	268 (70.3%)	267 (73.6%)	535 (71.9%)
UNKNOWN	92 (24.1%)	79 (21.8%)	171 (23.0%)

Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_dm.sas

Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_dm_CR_IT_GLOBAL_28JUN2021_39942.xls

08MAR2022 10:41

POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: --

MODEL: descriptive

STUDY: GO39942

Disposition of Patients per Arm

	Polatuzumab Vedotin + R-CHP (N=440)	R-CHOP (N=439)	Total (N=879)
End of treatment status			
Completed	387 (88.0%)	377 (85.9%)	764 (86.9%)
Discontinued	49 (11.1%)	60 (13.7%)	109 (12.4%)
Never Treated	4 (0.9%)	2 (0.5%)	6 (0.7%)
Reason for treatment discontinuation			
n	49	60	109
Adverse event	9 (2.0%)	17 (3.9%)	26 (3.0%)
Death	11 (2.5%)	4 (0.9%)	15 (1.7%)
Other	1 (0.2%)	3 (0.7%)	4 (0.5%)
Physician decision	10 (2.3%)	10 (2.3%)	20 (2.3%)
Progressive disease	12 (2.7%)	17 (3.9%)	29 (3.3%)
Withdrawal by subject	6 (1.4%)	9 (2.1%)	15 (1.7%)
End of study status			
Discontinued	66 (15.0%)	76 (17.3%)	142 (16.2%)
Ongoing	374 (85.0%)	363 (82.7%)	737 (83.8%)
Reason for study discontinuation			
n	66	76	142
Death	51 (11.6%)	57 (13.0%)	108 (12.3%)
Lost to follow-up	3 (0.7%)	2 (0.5%)	5 (0.6%)
Other	2 (0.5%)	1 (0.2%)	3 (0.3%)
Physician decision	3 (0.7%)	3 (0.7%)	6 (0.7%)
Withdrawal by subject	7 (1.6%)	13 (3.0%)	20 (2.3%)

Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_ds.sas

Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ds_IT_GLOBAL_28JUN2021_39942.xls

08MAR2022 10:44

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Overall Survival
MODEL: Unstratified analysis
STUDY: GO39942
Duration of Follow-up by Endpoint and Arm

	Polatuzumab Vedotin + R-CHP (N=440)	R-CHOP (N=439)	Total (N=879)
Patients with event (%)	387 (88.0%)	382 (87.0%)	769 (87.5%)
Latest contributing event			
Alive	387	382	769
Patients without event (%)	53 (12.0%)	57 (13.0%)	110 (12.5%)
Time to event (months)			
Median	28.1	28.2	28.2
95% CI	(27.7, 28.7)	(27.4, 28.8)	(27.8, 28.6)
25% and 75%-ile	25.9 - 31.3	25.7 - 31.4	25.8 - 31.4
Range	0 - 43	0 - 42	0 - 43

* Censored observation.
Summaries of Duration of Follow-up (median, percentiles) are based on reverse Kaplan-Meier estimates.
95% CI for median was computed using the method of Brookmeyer and Crowley.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_fu.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_fu_OSDFU_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 10:48

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Progression-Free Survival (PFS - INV)
MODEL: Unstratified analysis
STUDY: GO39942
Duration of Follow-up by Endpoint and Arm

	Polatuzumab Vedotin + R-CHP (N=440)	R-CHOP (N=439)	Total (N=879)
Patients with event (%)	333 (75.7%)	305 (69.5%)	638 (72.6%)
Latest contributing event			
Last Tumor Assessment	328	298	626
Randomization	5	7	12
Patients without event (%)	107 (24.3%)	134 (30.5%)	241 (27.4%)
Time to event (months)			
Median	24.7	24.7	24.7
95% CI	(24.5, 25.1)	(24.4, 24.9)	(24.5, 24.9)
25% and 75%-ile	23.9 - 30.0	23.8 - 30.1	23.9 - 30.0
Range	0 - 34	0 - 37	0 - 37

* Censored observation.
Summaries of Duration of Follow-up (median, percentiles) are based on reverse Kaplan-Meier estimates.
95% CI for median was computed using the method of Brookmeyer and Crowley.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_fu.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_fu_PFSDFU_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 10:47

POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: PRO

MODEL: Unstratified analysis

STUDY: GO39942

Duration of Follow-up by Endpoint and Arm

	Polatuzumab Vedotin + R-CHP (N=440)	R-CHOP (N=439)	Total (N=879)
PRO Duration of Follow-up (months)			
n	435	435	870
Median	24.4	24	24.2
95% CI for Median	(24.2, 24.6)	(23.7, 24.3)	(24.1, 24.4)
25% and 75%-ile	13.4 - 29.1	9.2 - 28.1	12.2 - 28.6
Min - Max	0 - 34	0 - 33	0 - 34

Duration of Follow-up is calculated as:

Date of last PRO assessment that the patient attended - Date of Randomization + 1.

Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_fu.sas

Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_fu_PRODFU_IT_GLOBAL_28JUN2021_39942.xls

22MAR2022 12:51

POPULATION: Global Population, Safety-Evaluable Population

ENDPOINT: First AE

MODEL: Unstratified analysis

STUDY: GO39942

Duration of Follow-up by Endpoint and Arm

	Polatuzumab Vedotin + R-CHP (N=435)	R-CHOP (N=438)	Total (N=873)
Patients with event (%)	9 (2.1%)	7 (1.6%)	16 (1.8%)
Latest contributing event			
LAST DOSE OF STUDY TREATMENT + 90 DAYS	9	4	13
NALT	0	3	3
Patients without event (%)	426 (97.9%)	431 (98.4%)	857 (98.2%)
Time to event (months)			
Median	7.8	7.8	7.8
95% CI	NE	(7.2, 7.8)	NE
25% and 75%-ile	7.8 - 7.8	7.2 - 7.8	7.8 - 7.8
Range	0* - 8	0* - 8	0* - 8

* Censored observation.

Summaries of Duration of Follow-up (median, percentiles) are based on reverse Kaplan-Meier estimates.

95% CI for median was computed using the method of Brookmeyer and Crowley.

Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_fu.sas

Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_fu_SAFFDFU_SE_GLOBAL_28JUN2021_39942.xls

08MAR2022 10:49

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: --
MODEL: descriptive
STUDY: GO39942
Number and Percentage of SAEs between randomization date and treatment start date

		Polatuzumab Vedotin + R-CHP (N=435)				R-CHOP (N=438)			
		All AEs		SAEs between randomization date and treatment start		All AEs		SAEs between randomization date and treatment start	
Name	Level	n	%	n	%	n	%	n	%
All	n/a	5559	100.0	0	0	5306	100.0	1	<0.1

Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_ae_rndtrt1.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_rndtrt1_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 10:45

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: --
MODEL: descriptive
STUDY: GO39942
Deaths and Primary Reason for Death

	Polatuzumab Vedotin + R-CHP (N=435)		R-CHOP (N=438)	
	n	%	n	%
All Deaths	52	12.0	59	13.5
Adverse event	13	3.0	11	2.5
Progressive disease	28	6.4	31	7.1
Other	11	2.5	17	3.9

Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_death.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_death_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 10:45


POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Overall Survival
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP (N=440)														R-CHOP (N=439)														Polatuzumab Vedotin + R-CHP vs. R-CHOP							
Patients				Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio								
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Media n	95% Upper CL for Media n	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Media n	95% Upper CL for Media n	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	Convergence Status					
All	n/a	440	100.0	53	12.0	387	88.0	NE	NE	NE	NE	NE	NE	439	100.0	57	13.0	382	87.0	39.3	39.3	NE	NE	NE	NE	0.7524	0.94	0.65	1.37	Convergence criterion (GCONV=1E-8) satisfied.					

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_tte_str_OS_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 10:55

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Overall Survival
STUDY: GO39942



Patients at risk																						
Pola + R-CHP	440	433	430	423	414	404	397	392	388	384	378	375	362	285	199	140	81	41	15	5	2	1
R-CHOP	439	432	421	414	409	403	401	388	381	376	370	367	355	273	194	132	82	47	20	8	6	1
Patients censored																						
Pola + R-CHP	0	2	2	3	8	9	9	10	12	13	14	16	29	106	191	248	308	346	372	382	385	386
R-CHOP	0	5	11	12	13	15	15	21	23	24	25	25	36	114	191	252	301	336	363	375	376	381

Pola = Polatuzumab Vedotin.
 Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
 Output: ..sis/ACE_PRIMARY_CSR_Pooled/prod/output_global/g_km_OS_IT_GLOBAL_28JUN2021_39942.pdf
 08MAR2022 11:06

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: CR (BOR)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	440	100.0	381	86.6	439	100.0	363	82.7	1.37	Convergence criterion (GCONV=1E-8) satisfied.	0.94	1.99	0.027	Algorithm converged.	-0.019	0.073	1.03	Algorithm converged.	0.98	1.09	0.1019	0.97	Algorithm converged.	0.92	1.03	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_CRBOR_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 11:05


POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)
ENDPOINT: Disease-Free Survival (DFS from first CR(Composite-INV))
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP(N=381)														R-CHOP (N=363)												Polatuzumab Vedotin + R-CHP vs. R-CHOP																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						
Patients				Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_tte_str_DFS_CR_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 10:58

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)
ENDPOINT: Disease-Free Survival (DFS from first CR(Composite-INV))
STUDY: GO39942



Patients at risk																	
Pola + R-CHP	381	375	350	342	339	331	322	312	297	266	235	149	106	86	23	2	NE
R-CHOP	363	354	333	326	314	295	282	273	262	238	217	124	96	80	22	5	2
Patients censored																	
Pola + R-CHP	0	2	9	12	14	16	22	29	39	65	93	173	215	234	297	318	NE
R-CHOP	0	6	12	14	16	18	23	29	34	55	75	164	192	207	263	279	282

Pola = Polatuzumab Vedotin.
 Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
 Output: ..ACE_PRIMARY_CSR_Pooled/prod/output_global/g_km_DFS_CR_IT_GLOBAL_28JUN2021_39942.pdf
 08MAR2022 11:08

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)
ENDPOINT: Time to Relapse (DFS from first CR(Composite-INV))
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP (N=381)												R-CHOP (N=363)												Polatuzumab Vedotin + R-CHP vs. R-CHOP							
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio						
								Q1 (month s)	95% Lower CL for Q1	95% Upper CL for Q1	Median (month s)	95% Lower CL for Media n	95% Upper CL for Media n							Q1 (month s)	95% Lower CL for Q1	95% Upper CL for Q1	Median (month s)	95% Lower CL for Media n	95% Upper CL for Media n	p-value	Hazara d Ratio	95% Lower CL	95% Upper CL	Convergence Status			
Nam e	Leve l	n	%	n	%	n	%							n	%	n	%	n	%														
All	n/a	381	100.0	54	14.2	327	85.8	30.5	30.5	NE	30.5	30.5	NE	363	100.0	66	18.2	297	81.8	NE	26.1	NE	NE	NE	NE	0.0834	0.73	0.50	1.04	Convergence criterion (GCONV=1E-8) satisfied.			


* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_tte_str_DFSPRG_CR_IT_GLOBAL_28JUN2021_39942.xls
29MAR2022 9:06

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)

ENDPOINT: Time to Relapse (DFS from first CR(Composite-INV))

STUDY: GO39942



Patients at risk																	
Pola + R-CHP	381	375	350	342	339	331	322	312	297	266	235	149	106	86	23	2	NE
R-CHOP	363	354	333	326	314	295	282	273	262	238	217	124	96	80	22	5	2
Patients censored																	
Pola + R-CHP	0	4	12	15	18	21	28	36	46	72	100	180	222	242	305	326	NE
R-CHOP	0	9	17	20	23	25	33	39	45	66	86	175	203	219	275	292	295

Pola = Polatuzumab Vedotin.
Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
Output: ..PRIMARY_CSR_Pooled/prod/output_global/g_km_DFSPRG_CR_IT_GLOBAL_28JUN2021_39942.pdf
29MAR2022 9:13

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)
ENDPOINT: Time to Death (DFS from first CR(Composite-INV))
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP (N=381)														R-CHOP (N=363)														Polatuzumab Vedotin + R-CHP vs. R-CHOP						
Patients				Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio							
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Media n	95% Upper CL for Media n	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Media n	95% Upper CL for Media n	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	Convergence Status				
All	n/a	381	100.0	8	2.1	373	97.9	NE	NE	NE	NE	NE	NE	363	100.0	13	3.6	350	96.4	NE	NE	NE	NE	NE	NE	0.1940	0.55	0.23	1.37	Convergence criterion (GCONV=1E-8) satisfied.				


* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_tte_str_DFSPTH_CR_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:01

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)

ENDPOINT: Time to Death (DFS from first CR(Composite-INV))

STUDY: GO39942



Patients at risk																	
Pola + R-CHP	381	375	350	342	339	331	322	312	297	266	235	149	106	86	23	2	NE
R-CHOP	363	354	333	326	314	295	282	273	262	238	217	124	96	80	22	5	2
Patients censored																	
Pola + R-CHP	0	4	28	36	38	45	53	62	78	108	139	225	268	287	350	371	NE
R-CHOP	0	6	25	31	42	61	71	80	90	114	135	228	256	271	329	345	348

Pola = Polatuzumab Vedotin.
Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
Output: ..PRIMARY_CSR_Pooled/prod/output_global/g_km_DFSDTH_CR_IT_GLOBAL_28JUN2021_39942.pdf
08MAR2022 11:10

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)
ENDPOINT: DFS (from first CR(Composite-INV)) Rate
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: G039942
Dichotomous Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=363)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R					
Patients				Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	
All	n/a	381	100.0	62	16.3	363	100.0	79	21.8		* NE			-0.054	Algorithm converged	-0.110	0.002	0.74	Algorithm converged	0.55	0.99	0.0535	1.36	Algorithm converged		1.01	1.83

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/G039942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/G039942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DFSFCRR_CR_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 16:29

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)
ENDPOINT: DFS (from first CR(Composite-INV))-Death Rate
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=363)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +							
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk									
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL			
												Convergence criterion (GCONV=1E-8) satisfied					WARNING: The relative Hessian convergence criterion of 0.3670002369 is greater than the limit of 0.0001. The convergence is questionable.				Algorithm converged			0.26	1.42	0.2164	1.66	Algorithm converged		0.70	3.92
All	n/a	381	100.0	8	2.1	363	100.0	13	3.6	0.57						*				0.60											

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE PRIMARY CSR Pooled/prod/output_global/t_eff_resp_str DFSFCRDR CR IT GLOBAL 28JUN2021 39942.xls
07MAR2022 16:37

POPULATION: Global Population, Intent-To-Treat Population, Complete Response Population (with CR, Composite-INV)
ENDPOINT: DFS (from first CR(Composite-INV))-Recurrence Rate
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHO (N=363)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio	Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk						
Name	Level	n	%	n	%	n	%	n	%		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL			
										Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL			
All	n/a	381	100.0	54	14.2	363	100.0	66	18.2	0.74	Convergen ce criterion (GCONV=1E- 8) satisfied .	0.50	1.10	-0.041	Algorithm converged .	-0.094	0.012	0.76	Algorithm converged .	0.55	1.06	0.1343	1.31	Algorithm converged .	0.94	1.82			

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DFSFCRRR_CR_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 16:33


POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Event-Free Survival (EFS - Efficacy, INV)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP (N=440)															R-CHOP (N=439)												Polatuzumab Vedotin + R-CHP vs. R-CHOP																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
		Patients		Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR Pooled/prod/output global/t_eff_tte_str EFSEFF IT GLOBAL 28JUN2021 39942.xls
08MAR2022 10:57

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Event-Free Survival (EFS - Efficacy, INV)
STUDY: GO39942



Patients at risk																			
Pola + R-CHP	440	430	416	402	363	358	348	336	332	323	305	291	243	126	111	78	5	1	NE
R-CHOP	439	428	407	386	348	335	327	306	301	294	273	266	218	114	106	78	7	5	3
Patients censored																			
Pola + R-CHP	0	5	8	9	15	16	17	20	22	26	38	49	94	205	219	251	324	327	NE
R-CHOP	0	7	13	17	21	21	22	24	27	30	39	45	93	193	200	225	294	296	298

Pola = Polatuzumab Vedotin.
 Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
 Output: ..ACE_PRIMARY_CSR_Pooled/prod/output_global/g_km_EFSEFF_IT_GLOBAL_28JUN2021_39942.pdf
 08MAR2022 11:07

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Event-Free Survival (EFS - Efficacy, INV)
MODEL: descriptive
STUDY: GO39942
Overview of EFS First Contributing Event

	Polatuzumab Vedotin + R-CHP (N=440)		R-CHOP (N=439)	
	Patients		Patients	
Type of Event	Number of Patients with Event ¹	%	Number of Patients with Event ¹	%
EFS	112	25.5	138	31.4
Death	18	4.1	20	4.6
Progression Disease	86	19.5	106	24.1
NALT due to efficacy reasons	8	1.8	6	1.4
NALT due to positive biopsy	0	NE	6	1.4

¹ Number of Patients with this Event as "first contributing event"
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_efs.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_efs_EFSEFF_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 10:50


POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Progression-Free Survival (PFS - INV)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP (N=440)														R-CHOP (N=439)														Polatuzumab Vedotin + R-CHP vs. R-CHOP													
Patients				Patients with Event				Censored				Time to event						Patients		Patients with Event				Censored				Time to event						log-rank		Hazard Ratio					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	Convergence Status									
All	n/a	440	100.0		107	24.3	333	75.7	25.4	18.9	NE	33.3	33.3	NE	439	100.0		134	30.5	305	69.5		15.8	12.1	19.3		NE	NE	NE	0.0177	0.73	0.57	0.95	Convergence criterion (GCONV=1E-8) satisfied.							

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_tte_str_PFS_IT_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:29

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Progression-Free Survival (PFS - INV)
STUDY: GO39942



Patients at risk																			
Pola + R-CHP	440	430	418	404	369	364	353	340	336	327	309	294	246	126	111	78	5	1	NE
R-CHOP	439	428	406	389	352	339	330	309	305	296	275	268	220	114	106	78	7	5	3
Patients censored																			
Pola + R-CHP	0	5	8	9	16	17	18	21	23	27	39	51	96	210	224	256	329	332	NE
R-CHOP	0	7	14	19	23	23	24	26	29	32	41	47	95	197	204	229	298	300	302

Pola = Polatuzumab Vedotin.
 Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
 Output: ..is/ACE_PRIMARY_CSR_Pooled/prod/output_global/g_km_PFS_IT_GLOBAL_28JUN2021_39942.pdf
 08MAR2022 11:04


POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Time to Progression/Relapse (PFS - INV)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP (N=440)															R-CHOP (N=439)												Polatuzumab Vedotin + R-CHP vs. R-CHOP						
Patients				Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio						
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	Convergence Status			
All	n/a	440	100.0	88	20.0	352	80.0	33.3	25.2	NE	33.3	33.3	NE	439	100.0	114	26.0	325	74.0	18.7	12.9	28.9	NE	NE	NE	0.0148	0.71	0.53	0.94	Convergence criterion (GCONV=1E-8) satisfied.			

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_tte_str_PFSPRG_IT_GLOBAL_28JUN2021_39942.xls
29MAR2022 9:03

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Time to Progression/Relapse (PFS - INV)
STUDY: GO39942



Patients at risk																			
Pola + R-CHP	440	430	418	404	369	364	353	340	336	327	309	294	246	126	111	78	5	1	NE
R-CHOP	439	428	406	389	352	339	330	309	305	296	275	268	220	114	106	78	7	5	3
Patients censored																			
Pola + R-CHP	0	10	16	21	28	31	34	38	40	45	57	69	114	228	242	275	348	351	NE
R-CHOP	0	9	19	29	35	36	37	41	44	48	59	65	113	215	222	248	318	320	322

Pola = Polatuzumab Vedotin.
 Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
 Output: ..ACE_PRIMARY_CSR_Pooled/prod/output_global/g_km_PFSPRG_IT_GLOBAL_28JUN2021_39942.pdf
 29MAR2022 9:10


POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Time to Death (PFS - Inv)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Time to Event Analysis (Efficacy)

Polatuzumab Vedotin + R-CHP (N=440)														R-CHOP (N=439)														Polatuzumab Vedotin + R-CHP vs. R-CHOP						
Patients				Patients with Event		Censored		Time to event						Patients		Patients with Event		Censored		Time to event						log-rank	Hazard Ratio							
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Media n	95% Upper CL for Media n	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Media n	95% Upper CL for Media n	p-value	Hazard Ratio	95% Lower CL	95% Upper CL	Convergence Status				
All	n/a	440	100.0	19	4.3	421	95.7	NE	NE	NE	NE	NE	NE	439	100.0	20	4.6	419	95.4	NE	NE	NE	NE	NE	NE	0.7262	0.89	0.47	1.68	Convergence criterion (GCONV=1E-8) satisfied.				

* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_tte.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_tte_str_PFSDTH_IT_GLOBAL_28JUN2021_39942.xls
28MAR2022 17:11

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: Time to Death (PFS - Inv)
STUDY: GO39942



Patients at risk																			
Pola + R-CHP	440	430	418	404	369	364	353	340	336	327	309	294	246	126	111	78	5	1	NE
R-CHOP	439	428	406	389	352	339	330	309	305	296	275	268	220	114	106	78	7	5	3
Patients censored																			
Pola + R-CHP	0	5	14	24	59	62	71	83	87	95	113	128	176	296	311	343	416	420	NE
R-CHOP	0	9	28	40	75	87	96	115	119	127	146	153	201	307	315	342	412	414	416

Pola = Polatuzumab Vedotin.
 Clinical cut-off: 28JUN2021

Program: ..al_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_km.sas
 Output: ..ACE_PRIMARY_CSR_Pooled/prod/output_global/g_km_PFSOTH_IT_GLOBAL_28JUN2021_39942.pdf
 28MAR2022 16:52

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Appetite loss

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD (Mean)	in study ¹	%	with value ¹	%	Mean ²	SD (Mean)
All														
	BASELINE	n/a	440	100.0	417	94.8	27.34	34.18	439	100.0	410	93.4	24.80	33.13
	CYCLE 2 DAY 1	n/a	431	98.0	417	96.8	19.82	28.61	432	98.4	415	96.1	18.80	27.51
	CYCLE 3 DAY 1	n/a	428	97.3	409	95.6	17.85	25.01	426	97.0	412	96.7	15.78	23.64
	CYCLE 5 DAY 1	n/a	424	96.4	405	95.5	17.45	24.77	420	95.7	400	95.2	17.50	26.48
	TREATMENT COMPLETION	n/a	412	93.6	391	94.9	9.04	20.34	400	91.1	368	92.0	7.16	16.69
	FOLLOW-UP MONTH 6	n/a	351	79.8	300	85.5	5.67	14.97	341	77.7	281	82.4	4.74	12.33
	FOLLOW-UP MONTH 12	n/a	334	75.9	288	86.2	5.67	15.58	303	69.0	248	81.8	4.70	14.08
	FOLLOW-UP MONTH 18	n/a	309	70.2	270	87.4	3.95	11.17	279	63.6	246	88.2	5.56	15.96
	FOLLOW-UP MONTH 24	n/a	135	30.7	104	77.0	5.77	14.27	126	28.7	92	73.0	4.35	12.32
	FOLLOW-UP MONTH 36	n/a	0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Cognitive functioning

		Polatuzumab Vedotin + R-CHP (N=440)							R-CHOP (N=439)					
		Patients				Statistics			Patients				Statistics	
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE		n/a	440	100.0	415	94.3	84.82	20.49	439	100.0	406	92.5	86.45	18.14
CYCLE 2 DAY 1		n/a	431	98.0	417	96.8	86.17	19.32	432	98.4	413	95.6	88.01	15.82
CYCLE 3 DAY 1		n/a	428	97.3	409	95.6	86.47	18.35	426	97.0	411	96.5	88.36	16.35
CYCLE 5 DAY 1		n/a	424	96.4	404	95.3	86.55	18.32	420	95.7	402	95.7	85.24	19.10
TREATMENT COMPLETION		n/a	412	93.6	390	94.7	86.75	18.58	400	91.1	371	92.8	87.20	17.93
FOLLOW-UP MONTH 6		n/a	351	79.8	298	84.9	86.91	18.76	341	77.7	276	80.9	86.47	18.92
FOLLOW-UP MONTH 12		n/a	334	75.9	288	86.2	85.76	19.12	303	69.0	245	80.9	87.55	17.02
FOLLOW-UP MONTH 18		n/a	309	70.2	270	87.4	86.98	16.64	279	63.6	246	88.2	87.53	18.02
FOLLOW-UP MONTH 24		n/a	135	30.7	105	77.8	85.87	19.03	126	28.7	91	72.2	89.01	18.29
FOLLOW-UP MONTH 36		n/a	0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Constipation

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	411	93.4	21.33	30.56	439	100.0	404	92.0	21.86	29.48
CYCLE 2 DAY 1	n/a		431	98.0	408	94.7	16.34	25.81	432	98.4	406	94.0	20.11	28.17
CYCLE 3 DAY 1	n/a		428	97.3	404	94.4	15.02	23.83	426	97.0	407	95.5	18.43	25.66
CYCLE 5 DAY 1	n/a		424	96.4	400	94.3	13.33	22.01	420	95.7	393	93.6	16.45	25.21
TREATMENT COMPLETION	n/a		412	93.6	386	93.7	9.84	20.27	400	91.1	360	90.0	7.96	18.07
FOLLOW-UP MONTH 6	n/a		351	79.8	295	84.0	9.38	17.99	341	77.7	276	80.9	10.63	21.08
FOLLOW-UP MONTH 12	n/a		334	75.9	287	85.9	11.38	20.91	303	69.0	244	80.5	9.43	19.77
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	11.11	21.51	279	63.6	246	88.2	10.30	22.18
FOLLOW-UP MONTH 24	n/a		135	30.7	105	77.8	11.43	21.60	126	28.7	92	73.0	5.43	13.33
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Diarrhoea

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	413	93.9	10.33	21.43	439	100.0	406	92.5	9.20	19.68
CYCLE 2 DAY 1	n/a		431	98.0	417	96.8	15.83	26.15	432	98.4	413	95.6	9.60	19.89
CYCLE 3 DAY 1	n/a		428	97.3	409	95.6	11.41	20.75	426	97.0	407	95.5	8.93	19.84
CYCLE 5 DAY 1	n/a		424	96.4	404	95.3	10.97	20.55	420	95.7	402	95.7	9.70	19.90
TREATMENT COMPLETION	n/a		412	93.6	389	94.4	7.46	18.96	400	91.1	371	92.8	6.38	14.64
FOLLOW-UP MONTH 6	n/a		351	79.8	297	84.6	7.86	18.73	341	77.7	275	80.6	6.30	14.54
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	7.87	18.66	303	69.0	245	80.9	5.71	15.21
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	6.91	16.05	279	63.6	246	88.2	5.69	14.26
FOLLOW-UP MONTH 24	n/a		135	30.7	105	77.8	4.13	11.96	126	28.7	93	73.8	5.38	13.27
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Dyspnoea

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	417	94.8	19.42	27.99	439	100.0	409	93.2	16.46	26.00
CYCLE 2 DAY 1	n/a		431	98.0	417	96.8	14.07	22.03	432	98.4	414	95.8	12.72	20.99
CYCLE 3 DAY 1	n/a		428	97.3	408	95.3	15.93	23.36	426	97.0	411	96.5	13.95	21.59
CYCLE 5 DAY 1	n/a		424	96.4	401	94.6	16.29	23.46	420	95.7	402	95.7	16.92	22.85
TREATMENT COMPLETION	n/a		412	93.6	392	95.1	14.63	22.90	400	91.1	369	92.3	11.02	19.17
FOLLOW-UP MONTH 6	n/a		351	79.8	300	85.5	13.78	21.36	341	77.7	280	82.1	11.31	19.22
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	11.69	22.22	303	69.0	247	81.5	12.96	19.79
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	11.60	20.85	279	63.6	246	88.2	11.79	21.11
FOLLOW-UP MONTH 24	n/a		135	30.7	104	77.0	12.82	22.42	126	28.7	91	72.2	15.02	20.04
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_mean_EQC30_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:46

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Emotional functioning

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	415	94.3	75.68	21.95	439	100.0	407	92.7	73.64	22.42
CYCLE 2 DAY 1	n/a		431	98.0	416	96.5	83.04	18.61	432	98.4	413	95.6	82.24	18.63
CYCLE 3 DAY 1	n/a		428	97.3	409	95.6	83.69	18.44	426	97.0	411	96.5	82.57	18.25
CYCLE 5 DAY 1	n/a		424	96.4	404	95.3	84.03	19.21	420	95.7	402	95.7	81.24	20.48
TREATMENT COMPLETION	n/a		412	93.6	390	94.7	84.75	17.99	400	91.1	371	92.8	84.73	18.00
FOLLOW-UP MONTH 6	n/a		351	79.8	298	84.9	84.89	19.67	341	77.7	276	80.9	85.78	18.22
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	84.87	19.94	303	69.0	245	80.9	85.88	17.24
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	85.85	16.74	279	63.6	246	88.2	87.43	17.72
FOLLOW-UP MONTH 24	n/a		135	30.7	105	77.8	86.98	18.41	126	28.7	91	72.2	89.19	14.14
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Fatigue

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	417	94.8	37.66	27.41	439	100.0	410	93.4	35.22	27.01
CYCLE 2 DAY 1	n/a		431	98.0	418	97.0	34.69	23.29	432	98.4	416	96.3	32.73	22.99
CYCLE 3 DAY 1	n/a		428	97.3	409	95.6	32.34	22.06	426	97.0	411	96.5	32.31	23.00
CYCLE 5 DAY 1	n/a		424	96.4	405	95.5	32.55	24.27	420	95.7	403	96.0	33.62	23.80
TREATMENT COMPLETION	n/a		412	93.6	392	95.1	24.99	22.27	400	91.1	369	92.3	25.20	21.19
FOLLOW-UP MONTH 6	n/a		351	79.8	300	85.5	21.50	22.18	341	77.7	281	82.4	21.12	19.63
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	20.41	21.47	303	69.0	248	81.8	20.27	21.11
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	18.52	19.91	279	63.6	246	88.2	20.73	22.54
FOLLOW-UP MONTH 24	n/a		135	30.7	104	77.0	19.44	21.38	126	28.7	92	73.0	18.18	18.38
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Financial difficulties

		Polatuzumab Vedotin + R-CHP (N=440)							R-CHOP (N=439)					
		Patients				Statistics			Patients				Statistics	
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	412	93.6	18.77	29.29	439	100.0	403	91.8	19.93	28.93
CYCLE 2 DAY 1	n/a		431	98.0	415	96.3	14.94	25.52	432	98.4	412	95.4	16.34	25.84
CYCLE 3 DAY 1	n/a		428	97.3	405	94.6	16.38	25.76	426	97.0	408	95.8	15.28	25.77
CYCLE 5 DAY 1	n/a		424	96.4	401	94.6	15.21	25.25	420	95.7	401	95.5	15.30	26.01
TREATMENT COMPLETION	n/a		412	93.6	387	93.9	15.07	24.93	400	91.1	368	92.0	13.41	24.64
FOLLOW-UP MONTH 6	n/a		351	79.8	297	84.6	10.89	20.81	341	77.7	276	80.9	12.56	22.09
FOLLOW-UP MONTH 12	n/a		334	75.9	287	85.9	9.18	19.44	303	69.0	245	80.9	11.70	22.36
FOLLOW-UP MONTH 18	n/a		309	70.2	268	86.7	8.21	18.67	279	63.6	245	87.8	8.57	19.65
FOLLOW-UP MONTH 24	n/a		135	30.7	105	77.8	6.98	18.89	126	28.7	91	72.2	8.06	21.28
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Nausea and vomiting

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	417	94.8	8.43	18.57	439	100.0	410	93.4	6.14	14.59
CYCLE 2 DAY 1	n/a		431	98.0	418	97.0	8.77	16.93	432	98.4	417	96.5	7.71	15.06
CYCLE 3 DAY 1	n/a		428	97.3	409	95.6	8.84	15.74	426	97.0	413	96.9	6.74	14.86
CYCLE 5 DAY 1	n/a		424	96.4	405	95.5	8.60	15.36	420	95.7	402	95.7	8.13	15.54
TREATMENT COMPLETION	n/a		412	93.6	392	95.1	2.98	9.88	400	91.1	369	92.3	2.39	7.84
FOLLOW-UP MONTH 6	n/a		351	79.8	300	85.5	2.33	8.19	341	77.7	281	82.4	2.31	8.54
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	3.76	11.74	303	69.0	248	81.8	1.81	6.71
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	2.41	7.83	279	63.6	246	88.2	2.51	10.51
FOLLOW-UP MONTH 24	n/a		135	30.7	104	77.0	1.28	6.44	126	28.7	92	73.0	0.91	4.53
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Pain

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	417	94.8	31.14	31.20	439	100.0	410	93.4	27.85	30.60
CYCLE 2 DAY 1	n/a		431	98.0	418	97.0	18.46	23.00	432	98.4	417	96.5	16.79	22.81
CYCLE 3 DAY 1	n/a		428	97.3	409	95.6	16.59	22.84	426	97.0	412	96.7	15.70	21.76
CYCLE 5 DAY 1	n/a		424	96.4	406	95.8	14.86	21.26	420	95.7	402	95.7	16.42	23.80
TREATMENT COMPLETION	n/a		412	93.6	393	95.4	18.28	24.92	400	91.1	372	93.0	16.08	23.89
FOLLOW-UP MONTH 6	n/a		351	79.8	300	85.5	15.56	23.23	341	77.7	280	82.1	14.05	21.61
FOLLOW-UP MONTH 12	n/a		334	75.9	289	86.5	16.03	25.16	303	69.0	248	81.8	15.39	23.56
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	15.37	23.20	279	63.6	246	88.2	15.24	24.73
FOLLOW-UP MONTH 24	n/a		135	30.7	105	77.8	16.83	26.20	126	28.7	92	73.0	11.59	21.07
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Physical functioning (revised)

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	416	94.5	79.71	22.31	439	100.0	410	93.4	80.35	22.68
CYCLE 2 DAY 1	n/a		431	98.0	417	96.8	79.88	19.51	432	98.4	415	96.1	81.88	19.24
CYCLE 3 DAY 1	n/a		428	97.3	409	95.6	81.77	19.10	426	97.0	412	96.7	81.86	19.87
CYCLE 5 DAY 1	n/a		424	96.4	406	95.8	81.77	19.28	420	95.7	403	96.0	80.88	19.52
TREATMENT COMPLETION	n/a		412	93.6	392	95.1	83.98	19.03	400	91.1	369	92.3	86.10	16.74
FOLLOW-UP MONTH 6	n/a		351	79.8	300	85.5	87.26	16.83	341	77.7	281	82.4	88.20	15.31
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	87.74	17.97	303	69.0	248	81.8	87.78	15.84
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	88.51	14.61	279	63.6	246	88.2	87.94	16.62
FOLLOW-UP MONTH 24	n/a		135	30.7	104	77.0	90.19	14.06	126	28.7	92	73.0	89.09	14.92
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Global health status/QoL (revised)

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	414	94.1	59.68	24.58	439	100.0	406	92.5	61.99	23.90
CYCLE 2 DAY 1	n/a		431	98.0	416	96.5	66.63	19.11	432	98.4	411	95.1	70.07	20.38
CYCLE 3 DAY 1	n/a		428	97.3	408	95.3	69.14	18.95	426	97.0	409	96.0	70.48	18.94
CYCLE 5 DAY 1	n/a		424	96.4	404	95.3	68.89	19.18	420	95.7	402	95.7	68.80	20.26
TREATMENT COMPLETION	n/a		412	93.6	390	94.7	72.88	20.43	400	91.1	370	92.5	75.99	17.08
FOLLOW-UP MONTH 6	n/a		351	79.8	298	84.9	76.71	18.94	341	77.7	275	80.6	77.85	18.12
FOLLOW-UP MONTH 12	n/a		334	75.9	287	85.9	76.57	20.55	303	69.0	244	80.5	77.77	16.53
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	77.25	17.55	279	63.6	246	88.2	78.79	16.89
FOLLOW-UP MONTH 24	n/a		135	30.7	105	77.8	75.71	19.72	126	28.7	92	73.0	78.17	17.38
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Role functioning (revised)

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	416	94.5	68.95	33.92	439	100.0	410	93.4	71.22	32.06
CYCLE 2 DAY 1	n/a		431	98.0	416	96.5	74.08	27.00	432	98.4	416	96.3	75.48	27.28
CYCLE 3 DAY 1	n/a		428	97.3	409	95.6	75.79	26.37	426	97.0	412	96.7	77.06	26.93
CYCLE 5 DAY 1	n/a		424	96.4	406	95.8	75.82	26.38	420	95.7	402	95.7	75.87	26.31
TREATMENT COMPLETION	n/a		412	93.6	392	95.1	80.44	25.20	400	91.1	369	92.3	83.83	22.33
FOLLOW-UP MONTH 6	n/a		351	79.8	300	85.5	85.17	23.08	341	77.7	281	82.4	87.54	19.44
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	86.86	23.74	303	69.0	247	81.5	88.80	19.66
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	88.09	20.90	279	63.6	246	88.2	86.92	22.63
FOLLOW-UP MONTH 24	n/a		135	30.7	104	77.0	89.26	19.42	126	28.7	92	73.0	88.59	21.39
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Social functioning

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	415	94.3	73.90	29.30	439	100.0	405	92.3	74.77	28.08
CYCLE 2 DAY 1	n/a		431	98.0	415	96.3	75.90	24.44	432	98.4	413	95.6	77.36	25.16
CYCLE 3 DAY 1	n/a		428	97.3	408	95.3	77.37	25.16	426	97.0	411	96.5	79.36	23.32
CYCLE 5 DAY 1	n/a		424	96.4	404	95.3	78.71	24.13	420	95.7	401	95.5	78.35	24.24
TREATMENT COMPLETION	n/a		412	93.6	389	94.4	82.73	24.52	400	91.1	371	92.8	86.21	20.59
FOLLOW-UP MONTH 6	n/a		351	79.8	298	84.9	89.09	20.23	341	77.7	276	80.9	88.65	18.58
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	90.62	19.05	303	69.0	245	80.9	90.00	18.19
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	90.37	19.70	279	63.6	246	88.2	91.06	18.29
FOLLOW-UP MONTH 24	n/a		135	30.7	105	77.8	91.75	18.51	126	28.7	91	72.2	92.86	15.54
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EORTC QLQ-C30: Insomnia

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a		440	100.0	416	94.5	37.18	34.11	439	100.0	409	93.2	36.84	34.00
CYCLE 2 DAY 1	n/a		431	98.0	418	97.0	27.11	29.99	432	98.4	416	96.3	26.20	28.71
CYCLE 3 DAY 1	n/a		428	97.3	407	95.1	24.32	27.70	426	97.0	408	95.8	24.84	27.62
CYCLE 5 DAY 1	n/a		424	96.4	404	95.3	23.27	27.24	420	95.7	402	95.7	23.47	27.64
TREATMENT COMPLETION	n/a		412	93.6	392	95.1	20.49	25.94	400	91.1	369	92.3	19.15	26.59
FOLLOW-UP MONTH 6	n/a		351	79.8	300	85.5	18.67	25.71	341	77.7	280	82.1	18.93	26.23
FOLLOW-UP MONTH 12	n/a		334	75.9	288	86.2	19.79	26.65	303	69.0	247	81.5	18.22	25.96
FOLLOW-UP MONTH 18	n/a		309	70.2	270	87.4	18.15	24.47	279	63.6	246	88.2	19.24	28.25
FOLLOW-UP MONTH 24	n/a		135	30.7	104	77.0	16.03	23.68	126	28.7	92	73.0	15.94	22.90
FOLLOW-UP MONTH 36	n/a		0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Appetite loss



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Cognitive functioning



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Constipation



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Diarrhoea



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Dyspnoea



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit


EORTC QLQ-C30: Emotional functioning



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
STUDY: GO39942
Line Plot of Mean by Visit
EORTC QLQ-C30: Fatigue



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Financial difficulties



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit


EORTC QLQ-C30: Nausea and vomiting



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
STUDY: GO39942
Line Plot of Mean by Visit
EORTC QLQ-C30: Pain



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Physical functioning (revised)



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Global health status/QoL (revised)



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit

EORTC QLQ-C30: Role functioning (revised)



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EORTC QoL 30

STUDY: GO39942

Line Plot of Mean by Visit


EORTC QLQ-C30: Social functioning



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QoL 30
STUDY: GO39942
Line Plot of Mean by Visit
EORTC QLQ-C30: Insomnia



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_EQC30_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:55

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)						
			N		Statistics			N		Statistics			Statistics						
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population		Method
Baseline	All	n/a	411	411	0	NE	NE	409	409	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 2 Day 1	All	n/a	410	410	403	-4.41	1.34	402	402	392	-5.23	1.36	0.82	1.91	-2.93	4.56	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 3 Day 1	All	n/a	408	408	398	-6.42	1.19	395	395	386	-8.15	1.21	1.73	1.69	-1.59	5.06	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 5 Day 1	All	n/a	401	401	385	-5.90	1.30	380	380	368	-6.43	1.32	0.52	1.85	-3.11	4.16	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	402	384	-14.98	0.97	398	398	364	-16.52	0.99	1.53	1.39	-1.19	4.26	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 6	All	n/a	336	336	289	-18.57	0.81	323	323	269	-19.41	0.84	0.85	1.16	-1.44	3.13	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 12	All	n/a	320	320	277	-18.24	0.89	289	289	238	-19.32	0.96	1.08	1.31	-1.49	3.64	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 18	All	n/a	298	298	260	-20.11	0.83	265	265	236	-18.38	0.87	-1.73	1.20	-4.08	0.62	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 24	All	n/a	131	131	102	-18.08	1.31	120	120	87	-20.03	1.42	1.95	1.93	-1.86	5.76	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)							
			N			Statistics		N			Statistics		Statistics							
Visit	Name	Level	Total	with baselin e value	included in analysis[1)	LSMeans[2)	SE (LSMeans)	Total	with baselin e value	included in analysis[1)	LSMeans[2)	SE (LSMeans)	LSMeans[3)	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method		
Baseline	All	n/a	411	410	0	NE	NE	409	405	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Cycle 2 Day 1	All	n/a	410	409	402	0.70	0.71	402	398	387	1.80	0.72	-1.10	1.01	-3.09	0.89	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Cycle 3 Day 1	All	n/a	408	407	397	1.11	0.75	395	391	383	2.13	0.76	-1.02	1.06	-3.11	1.07	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Cycle 5 Day 1	All	n/a	401	400	384	0.96	0.83	380	376	367	-0.50	0.85	1.46	1.19	-0.87	3.79	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Treatment Comp Or Early Discon	All	n/a	402	401	382	0.93	0.85	398	394	363	0.13	0.87	0.80	1.22	-1.59	3.18	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 6	All	n/a	336	335	286	1.29	0.93	323	320	262	0.72	0.96	0.57	1.34	-2.06	3.19	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 12	All	n/a	320	319	277	0.37	0.96	289	286	233	2.20	1.03	-1.84	1.41	-4.60	0.92	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 18	All	n/a	298	297	259	1.51	0.93	265	263	236	1.63	0.97	-0.12	1.34	-2.75	2.51	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 24	All	n/a	131	130	103	-0.88	1.39	120	119	85	3.16	1.51	-4.05	2.05	-8.09	-0.01	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N		Statistics			N		Statistics			Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1)	LSMeans[2)	SE (LSMeans)	Total	with baselin e value	included in analysis[1)	LSMeans[2)	SE (LSMeans)	LSMeans[3)	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	405	0	NE	NE	409	403	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 2 Day 1	All	n/a	410	404	393	-4.91	1.24	402	396	383	-1.13	1.26	-3.78	1.77	-7.25	-0.31	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 3 Day 1	All	n/a	408	402	391	-6.27	1.18	395	389	380	-3.00	1.20	-3.27	1.68	-6.57	0.03	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 5 Day 1	All	n/a	401	395	380	-7.63	1.14	380	374	359	-5.32	1.17	-2.31	1.64	-5.52	0.90	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	397	380	-11.11	0.96	398	392	357	-12.31	0.98	1.20	1.37	-1.49	3.89	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 6	All	n/a	336	331	282	-11.91	1.03	323	319	261	-11.09	1.07	-0.82	1.49	-3.74	2.11	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 12	All	n/a	320	315	274	-9.55	1.11	289	286	232	-11.86	1.19	2.31	1.63	-0.89	5.50	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 18	All	n/a	298	294	258	-9.99	1.23	265	262	233	-10.49	1.28	0.50	1.78	-2.98	3.99	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 24	All	n/a	131	130	103	-8.34	1.60	120	119	86	-12.47	1.74	4.13	2.37	-0.53	8.79	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)						R-CHOP (N=409)						Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics			N			Statistics						Statistics		
Visit	Name	Level	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)		Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)		LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	407	0	NE	NE		409	405	0	NE	NE		NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 2 Day 1	All	n/a	410	406	399	6.28	1.14		402	398	387	-0.02	1.16		6.31	1.62	3.12	9.49	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 3 Day 1	All	n/a	408	404	394	1.55	1.01		395	391	381	-0.60	1.02		2.15	1.43	-0.66	4.97	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 5 Day 1	All	n/a	401	397	381	1.19	0.99		380	376	367	0.12	1.01		1.07	1.41	-1.70	3.85	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Treatment Comp Or Early Discon	All	n/a	402	398	378	-1.93	0.88		398	394	363	-2.70	0.90		0.77	1.26	-1.69	3.23	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 6	All	n/a	336	332	282	-1.72	0.95		323	320	261	-2.77	0.99		1.05	1.37	-1.64	3.75	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 12	All	n/a	320	316	275	-1.68	0.98		289	286	233	-3.85	1.05		2.18	1.43	-0.64	4.99	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 18	All	n/a	298	294	257	-2.60	0.93		265	263	236	-3.61	0.97		1.02	1.34	-1.63	3.66	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 24	All	n/a	131	128	101	-5.22	1.18		120	119	87	-4.68	1.27		-0.54	1.74	-3.97	2.89	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 36	All	n/a	0	0	0	NE	NE		1	1	0	NE	NE		NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)						
			N		Statistics			N		Statistics			Statistics						
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population		Method
Baseline	All	n/a	411	411	0	NE	NE	409	408	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 2 Day 1	All	n/a	410	410	403	-3.87	0.97	402	401	391	-3.98	0.98	0.11	1.38	-2.60	2.82	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 3 Day 1	All	n/a	408	408	397	-1.87	1.05	395	394	385	-2.87	1.07	1.00	1.50	-1.95	3.94	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 5 Day 1	All	n/a	401	401	381	-1.12	1.15	380	379	369	0.15	1.16	-1.27	1.63	-4.48	1.93	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	402	385	-2.91	1.07	398	397	365	-5.18	1.09	2.26	1.53	-0.74	5.27	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 6	All	n/a	336	336	289	-4.16	1.09	323	322	267	-5.01	1.13	0.85	1.57	-2.23	3.93	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 12	All	n/a	320	320	277	-5.52	1.18	289	288	236	-2.93	1.26	-2.59	1.73	-5.98	0.80	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 18	All	n/a	298	298	260	-6.77	1.18	265	264	236	-4.06	1.23	-2.70	1.71	-6.06	0.65	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 24	All	n/a	131	131	102	-4.69	1.68	120	119	86	-2.59	1.81	-2.10	2.47	-6.96	2.76	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

EORTC QLQ-C30: Emotional functioning																		
			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics		N			Statistics		Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	410	0	NE	NE	409	406	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 2 Day 1	All	n/a	410	409	401	7.73	0.75	402	399	388	7.81	0.76	-0.08	1.06	-2.17	2.00	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 3 Day 1	All	n/a	408	407	397	8.26	0.80	395	392	384	7.76	0.81	0.50	1.14	-1.74	2.74	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 5 Day 1	All	n/a	401	400	384	8.35	0.87	380	377	368	6.80	0.88	1.55	1.24	-0.87	3.98	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	401	382	9.05	0.84	398	395	364	8.87	0.86	0.18	1.20	-2.18	2.54	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 6	All	n/a	336	335	286	8.50	0.95	323	320	262	10.79	0.98	-2.29	1.36	-4.96	0.38	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 12	All	n/a	320	319	277	9.13	0.96	289	286	233	11.56	1.03	-2.43	1.41	-5.20	0.34	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 18	All	n/a	298	297	259	9.43	0.91	265	263	236	12.45	0.95	-3.01	1.32	-5.61	-0.42	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 24	All	n/a	131	130	103	9.64	1.24	120	119	85	12.87	1.35	-3.23	1.83	-6.84	0.38	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)						
			N		Statistics			N		Statistics			Statistics						
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population		Method
Baseline	All	n/a	411	411	0	NE	NE	409	409	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 2 Day 1	All	n/a	410	410	404	-1.28	0.99	402	402	393	-2.75	1.00	1.47	1.40	-1.28	4.22	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 3 Day 1	All	n/a	408	408	398	-3.54	1.05	395	395	386	-2.72	1.06	-0.82	1.49	-3.75	2.12	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 5 Day 1	All	n/a	401	401	385	-2.83	1.15	380	380	370	-1.09	1.17	-1.74	1.65	-4.97	1.49	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	402	385	-10.49	1.07	398	398	364	-7.96	1.09	-2.53	1.52	-5.53	0.46	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 6	All	n/a	336	336	289	-13.88	1.10	323	323	269	-13.21	1.13	-0.67	1.58	-3.78	2.44	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 12	All	n/a	320	320	277	-14.62	1.16	289	289	238	-13.98	1.23	-0.64	1.69	-3.96	2.69	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 18	All	n/a	298	298	260	-16.50	1.17	265	265	236	-13.67	1.22	-2.83	1.69	-6.15	0.49	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 24	All	n/a	131	131	102	-15.78	1.59	120	120	87	-16.44	1.71	0.66	2.34	-3.95	5.27	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

EORTC QLQ-C30: Financial difficulties																		
			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics		N			Statistics		Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	407	0	NE	NE	409	402	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 2 Day 1	All	n/a	410	406	397	-3.97	1.00	402	395	384	-2.57	1.02	-1.40	1.43	-4.20	1.41	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 3 Day 1	All	n/a	408	404	392	-2.52	1.06	395	388	381	-3.74	1.07	1.22	1.50	-1.74	4.17	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 5 Day 1	All	n/a	401	397	380	-3.25	1.07	380	373	363	-3.64	1.09	0.40	1.53	-2.61	3.40	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Treatment Comp Or Early Discon	All	n/a	402	398	375	-3.18	1.08	398	391	358	-5.18	1.10	2.00	1.54	-1.02	5.03	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 6	All	n/a	336	332	283	-7.79	1.04	323	318	260	-7.93	1.08	0.13	1.50	-2.81	3.07	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 12	All	n/a	320	317	274	-9.95	1.07	289	284	232	-7.47	1.14	-2.48	1.57	-5.56	0.60	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 18	All	n/a	298	295	256	-9.89	1.05	265	261	233	-10.67	1.09	0.78	1.51	-2.19	3.75	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 24	All	n/a	131	128	103	-10.51	1.36	120	118	84	-14.18	1.50	3.66	2.02	-0.32	7.65	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

EORTC QLQ-C30: Nausea and vomiting																		
			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics		N			Statistics		Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	411	0	NE	NE	409	409	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 2 Day 1	All	n/a	410	410	404	1.74	0.78	402	402	393	0.91	0.79	0.83	1.11	-1.35	3.01	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 3 Day 1	All	n/a	408	408	398	1.65	0.75	395	395	387	-0.10	0.76	1.76	1.07	-0.34	3.86	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 5 Day 1	All	n/a	401	401	385	1.74	0.77	380	380	370	1.19	0.78	0.55	1.09	-1.60	2.70	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	402	385	-4.14	0.50	398	398	365	-3.95	0.51	-0.19	0.72	-1.60	1.22	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 6	All	n/a	336	336	289	-4.71	0.47	323	323	269	-4.59	0.49	-0.11	0.68	-1.45	1.23	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 12	All	n/a	320	320	277	-3.26	0.59	289	289	238	-4.99	0.63	1.72	0.86	0.04	3.41	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 18	All	n/a	298	298	260	-4.60	0.57	265	265	236	-4.24	0.60	-0.36	0.83	-1.98	1.26	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 24	All	n/a	131	131	102	-5.11	0.58	120	120	87	-5.51	0.62	0.40	0.85	-1.27	2.07	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)						
			N		Statistics			N		Statistics			Statistics						
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population		Method
Baseline	All	n/a	411	411	0	NE	NE	409	409	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 2 Day 1	All	n/a	410	410	404	-10.88	1.02	402	402	393	-11.79	1.03	0.91	1.45	-1.94	3.76	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 3 Day 1	All	n/a	408	408	398	-12.58	1.05	395	395	387	-12.45	1.06	-0.13	1.49	-3.06	2.80	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 5 Day 1	All	n/a	401	401	386	-13.99	1.07	380	380	370	-11.97	1.09	-2.02	1.53	-5.03	0.99	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	402	386	-10.58	1.23	398	398	367	-11.30	1.25	0.72	1.76	-2.73	4.16	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 6	All	n/a	336	336	289	-12.78	1.22	323	323	268	-13.88	1.25	1.10	1.75	-2.33	4.54	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 12	All	n/a	320	320	278	-12.24	1.37	289	289	238	-12.89	1.45	0.65	1.99	-3.27	4.56	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 18	All	n/a	298	298	260	-13.00	1.36	265	265	236	-12.86	1.42	-0.14	1.97	-4.01	3.72	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 24	All	n/a	131	131	103	-9.84	1.90	120	120	87	-16.65	2.05	6.81	2.80	1.30	12.31	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

EORTC QLQ-C30: Physical functioning (revised)																		
			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics		N			Statistics		Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2)	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2)	SE (LSMeans)	LSMeans[3)	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	411	0	NE	NE	409	409	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 2 Day 1	All	n/a	410	410	403	-0.41	0.73	402	402	393	1.33	0.73	-1.74	1.03	-3.76	0.29	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 3 Day 1	All	n/a	408	408	398	1.27	0.85	395	395	386	0.58	0.86	0.70	1.21	-1.68	3.07	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 5 Day 1	All	n/a	401	401	386	0.53	0.90	380	380	370	-0.45	0.91	0.98	1.28	-1.53	3.48	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	402	385	2.69	0.89	398	398	365	3.90	0.90	-1.22	1.27	-3.70	1.27	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 6	All	n/a	336	336	289	5.19	0.90	323	323	269	6.78	0.92	-1.59	1.28	-4.11	0.93	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 12	All	n/a	320	320	277	5.61	0.99	289	289	238	6.32	1.04	-0.71	1.43	-3.52	2.11	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 18	All	n/a	298	298	260	6.44	0.89	265	265	236	6.22	0.92	0.23	1.28	-2.29	2.75	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 24	All	n/a	131	131	102	6.37	1.14	120	120	87	6.92	1.22	-0.55	1.67	-3.83	2.74	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

EORTC QLQ-C30: Global health status/QoL (revised)																		
			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics		N			Statistics		Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2)	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2)	SE (LSMeans)	LSMeans[3)	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	409	0	NE	NE	409	405	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 2 Day 1	All	n/a	410	408	400	5.67	0.87	402	398	386	8.02	0.88	-2.36	1.24	-4.80	0.08	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 3 Day 1	All	n/a	408	406	395	8.10	0.91	395	391	382	7.92	0.92	0.18	1.29	-2.36	2.71	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Cycle 5 Day 1	All	n/a	401	399	383	7.55	0.96	380	376	367	7.02	0.98	0.54	1.37	-2.16	3.23	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	400	381	11.18	0.97	398	394	363	12.22	0.98	-1.04	1.38	-3.74	1.67	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 6	All	n/a	336	335	286	14.84	1.01	323	319	260	15.54	1.04	-0.71	1.45	-3.55	2.14	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 12	All	n/a	320	318	275	14.49	1.08	289	285	231	15.39	1.16	-0.90	1.59	-4.03	2.22	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 18	All	n/a	298	296	259	15.16	1.00	265	262	236	15.84	1.04	-0.68	1.44	-3.51	2.15	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 24	All	n/a	131	130	103	13.61	1.48	120	119	86	15.02	1.60	-1.41	2.18	-5.70	2.89	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

EORTC QLQ-C30: Role functioning (revised)

			Polatuzumab Vedotin			R-CHP (N=411)		R-CHOP (N=409)				Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)								
			N			Statistics		N			Statistics		Statistics							
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method		
Baseline	All	n/a	411	410	0	NE	NE	409	409	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Cycle 2 Day 1	All	n/a	410	409	401	3.42	1.15	402	402	393	4.38	1.16	-0.96	1.64	-4.18	2.25	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Cycle 3 Day 1	All	n/a	408	407	397	4.97	1.22	395	395	387	4.79	1.23	0.19	1.73	-3.21	3.59	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Cycle 5 Day 1	All	n/a	401	400	385	4.03	1.27	380	380	370	3.87	1.29	0.16	1.81	-3.39	3.71	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Treatment Comp Or Early Discon	All	n/a	402	401	384	9.16	1.21	398	398	365	10.58	1.23	-1.42	1.73	-4.82	1.97	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 6	All	n/a	336	335	288	13.01	1.19	323	323	269	15.64	1.23	-2.64	1.71	-6.00	0.72	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 12	All	n/a	320	320	277	14.38	1.28	289	289	237	16.63	1.36	-2.25	1.87	-5.92	1.42	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 18	All	n/a	298	298	260	15.70	1.28	265	265	236	14.79	1.34	0.90	1.85	-2.73	4.54	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 24	All	n/a	131	131	102	16.06	1.67	120	120	87	16.07	1.79	-0.01	2.45	-4.83	4.81	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjuste d		

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

EORTC QLQ-C30: Social functioning																		
			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics		N			Statistics		Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	411	410	0	NE	NE	409	404	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 2 Day 1	All	n/a	410	409	400	1.54	1.09	402	397	386	2.56	1.10	-1.02	1.55	-4.06	2.02	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 3 Day 1	All	n/a	408	407	396	2.89	1.12	395	390	383	3.91	1.14	-1.01	1.60	-4.15	2.13	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Cycle 5 Day 1	All	n/a	401	400	384	3.08	1.15	380	375	365	3.28	1.18	-0.20	1.65	-3.44	3.04	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Treatment Comp Or Early Discon	All	n/a	402	401	381	7.68	1.14	398	393	362	9.25	1.17	-1.57	1.63	-4.77	1.64	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 6	All	n/a	336	335	286	13.56	1.09	323	319	261	13.42	1.14	0.14	1.58	-2.96	3.24	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 12	All	n/a	320	319	277	15.13	1.06	289	285	232	14.25	1.13	0.88	1.55	-2.16	3.93	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 18	All	n/a	298	297	259	14.47	1.15	265	262	235	15.41	1.20	-0.94	1.66	-4.20	2.32	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 24	All	n/a	131	130	103	15.05	1.45	120	119	85	17.56	1.58	-2.50	2.15	-6.73	1.72	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30	unadjusted

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30
ENDPOINT: EORTC QoL 30
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EORTC QoL 30 (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=411)					R-CHOP (N=409)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)						
			N		Statistics			N		Statistics			Statistics						
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population		Method
Baseline	All	n/a	411	411	0	NE	NE	409	408	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 2 Day 1	All	n/a	410	410	404	-9.57	1.30	402	401	393	-10.38	1.32	0.81	1.85	-2.82	4.44	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 3 Day 1	All	n/a	408	408	396	-11.99	1.30	395	394	383	-11.14	1.32	-0.86	1.85	-4.49	2.78	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Cycle 5 Day 1	All	n/a	401	401	384	-13.02	1.30	380	379	369	-12.39	1.32	-0.63	1.86	-4.27	3.02	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Treatment Comp Or Early Discon	All	n/a	402	402	385	-15.52	1.29	398	397	364	-16.06	1.32	0.54	1.84	-3.07	4.15	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 6	All	n/a	336	336	289	-17.43	1.39	323	323	268	-17.10	1.43	-0.32	1.99	-4.23	3.59	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 12	All	n/a	320	320	277	-16.37	1.44	289	289	237	-17.35	1.53	0.98	2.10	-3.15	5.10	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 18	All	n/a	298	298	260	-17.70	1.43	265	265	236	-16.55	1.49	-1.15	2.07	-5.21	2.91	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 24	All	n/a	131	131	102	-19.57	1.97	120	120	87	-19.79	2.12	0.22	2.90	-5.49	5.93	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EORTC QLQ-C30		unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Appetite loss																															
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +							
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	
												Convergen ce criterion (GCONV=1E- 8) satisfied .						Algorithm converged .	-0.026	0.063	1.31		Algorithm converged .	0.84	2.06	0.2599	0.76		Algorithm converged .	0.48	1.20
All	n/a	379	86.1	41	10.8	346	78.8	29	8.4	1.33																					

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Cognitive functioning																																	
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +									
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk										
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL			
												Convergen ce criterion (GCONV=1E- 8) satisfied .											Algorithm converged .							Algorithm converged .			
All	n/a	377	85.7	86	22.8	345	78.6	85	24.6	0.91			0.64	1.28	-0.019		Algorithm converged .	-0.079	0.042	0.92			Algorithm converged .	0.71	1.20	0.5838	1.08		Algorithm converged .	0.83	1.40		

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Constipation																															
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +							
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	
												Convergen ce criterion (GCONV=1E- 8) satisfied					Algorithm converged						Algorithm converged						Algorithm converged		
All	n/a	375	85.2	44	11.7	339	77.2	24	7.1	1.73			1.03	2.91	0.044			0.001	0.087	1.67				1.04	2.69	0.0362	0.60			0.37	0.96

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Diarrhoea																											
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	
											Convergen ce criterion (GCONV=1E- 8) satisfied .				Algorithm converged .					Algorithm converged .					Algorithm converged .		
All	n/a	373	84.8	46	12.3	345	78.6	40	11.6	1.06		0.67	1.67	0.010		-0.037	0.056	1.05		0.71	1.56	0.8049	0.95		0.64	1.42	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Dyspnoea																																
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +								
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL		
												Convergen ce criterion (GCONV=1E- 8) satisfied .						Algorithm converged .					Algorithm converged .						Algorithm converged .			
All	n/a	380	86.4	72	18.9	347	79.0	52	15.0	1.36			0.92	2.02	0.047			-0.004	0.098	1.25				0.91	1.73	0.1258	0.80				0.58	1.10

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Emotional functioning																																	
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP													R-CHOP vs. Polatuzumab Vedotin +										
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk										
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL			
												Convergen ce criterion (GCONV=1E- 8) satisfied .											Algorithm converged .							Algorithm converged .			
All	n/a	377	85.7	41	10.9	346	78.8	25	7.2	1.56			0.93	2.62	0.027				-0.015	0.069	1.52				0.95	2.44	0.0935	0.66				0.41	1.06

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Fatigue																																	
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +									
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk										
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL			
												Convergen ce criterion (GCONV=1E- 8) satisfied .						Algorithm converged .					Algorithm converged .			0.3447			Algorithm converged .				
All	n/a	380	86.4	49	12.9	346	78.8	53	15.3	0.82			0.54	1.24	-0.023				-0.074	0.028	0.84				0.59	1.21		1.19				0.83	1.70

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Financial difficulties																															
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +							
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	
												Convergen ce criterion (GCONV=1E- 8) satisfied .						Algorithm converged .	-0.029	0.066	1.16		Algorithm converged .	0.78	1.74	0.3843	0.86		Algorithm converged .	0.57	1.29
All	n/a	371	84.3	47	12.7	340	77.4	37	10.9	1.23			0.77	1.95	0.018				-0.029	0.066	1.16			0.78	1.74	0.3843	0.86			0.57	1.29

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Nausea and vomiting																										
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP													R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL
											Convergen ce criterion (GCONV=1E- 8) satisfied .				Algorithm converged .											
All	n/a	380	86.4	33	8.7	347	79.0	29	8.4	1.06		0.63	1.79	0.006		-0.032	0.045	1.06		0.66	1.70	0.8285	0.95		0.59	1.52

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Pain																												
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +				
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk					
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL		
											Convergen ce criterion (GCONV=1E- 8) satisfied .				Algorithm converged .													
All	n/a	381	86.6	83	21.8	349	79.5	69	19.8	1.14		0.80	1.64	0.017		-0.041	0.076	1.11		0.84	1.47	0.4663	0.90		0.68	1.20		

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Physical functioning (revised)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
												Convergen ce criterion (GCONV=1E- 8) satisfied .											Algorithm converged .							Algorithm converged .																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30:Deterioration (MID=15) at EOT in Global health status/QoL (revised)																																
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +								
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL		
												Convergen ce criterion (GCONV=1E- 8) satisfied .						Algorithm converged .					Algorithm converged .			0.3393			Algorithm converged .			
All	n/a	376	85.5	67	17.8	345	78.6	53	15.4	1.21			0.82	1.80	0.026			-0.028	0.080	1.17				0.84	1.62		0.86				0.62	1.19

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Role functioning (revised)																											
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	
											Convergen ce criterion (GCONV=1E- 8) satisfied .				Algorithm converged .												
All	n/a	379	86.1	91	24.0	347	79.0	72	20.7	1.23		0.86	1.74	0.034		-0.026	0.094	1.16		0.88	1.52	0.2566	0.86		Algorithm converged .	0.66	1.13

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Social functioning																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
												Convergen ce criterion (GCONV=1E- 8) satisfied .											Algorithm converged .							Algorithm converged .																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at EOT
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at EOT in Insomnia																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										
		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk		Convergen ce Reason	95% Lower CL	95% Upper CL																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												
												Convergen ce criterion (GCONV=1E- 8) satisfied .											Algorithm converged .							Algorithm converged .																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												</

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30ET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:33

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Appetite loss																																	
Polatuzumab Vedotin + R-Patients						R-CHOP (N=439) Patients with						Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-Patients							
												Odds Ratio				Absolute Risk Difference						Relative Risk						Relative Risk					
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL							
											Convergence criterion (GCONV=1E-8) satisfied.	0.70	16.01	*	WARNING: The relative Hessian convergence criterion of 1.0467315936 is greater than the limit of 0.0001. The convergence is questionable.			3.26	Algorithm converged.	0.73	14.57	0.1091	0.31	Algorithm converged.	0.07	1.37							
All	n/a	102	23.2	9	8.8	87	19.8	2	2.3	3.36																							

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Cognitive functioning

		Polatuzumab Vedotin + R- Patients				R-CHOP (N=439) Patients with				Odds Ratio				Polatuzumab Vedotin + R-CHP vs. R-CHOP												R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients				Patients with				Odds Ratio				Absolute Risk Difference						Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relativ e Risk	Convergence Reason	95% Lower CL	95% Upper CL			
											Convergence criterion (GCONV=1E-8) satisfied.				Algorithm converged.	-0.031	0.224	1.40	Algorithm converged.	0.83	2.37	0.2689	0.71	Algorithm converged.	0.42	1.20			
All	n/a	103	23.4	30	29.1	85	19.4	17	20.0	1.47		0.74	2.91	0.096															

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Constipation																														
Polatuzumab Vedotin + R-				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-						
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	103	23.4	13	12.6	86	19.6	6	7.0	1.62		Convergence criterion (GCONV=1E-8) satisfied.	0.58	4.55	*		WARNING: The relative Hessian convergence criterion of 0.0067127796 is greater than the limit of 0.0001. The convergence is questionable.			1.73		Algorithm converged.	0.69	4.38	0.3585	0.58		Algorithm converged.	0.23	1.46

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Diarrhoea																													
Polatuzumab Vedotin						R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients		Patients		Patients with		Odds Ratio					Absolute Risk Difference					Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL			
All	n/a	101	23.0	8	7.9	87	19.8	8	9.2	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.23	1.98		* WARNING: The relative Hessian convergence criterion of 0.120055089 is greater than the limit of 0.0001. The convergence is questionable.				* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					* ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Dyspnoea																																		
		Polatuzumab Vedotin + R-				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-										
		Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk										
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio			Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk			Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk			Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk			Convergence Reason	95% Lower CL	95% Upper CL
													Convergence criterion (GCONV=1E-8) satisfied.	0.23	1.04	-0.094			Algorithm converged.	-0.210	0.021	0.57			Algorithm converged.	0.32	1.03	0.0604	1.75			Algorithm converged.	0.97	3.15
All	n/a	102	23.2	15	14.7	86	19.6	21	24.4	0.49																								

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Emotional functioning																										
		Polatuzumab Vedotin + R-				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP												R-CHOP vs. Polatuzumab Vedotin + R-				
		Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	103	23.4	10	9.7	85	19.4	5	5.9	1.57	Convergence criterion (GCONV=1E-8) satisfied.	0.49	4.98	*	WARNING: The relative Hessian convergence criterion of 0.0263247283 is greater than the limit of 0.0001. The convergence is questionable.			1.74	Algorithm converged.	0.62	4.91	0.4445	0.57	Algorithm converged.	0.20	1.62

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin +				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	102	23.2	14	13.7	87	19.8	7	8.0	1.59	Convergence criterion (GCONV=1E-8) satisfied.	0.61	4.17	0.048	Algorithm converged.	-0.051	0.147	1.69	Algorithm converged.	0.71	4.01	0.3427	0.59	Algorithm converged.	0.25	1.41	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Financial difficulties																															
		Polatuzumab Vedotin				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-					
		Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk								Relative Risk					
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	103	23.4	4	3.9	84	19.1	1	1.2	3.59		Convergence criterion (GCONV=1E-8) satisfied.	0.39	33.09		*	WARNING: The relative Hessian convergence criterion of 1.4582936886 is greater than the limit of 0.0001. The convergence is questionable.			3.19			Algorithm converged.	0.36	28.14	0.2299	0.31		Algorithm converged.	0.04	2.77

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Nausea and vomiting																														
		Polatuzumab Vedotin				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-CHP						
		Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk						
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	102	23.2	3	2.9	87	19.8	1	1.1	1.20		Convergence criterion (GCONV=1E-8) satisfied.	0.11	13.48	*	WARNING: The relative Hessian convergence criterion of 3.2402697584 is greater than the limit of 0.0001. The convergence is questionable.				*		ERROR: The mean parameter is either invalid or at a limit of its range for some observations.				*		ERROR: The mean parameter is either invalid or at a limit of its range for some observations.		

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Pain																														
Polatuzumab Vedotin + R-						R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-CHP				
		Patients		Patients with		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk						
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	103	23.4	23	22.3	87	19.8	6	6.9	4.27		Convergence criterion (GCONV=1E-8) satisfied.	1.62	11.25	*		WARNING: The relative Hessian convergence criterion of 0.10954613 is greater than the limit of 0.0001. The convergence is questionable.			3.56		Algorithm converged.	1.54	8.25	0.0020	0.28		Algorithm converged.	0.12	0.65

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Physical functioning (revised)

		Polatuzumab Vedotin + R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP															R-CHOP vs. Polatuzumab Vedotin + R-CHP					
		Patients		Patients		Patients		Patient		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	102	23.2	9	8.8	87	19.8	6	6.9	1.42	Convergence criterion (GCONV=1E-8) satisfied.	0.49	4.13	0.038	Algorithm converged.	-0.054	0.130	1.29	Algorithm converged.	0.48	3.51	0.5218	0.77	Algorithm converged.	0.28	2.10

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30:Deterioration (MID=15) at FU24 in Global health status/QoL (revised)																														
		Polatuzumab Vedotin + R-				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-						
		Patients		Patients		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk							
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
												Convergence criterion (GCONV=1E-8) satisfied.	0.38	2.00	0.003		Algorithm converged.	-0.099	0.105	0.98		Algorithm converged.	0.50	1.92	0.7513	1.02		Algorithm converged.	0.52	1.99
All	n/a	103	23.4	16	15.5	86	19.6	13	15.1	0.88																				

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Role functioning (revised)

		Polatuzumab Vedotin +				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	102	23.2	16	15.7	87	19.8	11	12.6	1.30	Convergence criterion (GCONV=1E-8) satisfied.	0.57	2.98	0.012	Algorithm converged.	-0.105	0.129	1.26	Algorithm converged.	0.61	2.57	0.5309	0.80	Algorithm converged.	0.39	1.63	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Social functioning																												
Polatuzumab Vedotin + R-				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																	R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk							Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL		
All	n/a	103	23.4	11	10.7	85	19.4	9	10.6	0.90	Convergence criterion (GCONV=1E-8) satisfied.	0.35	2.34	-0.007	Algorithm converged.	-0.105	0.091	0.98	Algorithm converged.	0.42	2.26	0.8344	1.02	Algorithm converged.	0.44	2.36		

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EORTC QLQ-C30: Deterioration (MID=15) at FU Month 24
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

EORTC QLQ-C30: Deterioration (MID=15) at FU24 in Insomnia																															
		Polatuzumab Vedotin + R-CHOP (N=439)								Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-CHOP							
		Patients		Patients		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk							
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	102	23.2	11	10.8	87	19.8	13	14.9	0.56		Convergence criterion (GCONV=1E-8) satisfied.	0.23	1.37		*	WARNING: The relative Hessian convergence criterion of 0.0075271015 is greater than the limit of 0.0001. The convergence is questionable.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.					*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQC30FU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: FACT-G NTX
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

FACT-GOG-NTX: Neurotoxicity subscale (NtxS)

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)					
		Patients				Statistics		Patients				Statistics	
Name Visit	Level	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)	in study ¹	%	with value ¹	%	Mean ²	SD(Mean)
All													
BASELINE	n/a	440	100.0	412	93.6	39.75	4.50	439	100.0	407	92.7	39.48	4.99
CYCLE 2 DAY 1	n/a	431	98.0	418	97.0	39.90	4.63	432	98.4	413	95.6	39.54	5.04
CYCLE 3 DAY 1	n/a	428	97.3	409	95.6	39.94	4.71	426	97.0	410	96.2	38.82	5.89
CYCLE 4 DAY 1	n/a	425	96.6	414	97.4	39.40	5.06	419	95.4	398	95.0	38.17	6.28
CYCLE 5 DAY 1	n/a	424	96.4	408	96.2	38.88	5.88	414	94.3	398	96.1	37.52	6.91
CYCLE 6 DAY 1	n/a	411	93.4	400	97.3	37.88	6.77	400	91.1	389	97.3	36.97	7.04
CYCLE 7 DAY 1	n/a	402	91.4	389	96.8	37.00	7.05	390	88.8	377	96.7	36.21	7.56
CYCLE 8 DAY 1	n/a	397	90.2	385	97.0	37.37	7.34	387	88.2	378	97.7	37.32	7.33
TREATMENT COMPLETION	n/a	396	90.0	380	96.0	36.80	7.34	383	87.2	366	95.6	37.83	6.76
FOLLOW-UP MONTH 6	n/a	351	79.8	301	85.8	38.11	6.62	341	77.7	280	82.1	38.56	6.20
FOLLOW-UP MONTH 12	n/a	334	75.9	287	85.9	38.33	6.40	303	69.0	247	81.5	38.07	6.59
FOLLOW-UP MONTH 18	n/a	309	70.2	270	87.4	38.01	6.94	279	63.6	245	87.8	37.90	6.84
FOLLOW-UP MONTH 24	n/a	135	30.7	105	77.8	38.02	6.21	126	28.7	93	73.8	38.80	7.05
FOLLOW-UP MONTH 36	n/a	0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_mean.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_mean_PFGNTX_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:48


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: FACT-G NTX

STUDY: GO39942

Line Plot of Mean by Visit

FACT-GOG-NTX: Neurotoxicity subscale (NtxS)



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..MARY_CSR_Pooled/prod/output_global/g_mean_plot_PFGNTX_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 10:01

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX
ENDPOINT: FACT-G NTX
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in FACT-G NTX (Analysis of MMRM)

			Polatuzumab Vedotin + R-CHP (N=407)					R-CHOP (N=406)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)						
			N			Statistics		N			Statistics		Statistics						
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population		Method
Baseline	All	n/a	407	407	0	NE	NE	406	406	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Cycle 2 Day 1	All	n/a	406	406	398	0.22	0.18	399	399	387	0.01	0.18	0.21	0.25	-0.29	0.71	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Cycle 3 Day 1	All	n/a	404	404	393	0.17	0.21	391	391	384	-0.76	0.22	0.93	0.30	0.33	1.53	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Cycle 4 Day 1	All	n/a	404	404	395	-0.48	0.23	384	384	370	-1.51	0.24	1.03	0.33	0.37	1.68	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Cycle 5 Day 1	All	n/a	397	397	384	-0.98	0.27	376	376	368	-2.15	0.28	1.16	0.39	0.40	1.93	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Cycle 6 Day 1	All	n/a	386	386	377	-1.96	0.31	371	371	366	-2.89	0.31	0.93	0.44	0.07	1.78	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Cycle 7 Day 1	All	n/a	377	377	367	-2.71	0.33	356	356	346	-3.51	0.33	0.80	0.47	-0.12	1.72	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Cycle 8 Day 1	All	n/a	368	368	358	-2.53	0.34	352	352	346	-2.50	0.34	-0.02	0.48	-0.96	0.91	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Treatment Comp Or Early Discon	All	n/a	398	398	384	-2.96	0.32	395	395	375	-1.90	0.32	-1.06	0.45	-1.94	-0.18	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Follow-Up Month 6	All	n/a	333	333	286	-1.51	0.29	319	319	264	-1.26	0.30	-0.25	0.42	-1.08	0.58	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Follow-Up Month 12	All	n/a	317	317	273	-1.46	0.32	285	285	235	-1.28	0.33	-0.18	0.46	-1.08	0.71	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Follow-Up Month 18	All	n/a	294	294	256	-1.72	0.34	261	261	234	-1.65	0.35	-0.07	0.49	-1.04	0.89	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Follow-Up Month 24	All	n/a	131	131	103	-1.63	0.46	118	118	87	-1.60	0.50	-0.04	0.68	-1.37	1.30	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-G NTX		unadjuste d

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: FACT-GOG-NTX: Deterioration (MID=7) at EOT in Neurotoxicity subscale (NtxS)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHOP(N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	
											Convergen ce criterion (GCONV=1E- 8) satisfied .	1.12	2.38	0.073	Algorithm converged .	0.015	0.131	1.46	Algorithm converged .	1.09	1.98	0.0102	0.68	Algorithm converged .	0.51	0.92	
All	n/a	363	82.5	87	24.0	343	78.1	56	16.3	1.63																	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DPFGNTXET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:38

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: FACT-GOG-NTX: Deterioration (MID=7) at FU Month 24 in Neurotoxicity subscale (NtxS)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=39)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk								Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL			
All	n/a	103	23.4	19	18.4	87	19.8	9	10.3	1.86	Convergence criterion (GCONV=1E-8) satisfied .	0.78	4.41	*	WARNING: The relative Hessian convergence criterion of 0.0056926352 is greater than the limit of 0.0001. The convergence is questionable.			1.82	Algorithm converged .	0.87	3.82	0.1578	0.55	Algorithm converged .	0.26	1.15			

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DPFGNITXFU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:45

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EQ-5D-5L HEALTH STATE (VAS)
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

EQ-5D-5L: Your Health Today (VAS)

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
	BASELINE	n/a	440	100.0	405	92.0	68.74	21.65	439	100.0	406	92.5	69.97	19.84
	CYCLE 2 DAY 1	n/a	431	98.0	408	94.7	72.38	18.87	432	98.4	410	94.9	75.14	16.60
	CYCLE 3 DAY 1	n/a	428	97.3	408	95.3	74.87	17.44	426	97.0	406	95.3	75.61	16.87
	CYCLE 5 DAY 1	n/a	424	96.4	399	94.1	75.68	16.75	420	95.7	398	94.8	75.35	17.27
	TREATMENT COMPLETION	n/a	412	93.6	388	94.2	79.56	16.60	400	91.1	365	91.3	81.43	13.93
	FOLLOW-UP MONTH 6	n/a	351	79.8	288	82.1	81.36	16.26	341	77.7	273	80.1	81.88	13.65
	FOLLOW-UP MONTH 12	n/a	334	75.9	274	82.0	81.26	16.72	303	69.0	238	78.5	82.87	14.04
	FOLLOW-UP MONTH 18	n/a	309	70.2	267	86.4	82.04	15.02	279	63.6	234	83.9	83.33	14.41
	FOLLOW-UP MONTH 24	n/a	135	30.7	114	84.4	81.92	15.17	126	28.7	110	87.3	82.74	14.73
	FOLLOW-UP MONTH 36	n/a	0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: EQ-5D-5L HEALTH STATE (VAS)

STUDY: GO39942

Line Plot of Mean by Visit

EQ-5D-5L: Your Health Today (VAS)



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..ARY_CSR_Pooled/prod/output_global/g_mean_plot_EQ5DVAS_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 10:04

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)
ENDPOINT: EQ-5D-5L HEALTH STATE (VAS)
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in EQ-5D-5L HEALTH STATE (VAS) (Analysis of MMRM)

EQ-5D-5L: Your Health Today (VAS)																		
			Polatuzumab Vedotin + R-CHP (N=400)					R-CHOP (N=404)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N			Statistics		N			Statistics		Statistics					
Visit	Name	Level	Total	with baselin e value	included in analysis[1]	LSMeans[2)	SE (LSMeans)	Total	with baselin e value	included in analysis[1]	LSMeans[2)	SE (LSMeans)	LSMeans[3)	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	400	400	0	NE	NE	404	404	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Cycle 2 Day 1	All	n/a	399	399	382	3.04	0.73	397	397	383	4.90	0.72	-1.86	1.02	-3.87	0.15	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Cycle 3 Day 1	All	n/a	397	397	384	5.27	0.76	389	389	377	5.08	0.76	0.19	1.08	-1.93	2.30	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Cycle 5 Day 1	All	n/a	390	390	368	5.87	0.80	374	374	361	5.44	0.80	0.43	1.13	-1.80	2.66	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Treatment Comp Or Early Discon	All	n/a	391	391	370	9.39	0.78	394	394	358	10.36	0.78	-0.96	1.10	-3.13	1.20	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Follow-Up Month 6	All	n/a	325	325	268	10.73	0.82	319	319	259	11.55	0.83	-0.83	1.17	-3.13	1.48	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Follow-Up Month 12	All	n/a	309	309	256	10.03	0.88	285	285	228	12.67	0.92	-2.64	1.28	-5.14	-0.14	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Follow-Up Month 18	All	n/a	287	287	249	11.13	0.84	261	261	221	12.79	0.87	-1.66	1.21	-4.04	0.72	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Follow-Up Month 24	All	n/a	127	127	108	11.51	1.02	117	117	102	11.67	1.04	-0.16	1.46	-3.03	2.71	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for EQ-5D-5L (VAS)	unadjusted

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EQ-5D-5L: Deterioration (MID=15) at EOT in Health State (VAS)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran- Mantel- Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	
											Convergen ce criterion (GCONV=1E- 8) satisfied .	0.66	1.87	-0.003	Algorithm converged .	-0.049	0.042	1.10	Algorithm converged .	0.69	1.76	0.6827	0.91	Algorithm converged .	0.57	1.46	
All	n/a	365	83.0	34	9.3	340	77.4	29	8.5	1.11																	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQVASET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:42

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: EQ-5D-5L: Deterioration (MID=15) at FU Month 24 in Health State (VAS)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab				
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk								Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
												Convergence criterion (GCONV=1E-8) satisfied.	0.50	6.20	0.018		Algorithm converged.	-0.044	0.081	2.01		Algorithm converged.	0.63	6.44	0.3719	0.50		Algorithm converged.	0.16	1.60
All	n/a	108	24.5	8	7.4	102	23.2	4	3.9	1.76																				

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DEQVASFU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:44

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: FACT-LYM Subscale
MODEL: descriptive
STUDY: GO39942
Compliance/Mean

FACT-LYM: Lymphoma subscale (LYMS)

		Polatuzumab Vedotin + R-CHP (N=440)						R-CHOP (N=439)						
		Patients				Statistics		Patients				Statistics		
Name	Visit	Level	in study¹	%	with value¹	%	Mean²	SD (Mean)	in study¹	%	with value¹	%	Mean²	SD (Mean)
All														
BASELINE	n/a	440	100.0	410	93.2	44.55	9.96	439	100.0	405	92.3	45.23	9.97	
CYCLE 2 DAY 1	n/a	431	98.0	417	96.8	48.60	8.29	432	98.4	415	96.1	49.37	7.89	
CYCLE 3 DAY 1	n/a	428	97.3	412	96.3	49.60	8.33	426	97.0	411	96.5	50.03	7.97	
CYCLE 5 DAY 1	n/a	424	96.4	404	95.3	50.01	8.17	420	95.7	401	95.5	49.72	8.69	
TREATMENT COMPLETION	n/a	412	93.6	391	94.9	51.77	7.73	400	91.1	368	92.0	52.20	7.10	
FOLLOW-UP MONTH 6	n/a	351	79.8	299	85.2	52.43	7.94	341	77.7	281	82.4	52.33	7.01	
FOLLOW-UP MONTH 12	n/a	334	75.9	288	86.2	52.48	7.45	303	69.0	246	81.2	52.20	7.26	
FOLLOW-UP MONTH 18	n/a	309	70.2	269	87.1	53.03	7.00	279	63.6	244	87.5	52.57	7.88	
FOLLOW-UP MONTH 24	n/a	135	30.7	104	77.0	52.94	7.48	126	28.7	95	75.4	53.34	7.66	
FOLLOW-UP MONTH 36	n/a	0	NE	0	NE	NE	NE	1	0.2	0	NE	NE	NE	

¹ in study: number of subjects in study at respective visit; % based on baseline
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit
² mean: descriptive statistics - absolute values
Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the table.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021


POPULATION: Global Population, Intent-To-Treat Population

ENDPOINT: FACT-LYM Subscale

STUDY: GO39942

Line Plot of Mean by Visit

FACT-LYM: Lymphoma subscale (LYMS)



Baseline is defined as the last assessment prior to the first dose of study treatment. Only scheduled assessments are included in the plot.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: ..ies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/g_mean_plot.sas
Output: ..IMARY_CSR_Pooled/prod/output_global/g_mean_plot_PLYMS_IT_GLOBAL_28JUN2021_39942.pdf
07MAR2022 9:59

POPULATION: Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale
ENDPOINT: FACT-LYM Subscale
MODEL: Unadjusted Analysis
STUDY: GO39942
Change from Baseline in FACT-LYM Subscale (Analysis of MMRM)

FACT-LYM: Lymphoma subscale (LYMS)																		
			Polatuzumab Vedotin + R-CHP (N=405)					R-CHOP (N=403)					Difference between Treatments (Polatuzumab Vedotin + R-CHP - R-CHOP)					
			N		Statistics			N		Statistics			Statistics					
Visit	Name	Level	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	Total	with baseline value	included in analysis[1]	LSMeans[2]	SE (LSMeans)	LSMeans[3]	SE (LSMeans)	95% CI (LL)	95% CI (UL)	Population	Method
Baseline	All	n/a	405	405	0	NE	NE	403	403	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Cycle 2 Day 1	All	n/a	404	404	394	3.60	0.30	397	397	387	4.13	0.30	-0.53	0.43	-1.37	0.31	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Cycle 3 Day 1	All	n/a	402	402	393	4.59	0.35	389	389	380	4.47	0.35	0.12	0.50	-0.85	1.10	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Cycle 5 Day 1	All	n/a	395	395	378	4.65	0.37	374	374	364	4.33	0.37	0.32	0.52	-0.70	1.35	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Treatment Comp Or Early Discon	All	n/a	396	396	377	6.73	0.35	393	393	359	6.22	0.36	0.51	0.50	-0.48	1.50	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Follow-Up Month 6	All	n/a	332	332	283	7.21	0.36	319	319	266	6.81	0.37	0.40	0.51	-0.61	1.40	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Follow-Up Month 12	All	n/a	315	315	274	7.31	0.38	285	285	232	6.94	0.40	0.37	0.56	-0.73	1.46	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Follow-Up Month 18	All	n/a	293	293	255	7.71	0.39	261	261	231	7.03	0.41	0.68	0.57	-0.44	1.80	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Follow-Up Month 24	All	n/a	131	131	102	7.16	0.58	117	117	88	7.28	0.62	-0.12	0.84	-1.78	1.54	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted
Follow-Up Month 36	All	n/a	0	0	0	NE	NE	1	1	0	NE	NE	NE	NE	NE	NE	Global Population, Intent-To-Treat Population, PRO-Evaluable for FACT-Lymphoma Subscale	unadjusted

[1] Patients with a value at baseline and a post-baseline value at the respective visit.
[2] LSMeans of change from baseline from MMRM (including all available records from all scheduled visits)
[3] Contrasts from MMRM
[4] Factors/Covariates: treatment, visit, treatment-by-visit interaction, baseline value.
Clinical cut-off: 28JUN2021

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: FACT-LYM: Deterioration (MID=9) at EOT in Lymphoma subscale (LYMS)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk					Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergen ce Reason	95% Lower CL	95% Upper CL	Absolut e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relativ e Risk	Convergen ce Reason	95% Lower CL	95% Upper CL	
											Convergen ce criterion (GCONV=1E-8) satisfied .	0.31	1.87	-0.006	Algorithm converged .	-0.030	0.019	0.75	Algorithm converged .	0.31	1.78	0.5554	1.34	Algorithm converged .	0.56	3.19	
All	n/a	372	84.5	9	2.4	342	77.9	11	3.2	0.77																	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and EOT are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DPLYMSET_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 8:35

POPULATION: Global Population, Intent-To-Treat Population
ENDPOINT: FACT-LYM: Deterioration (MID=9) at FU Month 24 in Lymphoma subscale (LYMS)
MODEL: Stratified Analysis by IPI score, Bulky disease, Geographical region
STUDY: GO39942
Dichotomous Analysis (Efficacy)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=439)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							
		Patients		Patients with Event		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Cochran-Mantel-Haenszel)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
All	n/a	102	23.2	3	2.9	88	20.0	1	1.1	1.28		Convergence criterion (GCONV=1E-8) satisfied .	0.11	14.70		*	WARNING: The relative Hessian convergence criterion of 7.7566700014 is greater than the limit of 0.0001. The convergence is questionable.			2.15		Algorithm converged .	0.24	19.50	0.8424	0.47		Algorithm converged .	0.05	4.23																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	

* indicates convergence problem. Result is uninterpretable.
OR is computed by stratified analysis, RR and ARD by adjusted analysis
Only Patients with a value at Baseline and Follow-up Month 24 are included in analysis.
ETTV is mapped to the scheduled assessment that fits best after the last dose assessment (but will not be mapped to Follow-up assessments).
Clinical cut-off: 28JUN2021

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_BASE/prod/program/t_eff_resp.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_eff_resp_str_DPLYMSFU_IT_GLOBAL_28JUN2021_39942.xls
07MAR2022 9:42

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Any AEs
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-							
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk							
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason			95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason		95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL
											Convergence criterion (GCONV=1E-8) satisfied.							Algorithm converged.						Algorithm converged.							
All	n/a	435	100.0	426	97.9	438	100.0	431	98.4	0.77	Convergence criterion (GCONV=1E-8) satisfied.			0.28	2.08	-0.005	Algorithm converged.		-0.023	0.013	1.00	Algorithm converged.		0.98	1.01	0.6043	1.00	Algorithm converged.		0.99	1.02

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_AE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:03

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 3
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients with		Patients		Patients with				Odds Ratio				Absolute Risk Difference				Relative Risk									
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio			Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	435	100.0	125	28.7	438	100.0	113	25.8	1.16			Convergence criterion (GCONV=1E-8) satisfied.	0.86	1.56	0.029	Algorithm converged.	-0.030	0.088	1.11	Algorithm converged.	0.90	1.38	0.3304	0.90	Algorithm converged.	0.72	1.12	

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Only AEs of highest severity are counted.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_WGR3AE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:04

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 4
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients with		Patients		Patients with				Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk					
Nam e	Leve l	n	%	n	%	n	%	n	%	Odds Rati o		Convergence Reason	95% Lowe r CL	95% Uppe r CL	Absolu te Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relati ve Risk	Convergence Reason	95% Lowe r CL	95% Uppe r CL	p- value (Wald)	Relati ve Risk	Convergence Reason	95% Lowe r CL	95% Uppe r CL		
All	n/a	435	100.0	126	29.0	438	100.0	139	31.7	0.88		Convergence criterion (GCONV=1E-8) satisfied.	0.66	1.17	-0.028	Algorithm converged.	-0.089	0.033	0.91	Algorithm converged.	0.75	1.12	0.3739	1.10	Algorithm converged.	0.90	1.34		

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Only AEs of highest severity are counted.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_WGR4AE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:06

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-									
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk									
Nam	Leve	n	%	n	%	n	%	n	%	Odds Rati	Convergence Reason			95% Lower CL	95% Upper CL	Absolu	Convergence Reason		95% Lower CL	95% Upper CL	Relati	Convergence Reason		95% Lower CL	95% Upper CL	p-value (Wald)	Relati	Convergence Reason		95% Lower CL	95% Upper CL
All	n/a	435	100.0	264	60.7	438	100.0	262	59.8	1.04	Convergence criterion (GCONV=1E-8) satisfied.			0.79	1.36	0.009	Algorithm converged.		-0.056	0.074	1.01	Algorithm converged.		0.91	1.13	0.7923	0.99	Algorithm converged.		0.88	1.10

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Only AEs of highest severity are counted.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_WGR35AE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:01

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 5 (AEs leading to Death)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-										
		Patients		Patients with		Patients		Patients with				Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk										
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason		95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason		95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL			
												Convergence criterion (GCONV=1E-8) satisfied.			Algorithm converged.				Algorithm converged.				Algorithm converged.											
All	n/a	435	100.0	13	3.0	438	100.0	10	2.3	1.32		Convergence criterion (GCONV=1E-8) satisfied.		0.57	3.04	0.007		Algorithm converged.		-0.014	0.028	1.31		Algorithm converged.		0.58	2.95	0.5166	0.76		Algorithm converged.		0.34	1.72

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Only AEs of highest severity are counted.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_WGR5AE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:09

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs leading to any Study Treatment Discontinuation
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-							
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk									
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason			95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason		95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL
All	n/a	435	100.0	27	6.2	438	100.0	29	6.6	0.93	Convergence criterion (GCONV=1E-8) satisfied.			0.54	1.60	-0.004	Algorithm converged.		-0.037	0.028	0.94	Algorithm converged.		0.56	1.56	0.8029	1.07	Algorithm converged.		0.64	1.77

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_WDSTAE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:12

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Any SAEs
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-				
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk				
Nam	Leve	n	%	n	%	n	%	n	%	Odds Rati	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	435	100.0	148	34.0	438	100.0	134	30.6	1.17	Convergence criterion (GCONV=1E-8) satisfied.	0.88	1.55	0.034	Algorithm converged.	-0.028	0.096	1.11	Algorithm converged.	0.92	1.35	0.2791	0.90	Algorithm converged.	0.74	1.09

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_SAE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:12

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Any AEs
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

All

			Polatuzumab Vedotin +				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +					
			Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference						Relative Risk						Relative Risk			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL			
Blood and lymphatic system disorders		n/a	435	100.0	237	54.5	438	100.0	221	50.5	1.18	Convergence criterion (GCONV=1E-8) satisfied.	0.90	1.53	0.040	Algorithm converged.	-0.026	0.106	1.08	Algorithm converged.	0.95	1.23	0.2341	0.93	Algorithm converged.	0.82	1.05			
Blood and lymphatic system disorders	Agranulocytosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE			
Blood and lymphatic system disorders	Anaemia	n/a	435	100.0	125	28.7	438	100.0	114	26.0	1.15	Convergence criterion (GCONV=1E-8) satisfied.	0.85	1.54	0.027	Algorithm converged.	-0.032	0.086	1.10	Algorithm converged.	0.89	1.37	0.3700	0.91	Algorithm converged.	0.73	1.12			
Blood and lymphatic system disorders	Aplasia pure red cell	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83			
Blood and lymphatic system disorders	Cytopenia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE			
Blood and lymphatic system disorders	Erythropenia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE			
Blood and lymphatic system disorders	Febrile bone marrow aplasia	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83			

Blood and lymphatic system disorders	Febrile neutropenia	n/a	435	100.0	62	14.3	438	100.0	35	8.0	1.91	Convergence criterion (GCONV=1E-8) satisfied.	1.24	2.96	0.063	Algorithm converged.	0.021	0.104	1.78	Algorithm converged.	1.20	2.64	0.0039	0.56	Algorithm converged.	0.38	0.83
Blood and lymphatic system disorders	Hypofibrinogenaemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Blood and lymphatic system disorders	Increased tendency to bruise	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Blood and lymphatic system disorders	Iron deficiency anaemia	n/a	435	100.0	0	0.0	438	100.0	2	0.5		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Blood and lymphatic system disorders	Leukocytosis	n/a	435	100.0	0	0.0	438	100.0	3	0.7		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Blood and lymphatic system disorders	Leukopenia	n/a	435	100.0	35	8.0	438	100.0	37	8.4	0.95	Convergence criterion (GCONV=1E-8) satisfied.	0.59	1.54	-0.004	Algorithm converged.	-0.041	0.032	0.95	Algorithm converged.	0.61	1.48	0.8293	1.05	Algorithm converged.	0.67	1.63
Blood and lymphatic system disorders	Lymph node pain	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Blood and lymphatic system disorders	Lymphadenopathy	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Blood and lymphatic system disorders	Lymphopenia	n/a	435	100.0	11	2.5	438	100.0	15	3.4	0.73	Convergence criterion (GCONV=1E-8) satisfied.	0.33	1.61	-0.009	Algorithm converged.	-0.031	0.014	0.74	Algorithm converged.	0.34	1.59	0.4381	1.35	Algorithm converged.	0.63	2.92
Blood and lymphatic system disorders	Neutropenia	n/a	435	100.0	134	30.8	438	100.0	143	32.6	0.92	Convergence criterion (GCONV=1E-8) satisfied.	0.69	1.22	-0.018	Algorithm converged.	-0.080	0.043	0.94	Algorithm converged.	0.78	1.15	0.5585	1.06	Algorithm converged.	0.87	1.29
Blood and lymphatic system disorders	Neutrophilia	n/a	435	100.0	0	0.0	438	100.0	3	0.7		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Blood and lymphatic system disorders	Pancytopenia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Blood and lymphatic system disorders	Splenic infarction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Blood and lymphatic system disorders	Thrombocytopenia	n/a	435	100.0	39	9.0	438	100.0	41	9.4	0.95	Convergence criterion (GCONV=1E-8) satisfied.	0.60	1.51	-0.004		Algorithm converged.	-0.042	0.034	0.96	Algorithm converged.	0.63	1.45	0.8396	1.04	Algorithm converged.	0.69	1.59
Cardiac disorders		n/a	435	100.0	34	7.8	438	100.0	55	12.6	0.59	Convergence criterion (GCONV=1E-8) satisfied.	0.38	0.93	-0.047		Algorithm converged.	-0.087	-0.007	0.62	Algorithm converged.	0.41	0.93	0.0223	1.61	Algorithm converged.	1.07	2.41
Cardiac disorders	Acute myocardial infarction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Cardiac disorders	Angina pectoris	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Cardiac disorders	Arrhythmia	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Atrial fibrillation	n/a	435	100.0	5	1.1	438	100.0	8	1.8	0.63	Convergence criterion (GCONV=1E-8) satisfied.	0.20	1.93	-0.007	Algorithm converged.	-0.023	0.009	0.63	Algorithm converged.	0.21	1.91	0.4133	1.59	Algorithm converged.	0.52	4.82
Cardiac disorders	Atrial flutter	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Cardiac disorders	Atrioventricular block	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Atrioventricular block complete	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Atrioventricular block first degree	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Bradycardia	n/a	435	100.0	2	0.5	438	100.0	4	0.9	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.09	2.75	-0.005	Algorithm converged.	-0.015	0.006	0.50	Algorithm converged.	0.09	2.73	0.4267	1.99	Algorithm converged.	0.37	10.79
Cardiac disorders	Cardiac disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Cardiac disorders	Cardiac dysfunction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Cardiac failure	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Cardiac disorders	Cardiac failure congestive	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Cardiac disorders	Cardiomyopathy	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Cardiac disorders	Cardiopulmonary failure	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Diastolic dysfunction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Left ventricular dysfunction	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87

Cardiac disorders	Myocardial infarction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Palpitations	n/a	435	100.0	2	0.5	438	100.0	9	2.1	0.22	Convergence criterion (GCONV=1E-8) satisfied.	0.05	1.02	-0.016		Algorithm converged.	-0.031	-0.001	0.22	Algorithm converged.	0.05	1.03	0.0545	4.47	Algorithm converged.	0.97	20.57
Cardiac disorders	Pericardial effusion	n/a	435	100.0	0	0.0	438	100.0	3	0.7		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Pericarditis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Sinus tachycardia	n/a	435	100.0	4	0.9	438	100.0	3	0.7	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.30	6.05	0.002		Algorithm converged.	-0.009	0.014	1.34	Algorithm converged.	0.30	5.96	0.6986	0.74	Algorithm converged.	0.17	3.31
Cardiac disorders	Supraventricular extrasystoles	n/a	435	100.0	0	0.0	438	100.0	2	0.5		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Cardiac disorders	Supraventricular tachycardia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Tachycardia	n/a	435	100.0	11	2.5	438	100.0	14	3.2	0.79	Convergence criterion (GCONV=1E-8) satisfied.	0.35	1.75	-0.007		Algorithm converged.	-0.029	0.015	0.79	Algorithm converged.	0.36	1.72	0.5553	1.26	Algorithm converged.	0.58	2.75
Cardiac disorders	Ventricular extrasystoles	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Congenital, familial and genetic disorders		n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Congenital, familial and genetic disorders	Aplasia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Congenital, familial and genetic disorders	Dacryocystocoele	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Congenital, familial and genetic disorders	Porokeratosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Congenital, familial and genetic disorders	Pyloric stenosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Ear and labyrinth disorders		n/a	435	100.0	29	6.7	438	100.0	22	5.0	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.76	2.39	0.016		Algorithm converged.	-0.015	0.048	1.33	Algorithm converged.	0.77	2.27	0.3024	0.75	Algorithm converged.	0.44	1.29
Ear and labyrinth disorders	Deafness	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Ear and labyrinth disorders	Deafness unilateral	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Ear and labyrinth disorders	Ear congestion	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Ear and labyrinth disorders	Ear discomfort	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Ear and labyrinth disorders	Ear disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Ear and labyrinth disorders	Ear pain	n/a	435	100.0	5	1.1	438	100.0	5	1.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.29	3.50	0.000		Algorithm converged.	-0.014	0.014	1.01	Algorithm converged.	0.29	3.45	0.9913	0.99	Algorithm converged.	0.29	3.41
Ear and labyrinth disorders	Ear pruritus	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005		Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
Ear and labyrinth disorders	Hypacusis	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Ear and labyrinth disorders	Meniere's disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Ear and labyrinth disorders	Mixed deafness	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Ear and labyrinth disorders	Paraesthesia ear	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Ear and labyrinth disorders	Tinnitus	n/a	435	100.0	12	2.8	438	100.0	5	1.1	2.46	Convergence criterion (GCONV=1E-8) satisfied.	0.86	7.03	0.016	Algorithm converged.	-0.002	0.034	2.42	Algorithm converged.	0.86	6.80	0.0947	0.41	Algorithm converged.	0.15	1.16
Ear and labyrinth disorders	Tympanic membrane perforation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Ear and labyrinth disorders	Vertigo	n/a	435	100.0	7	1.6	438	100.0	3	0.7	2.37	Convergence criterion (GCONV=1E-8) satisfied.	0.61	9.23	0.009	Algorithm converged.	-0.005	0.023	2.35	Algorithm converged.	0.61	9.03	0.2136	0.43	Algorithm converged.	0.11	1.64
Endocrine disorders		n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69	Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005	Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
Endocrine disorders	Adrenal insufficiency	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Endocrine disorders	Diabetes insipidus	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Endocrine disorders	Glucocorticoid deficiency	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Endocrine disorders	Hyperthyroidism	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Endocrine disorders	Hypopituitarism	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Endocrine disorders	Hypothyroidism	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Endocrine disorders	Steroid withdrawal syndrome	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders		n/a	435	100.0	60	13.8	438	100.0	49	11.2	1.27	Convergence criterion (GCONV=1E-8) satisfied.	0.85	1.90	0.026	Algorithm converged.	-0.018	0.070	1.23	Algorithm converged.	0.87	1.76	0.2454	0.81	Algorithm converged.	0.57	1.15
Eye disorders	Angle closure glaucoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Asthenopia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Blepharitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Eye disorders	Blindness	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Eye disorders	Cataract	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007	Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Eye disorders	Chalazion	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Conjunctival haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Conjunctival hyperaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Conjunctivitis allergic	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Dacryostenosis acquired	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Eye disorders	Diplopia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Dry eye	n/a	435	100.0	12	2.8	438	100.0	10	2.3	1.21	Convergence criterion (GCONV=1E-8) satisfied.	0.52	2.84	0.005		Algorithm converged.	-0.016	0.026	1.21	Algorithm converged.	0.53	2.77	0.6545	0.83	Algorithm converged.	0.36	1.90
Eye disorders	Ectropion	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Erythema of eyelid	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Exophthalmos	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Eye discharge	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Eye disorders	Eye inflammation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Eye irritation	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives , or the variance function.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Eye movement disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Eye pain	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Eye disorders	Eye pruritus	n/a	435	100.0	2	0.5	438	100.0	5	1.1	0.40	Convergence criterion (GCONV=1E-8) satisfied.	0.08	2.07	-0.007		Algorithm converged.	-0.019	0.005	0.40	Algorithm converged.	0.08	2.06	0.2755	2.48	Algorithm converged.	0.48	12.73
Eye disorders	Eyelid cyst	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Eyelid irritation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Eye disorders	Eyelid oedema	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Eye disorders	Eyelid ptosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Foreign body sensation in eyes	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Glaucoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Inflammation of lacrimal passage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Lacrimation increased	n/a	435	100.0	11	2.5	438	100.0	9	2.1	1.24	Convergence criterion (GCONV=1E-8) satisfied.	0.51	3.01	0.005	Algorithm converged.	-0.015	0.025	1.23	Algorithm converged.	0.52	2.94	0.6404	0.81	Algorithm converged.	0.34	1.94

Eye disorders	Mydriasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Ocular hyperaemia	n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005	Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70	
Eye disorders	Photophobia	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Retinal vein occlusion	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Retinopathy	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Rhegmatogenous retinal detachment	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Swelling of eyelid	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Eye disorders	Uveitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Vision blurred	n/a	435	100.0	8	1.8	438	100.0	12	2.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.27	1.64	-0.009	Algorithm converged.	-0.029	0.011	0.67	Algorithm converged.	0.28	1.63	0.3772	1.49	Algorithm converged.	0.62	3.61	
Eye disorders	Visual acuity reduced	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders	Visual field defect	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Eye disorders	Visual impairment	n/a	435	100.0	5	1.1	438	100.0	1	0.2	5.08	Convergence criterion (GCONV=1E-8) satisfied.	0.59	43.67	0.009	Algorithm converged.	-0.002	0.020	5.03	Algorithm converged.	0.59	42.92	0.1393	0.20	Algorithm converged.	0.02	1.69	
Eye disorders	Vitreous detachment	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Eye disorders	Vitreous floaters	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Vitreous haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Eye disorders	Xerophthalmia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders		n/a	435	100.0	331	76.1	438	100.0	315	71.9	1.24	Convergence criterion (GCONV=1E-8) satisfied.	0.92	1.68	0.042		Algorithm converged.	-0.016	0.100	1.06	Algorithm converged.	0.98	1.14	0.1602	0.95	Algorithm converged.	0.87	1.02
Gastrointestinal disorders	Abdominal discomfort	n/a	435	100.0	4	0.9	438	100.0	5	1.1	0.80	Convergence criterion (GCONV=1E-8) satisfied.	0.21	3.01	-0.002		Algorithm converged.	-0.016	0.011	0.81	Algorithm converged.	0.22	2.98	0.7459	1.24	Algorithm converged.	0.34	4.59

Gastrointestinal disorders	Abdominal distension	n/a	435	100.0	5	1.1	438	100.0	6	1.4	0.84	Convergence criterion (GCONV=1E-8) satisfied.	0.25	2.76	-0.002	Algorithm converged.	-0.017	0.013	0.84	Algorithm converged.	0.26	2.73	0.7706	1.19	Algorithm converged.	0.37	3.88
Gastrointestinal disorders	Abdominal hernia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Abdominal pain	n/a	435	100.0	43	9.9	438	100.0	40	9.1	1.09	Convergence criterion (GCONV=1E-8) satisfied.	0.69	1.72	0.008	Algorithm converged.	-0.031	0.046	1.08	Algorithm converged.	0.72	1.63	0.7047	0.92	Algorithm converged.	0.61	1.39
Gastrointestinal disorders	Abdominal pain lower	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Gastrointestinal disorders	Abdominal pain upper	n/a	435	100.0	19	4.4	438	100.0	21	4.8	0.91	Convergence criterion (GCONV=1E-8) satisfied.	0.48	1.71	-0.004	Algorithm converged.	-0.032	0.023	0.91	Algorithm converged.	0.50	1.67	0.7631	1.10	Algorithm converged.	0.60	2.01
Gastrointestinal disorders	Abdominal rigidity	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Abdominal wall haematoma	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Anal fissure	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Anal fissure haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Anal fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Anal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Anal incontinence	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Anal pruritus	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Anal stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Angular cheilitis	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Anorectal discomfort	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Aphthous ulcer	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007	Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Gastrointestinal disorders	Cheilitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Colitis	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005	Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
Gastrointestinal disorders	Constipation	n/a	435	100.0	125	28.7	438	100.0	127	29.0	0.99	Convergence criterion (GCONV=1E-8) satisfied.	0.74	1.32	-0.003	Algorithm converged.	-0.063	0.058	0.99	Algorithm converged.	0.80	1.22	0.9325	1.01	Algorithm converged.	0.82	1.24
Gastrointestinal disorders	Dental caries	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Gastrointestinal disorders	Diarrhoea	n/a	435	100.0	134	30.8	438	100.0	88	20.1	1.77	Convergence criterion (GCONV=1E-8) satisfied.	1.30	2.41	0.107	Algorithm converged.	0.050	0.164	1.53	Algorithm converged.	1.21	1.94	0.0003	0.65	Algorithm converged.	0.52	0.82
Gastrointestinal disorders	Diverticulum	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Dry mouth	n/a	435	100.0	10	2.3	438	100.0	16	3.7	0.62	Convergence criterion (GCONV=1E-8) satisfied.	0.28	1.38	-0.014	Algorithm converged.	-0.036	0.009	0.63	Algorithm converged.	0.29	1.37	0.2438	1.59	Algorithm converged.	0.73	3.46
Gastrointestinal disorders	Duodenitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Dyspepsia	n/a	435	100.0	20	4.6	438	100.0	19	4.3	1.06	Convergence criterion (GCONV=1E-8) satisfied.	0.56	2.02	0.003	Algorithm converged.	-0.025	0.030	1.06	Algorithm converged.	0.57	1.96	0.8526	0.94	Algorithm converged.	0.51	1.74
Gastrointestinal disorders	Dysphagia	n/a	435	100.0	11	2.5	438	100.0	8	1.8	1.39	Convergence criterion (GCONV=1E-8) satisfied.	0.56	3.50	0.007	Algorithm converged.	-0.012	0.026	1.38	Algorithm converged.	0.56	3.41	0.4791	0.72	Algorithm converged.	0.29	1.78

Gastrointestinal disorders	Enteritis	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Epigastric discomfort	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Eructation	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Faecaloma	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Faeces discoloured	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Faeces soft	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Flatulence	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69	Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005	Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
Gastrointestinal disorders	Gastric ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Gastritis	n/a	435	100.0	2	0.5	438	100.0	4	0.9	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.09	2.75	-0.005	Algorithm converged.	-0.015	0.006	0.50	Algorithm converged.	0.09	2.73	0.4267	1.99	Algorithm converged.	0.37	10.79
Gastrointestinal disorders	Gastrointestinal haemorrhage	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Gastrointestinal disorders	Gastrointestinal pain	n/a	435	100.0	3	0.7	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastrointestinal scarring	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Gastrointestinal toxicity	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	435	100.0	16	3.7	438	100.0	17	3.9	0.95	Convergence criterion (GCONV=1E-8) satisfied.	0.47	1.90	-0.002	Algorithm converged.	-0.027	0.023	0.95	Algorithm converged.	0.49	1.85	0.8750	1.06	Algorithm converged.	0.54	2.06
Gastrointestinal disorders	Gingival bleeding	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Gingival erythema	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Gingival pain	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Gastrointestinal disorders	Gingival swelling	n/a	435	100.0	0	0.0	438	100.0	2	0.5		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Glossodynia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Haematemesis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Haematochezia	n/a	435	100.0	3	0.7	438	100.0	4	0.9	0.75	Convergence criterion (GCONV=1E-8) satisfied.	0.17	3.39	-0.002		Algorithm converged.	-0.014	0.010	0.76	Algorithm converged.	0.17	3.35	0.7120	1.32	Algorithm converged.	0.30	5.88
Gastrointestinal disorders	Haemorrhoidal haemorrhage	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Gastrointestinal disorders	Haemorrhoids	n/a	435	100.0	12	2.8	438	100.0	12	2.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.45	2.27	0.000		Algorithm converged.	-0.022	0.022	1.01	Algorithm converged.	0.46	2.22	0.9864	0.99	Algorithm converged.	0.45	2.19
Gastrointestinal disorders	Haemorrhoids thrombosed	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Hiatus hernia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Hyperaesthesia teeth	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Ileus	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Gastrointestinal disorders	Impaired gastric emptying	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Inguinal hernia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Intestinal obstruction	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Intestinal perforation	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Gastrointestinal disorders	Intra-abdominal haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Large intestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Large intestine polyp	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Lip pain	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Lip scab	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Lip ulceration	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Loose tooth	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Malpositioned teeth	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Melaena	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Gastrointestinal disorders	Mouth haemorrhage	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Mouth swelling	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Mouth ulceration	n/a	435	100.0	5	1.1	438	100.0	9	2.1	0.55	Convergence criterion (GCONV=1E-8) satisfied.	0.18	1.67	-0.009	Algorithm converged.	-0.026	0.008	0.56	Algorithm converged.	0.19	1.66	0.2941	1.79	Algorithm converged.	0.60	5.29
Gastrointestinal disorders	Nausea	n/a	435	100.0	181	41.6	438	100.0	161	36.8	1.23	Convergence criterion (GCONV=1E-8) satisfied.	0.93	1.61	0.049	Algorithm converged.	-0.016	0.113	1.13	Algorithm converged.	0.96	1.34	0.1428	0.88	Algorithm converged.	0.75	1.04

Gastrointestinal disorders	Necrotising colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Neutropenic colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Noninfective gingivitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Obstruction gastric	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Odynophagia	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Gastrointestinal disorders	Oedema mouth	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Oesophageal achalasia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Oesophageal discomfort	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Gastrointestinal disorders	Oesophageal pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Oesophageal stenosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Oesophagitis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Gastrointestinal disorders	Oral discomfort	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Oral dysaesthesia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Oral pain	n/a	435	100.0	7	1.6	438	100.0	4	0.9	1.77	Convergence criterion (GCONV=1E-8) satisfied.	0.52	6.11	0.007	Algorithm converged.	-0.008	0.022	1.76	Algorithm converged.	0.52	5.98	0.3633	0.57	Algorithm converged.	0.17	1.92
Gastrointestinal disorders	Oral pruritus	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Pancreatic disorder	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Pancreatic failure	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Pancreatitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Paraesthesia oral	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Gastrointestinal disorders	Periodontal disease	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Post-tussive vomiting	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Proctalgia	n/a	435	100.0	6	1.4	438	100.0	3	0.7	2.03		Convergence criterion (GCONV=1E-8) satisfied.	0.50	8.16	0.007		Algorithm converged.	-0.006	0.020	2.01	Algorithm converged.	0.51	8.00	0.3200	0.50	Algorithm converged.	0.12	1.97
Gastrointestinal disorders	Proctitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Rectal haemorrhage	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69		Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005		Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
Gastrointestinal disorders	Retching	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Small intestinal obstruction	n/a	435	100.0	0	0.0	438	100.0	5	1.1		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Small intestinal perforation	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Stomatitis	n/a	435	100.0	42	9.7	438	100.0	30	6.8	1.45		Convergence criterion (GCONV=1E-8) satisfied.	0.89	2.37	0.028		Algorithm converged.	-0.008	0.065	1.41	Algorithm converged.	0.90	2.21	0.1342	0.71	Algorithm converged.	0.45	1.11

Gastrointestinal disorders	Subileus	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Swollen tongue	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Tongue blistering	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Tongue coated	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Tongue discolouration	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Tongue pigmentation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Tongue ulceration	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Tooth loss	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Toothache	n/a	435	100.0	4	0.9	438	100.0	5	1.1	0.80	Convergence criterion (GCONV=1E-8) satisfied.	0.21	3.01	-0.002		Algorithm converged.	-0.016	0.011	0.81	Algorithm converged.	0.22	2.98	0.7459	1.24	Algorithm converged.	0.34	4.59
Gastrointestinal disorders	Umbilical hernia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Upper gastrointestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Vomiting	n/a	435	100.0	65	14.9	438	100.0	63	14.4	1.05	Convergence criterion (GCONV=1E-8) satisfied.	0.72	1.52	0.006		Algorithm converged.	-0.041	0.053	1.04	Algorithm converged.	0.75	1.43	0.8154	0.96	Algorithm converged.	0.70	1.33
General disorders and administration site conditions		n/a	435	100.0	271	62.3	438	100.0	272	62.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.77	1.33	0.002		Algorithm converged.	-0.062	0.066	1.00	Algorithm converged.	0.90	1.11	0.9518	1.00	Algorithm converged.	0.90	1.11
General disorders and administration site conditions	Application site pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Asthenia	n/a	435	100.0	53	12.2	438	100.0	53	12.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.67	1.51	0.001		Algorithm converged.	-0.042	0.044	1.01	Algorithm converged.	0.70	1.44	0.9699	0.99	Algorithm converged.	0.70	1.42
General disorders and administration site conditions	Cardiac death	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

General disorders and administration site conditions	Catheter site bruise	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Catheter site erythema	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	Catheter site haemorrhage	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
General disorders and administration site conditions	Catheter site induration	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Catheter site inflammation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Catheter site oedema	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

General disorders and administration site conditions	Catheter site pain	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
General disorders and administration site conditions	Catheter site pruritus	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Catheter site related reaction	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Chest discomfort	n/a	435	100.0	11	2.5	438	100.0	7	1.6	1.60	Convergence criterion (GCONV=1E-8) satisfied.	0.61	4.16	0.009	Algorithm converged.	-0.010	0.028	1.58	Algorithm converged.	0.62	4.04	0.3378	0.63	Algorithm converged.	0.25	1.62
General disorders and administration site conditions	Chest pain	n/a	435	100.0	13	3.0	438	100.0	16	3.7	0.81	Convergence criterion (GCONV=1E-8) satisfied.	0.39	1.71	-0.007	Algorithm converged.	-0.030	0.017	0.82	Algorithm converged.	0.40	1.68	0.5846	1.22	Algorithm converged.	0.60	2.51
General disorders and administration site conditions	Chills	n/a	435	100.0	20	4.6	438	100.0	23	5.3	0.87	Convergence criterion (GCONV=1E-8) satisfied.	0.47	1.61	-0.007	Algorithm converged.	-0.035	0.022	0.88	Algorithm converged.	0.49	1.57	0.6558	1.14	Algorithm converged.	0.64	2.05

General disorders and administration site conditions	Cyst	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Death	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007	Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21	
General disorders and administration site conditions	Device related thrombosis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
General disorders and administration site conditions	Discomfort	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83	
General disorders and administration site conditions	Face oedema	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005	Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53	
General disorders and administration site conditions	Facial pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Fatigue	n/a	435	100.0	112	25.7	438	100.0	116	26.5	0.96	Convergence criterion (GCONV=1E-8) satisfied.	0.71	1.30	-0.007	Algorithm converged.	-0.066	0.051	0.97	Algorithm converged.	0.78	1.22	0.8043	1.03	Algorithm converged.	0.82	1.29	

General disorders and administration site conditions	Feeling cold	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Feeling hot	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
General disorders and administration site conditions	Gait disturbance	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	General physical health deterioration	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
General disorders and administration site conditions	Hernia pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Hunger	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Hyperthermia	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005		Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
General disorders and administration site conditions	Hypothermia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

General disorders and administration site conditions	Ill-defined disorder	n/a	435	100.0	4	0.9	438	100.0	3	0.7	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.30	6.05	0.002	Algorithm converged.	-0.009	0.014	1.34	Algorithm converged.	0.30	5.96	0.6986	0.74	Algorithm converged.	0.17	3.31
General disorders and administration site conditions	Impaired healing	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Inflammatory pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Influenza like illness	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
General disorders and administration site conditions	Infusion site extravasation	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
General disorders and administration site conditions	Infusion site induration	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

General disorders and administration site conditions	Infusion site pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Injection site extravasation	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
General disorders and administration site conditions	Injection site haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Injection site pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
General disorders and administration site conditions	Injection site pruritus	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
General disorders and administration site conditions	Injection site reaction	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005		Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
General disorders and administration site conditions	Localised oedema	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	Malaise	n/a	435	100.0	22	5.1	438	100.0	23	5.3	0.96	Convergence criterion (GCONV=1E-8) satisfied.	0.53	1.75	-0.002		Algorithm converged.	-0.031	0.027	0.96	Algorithm converged.	0.55	1.70	0.8970	1.04	Algorithm converged.	0.59	1.83

General disorders and administration site conditions	Mucosal inflammation	n/a	435	100.0	15	3.4	438	100.0	25	5.7	0.59	Convergence criterion (GCONV=1E-8) satisfied.	0.31	1.14	-0.023	Algorithm converged.	-0.050	0.005	0.60	Algorithm converged.	0.32	1.13	0.1147	1.66	Algorithm converged.	0.88	3.10
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Nodule	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.		NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Non-cardiac chest pain	n/a	435	100.0	5	1.1	438	100.0	8	1.8	0.63	Convergence criterion (GCONV=1E-8) satisfied.	0.20	1.93	-0.007	Algorithm converged.	-0.023	0.009	0.63	Algorithm converged.	0.21	1.91	0.4133	1.59	Algorithm converged.	0.52	4.82
General disorders and administration site conditions	Oedema	n/a	435	100.0	7	1.6	438	100.0	4	0.9	1.77	Convergence criterion (GCONV=1E-8) satisfied.	0.52	6.11	0.007	Algorithm converged.	-0.008	0.022	1.76	Algorithm converged.	0.52	5.98	0.3633	0.57	Algorithm converged.	0.17	1.92
General disorders and administration site conditions	Oedema peripheral	n/a	435	100.0	42	9.7	438	100.0	37	8.4	1.16	Convergence criterion (GCONV=1E-8) satisfied.	0.73	1.84	0.012	Algorithm converged.	-0.026	0.050	1.14	Algorithm converged.	0.75	1.74	0.5344	0.87	Algorithm converged.	0.57	1.33
General disorders and administration site conditions	Pain	n/a	435	100.0	11	2.5	438	100.0	12	2.7	0.92	Convergence criterion (GCONV=1E-8) satisfied.	0.40	2.11	-0.002	Algorithm converged.	-0.023	0.019	0.92	Algorithm converged.	0.41	2.07	0.8457	1.08	Algorithm converged.	0.48	2.43
General disorders and administration site conditions	Peripheral swelling	n/a	435	100.0	8	1.8	438	100.0	4	0.9	2.03	Convergence criterion (GCONV=1E-8) satisfied.	0.61	6.80	0.009	Algorithm converged.	-0.006	0.025	2.01	Algorithm converged.	0.61	6.64	0.2501	0.50	Algorithm converged.	0.15	1.64
General disorders and administration site conditions	Physical deconditioning	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Pyrexia	n/a	435	100.0	68	15.6	438	100.0	55	12.6	1.29	Convergence criterion (GCONV=1E-8) satisfied.	0.88	1.89	0.031	Algorithm converged.	-0.015	0.077	1.24	Algorithm converged.	0.90	1.73	0.1929	0.80	Algorithm converged.	0.58	1.12
General disorders and administration site conditions	Scar inflammation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

General disorders and administration site conditions	Secretion discharge	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Sensation of foreign body	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Swelling	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	Swelling face	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	Ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Vaccination site pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

General disorders and administration site conditions	Vascular device occlusion	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Vascular stent thrombosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
General disorders and administration site conditions	Xerosis	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
												Convergence criterion (GCONV=1E-8) satisfied.																
Hepatobiliary disorders		n/a	435	100.0	14	3.2	438	100.0	8	1.8	1.79	Convergence criterion (GCONV=1E-8) satisfied.	0.74	4.30	0.014		Algorithm converged.	-0.007	0.035	1.76	Algorithm converged.	0.75	4.16	0.1959	0.57	Algorithm converged.	0.24	1.34
Hepatobiliary disorders	Bile duct stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
																	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.			NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Bile duct stone	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				*				NE	Algorithm converged.			NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Biliary colic	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00		

Hepatobiliary disorders	Biliary obstruction	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Cholangitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Hepatobiliary disorders	Cholecystitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Hepatobiliary disorders	Cholecystitis acute	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Cholecystitis chronic	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Hepatobiliary disorders	Cholelithiasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Hepatobiliary disorders	Cholestasis	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Hepatic cytolysis	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Hepatic function abnormal	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007	Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Hepatobiliary disorders	Hepatic pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Hepatobiliary disorders	Hepatic steatosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Hyperbilirubinaemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Immune system disorders		n/a	435	100.0	13	3.0	438	100.0	14	3.2	0.93	Convergence criterion (GCONV=1E-8) satisfied.	0.43	2.01	-0.002	Algorithm converged.	-0.025	0.021	0.93	Algorithm converged.	0.44	1.97	0.8593	1.07	Algorithm converged.	0.51	2.25
Immune system disorders	Contrast media allergy	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Immune system disorders	Drug hypersensitivity	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Immune system disorders	Food allergy	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Immune system disorders	Haemophagocytic lymphohistiocytosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99		Algorithm converged.	0.00	NE	
Immune system disorders	Hypersensitivity	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000		Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Immune system disorders	Hypogammaglobulin aemia	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69		Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005		Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
Immune system disorders	Sarcoidosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Immune system disorders	Seasonal allergy	n/a	435	100.0	2	0.5	438	100.0	4	0.9	0.50		Convergence criterion (GCONV=1E-8) satisfied.	0.09	2.75	-0.005		Algorithm converged.	-0.015	0.006	0.50	Algorithm converged.	0.09	2.73	0.4267	1.99	Algorithm converged.	0.37	10.79
Infections and infestations		n/a	435	100.0	216	49.7	438	100.0	187	42.7	1.32		Convergence criterion (GCONV=1E-8) satisfied.	1.01	1.73	0.070		Algorithm converged.	0.004	0.136	1.16	Algorithm converged.	1.01	1.34	0.0398	0.86	Algorithm converged.	0.74	0.99

Infections and infestations	Abdominal abscess	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Abdominal infection	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Abscess	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Actinomycotic abdominal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Acute sinusitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Anal fistula infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Anorectal infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Appendicitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Aspergillus infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Atypical pneumonia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Bacteraemia	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Infections and infestations	Bacterial infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Bacteriuria	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Bordetella infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Bronchiolitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Bronchitis	n/a	435	100.0	9	2.1	438	100.0	13	3.0	0.69	Convergence criterion (GCONV=1E-8) satisfied.	0.29	1.63	-0.009		Algorithm converged.	-0.030	0.012	0.70	Algorithm converged.	0.30	1.61	0.3995	1.43	Algorithm converged.	0.62	3.32
Infections and infestations	Bronchitis bacterial	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Bronchopulmonary aspergillosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Campylobacter gastroenteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Candida infection	n/a	435	100.0	4	0.9	438	100.0	9	2.1	0.44	Convergence criterion (GCONV=1E-8) satisfied.	0.14	1.45	-0.011		Algorithm converged.	-0.027	0.005	0.45	Algorithm converged.	0.14	1.44	0.1781	2.23	Algorithm converged.	0.69	7.20
Infections and infestations	Catheter site cellulitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Catheter site infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Cellulitis	n/a	435	100.0	9	2.1	438	100.0	5	1.1	1.83	Convergence criterion (GCONV=1E-8) satisfied.	0.61	5.50	0.009		Algorithm converged.	-0.007	0.026	1.81	Algorithm converged.	0.61	5.36	0.2828	0.55	Algorithm converged.	0.19	1.63

Infections and infestations	Cervicitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Clostridial infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Clostridium colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Clostridium difficile colitis	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Clostridium difficile infection	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Colonic abscess	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Conjunctivitis	n/a	435	100.0	10	2.3	438	100.0	5	1.1	2.04	Convergence criterion (GCONV=1E-8) satisfied.	0.69	6.01	0.012	Algorithm converged.	-0.006	0.029	2.01	Algorithm converged.	0.69	5.84	0.1978	0.50	Algorithm converged.	0.17	1.44
Infections and infestations	Conjunctivitis bacterial	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Coronavirus infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Cystitis	n/a	435	100.0	1	0.2	438	100.0	6	1.4	0.17	Convergence criterion (GCONV=1E-8) satisfied.	0.02	1.38	-0.011	Algorithm converged.	-0.023	0.000	0.17	Algorithm converged.	0.02	1.39	0.0978	5.96	Algorithm converged.	0.72	49.29
Infections and infestations	Cytomegalovirus enteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Cytomegalovirus infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Cytomegalovirus reactivation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Device related infection	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17

Infections and infestations	Device related sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Diarrhoea infectious	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Infections and infestations	Diverticulitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Ear infection	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000		Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Infections and infestations	Enteritis infectious	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932836 3 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Enterobacter infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Erysipelas	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia bacteraemia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Infections and infestations	Escherichia infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia sepsis	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Eye infection	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Infections and infestations	Eyelid infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Folliculitis	n/a	435	100.0	4	0.9	438	100.0	4	0.9	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.25	4.05	0.000	Algorithm converged.	-0.013	0.013	1.01	Algorithm converged.	0.25	4.00	0.9922	0.99	Algorithm converged.	0.25	3.95
Infections and infestations	Fungal infection	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Infections and infestations	Fungal skin infection	n/a	435	100.0	5	1.1	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Furuncle	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Gastroenteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Gastroenteritis viral	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932836 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Gastrointestinal candidiasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Genital herpes	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Genital infection fungal	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Genitourinary tract infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Gingival abscess	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Gingivitis	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83	
Infections and infestations	Groin infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Helicobacter gastritis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46	

Infections and infestations	Hepatitis B	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Herpes simplex	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Infections and infestations	Herpes simplex reactivation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Herpes virus infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Herpes zoster	n/a	435	100.0	6	1.4	438	100.0	4	0.9	1.52	Convergence criterion (GCONV=1E-8) satisfied.	0.43	5.41	0.005		Algorithm converged.	-0.009	0.019	1.51	Algorithm converged.	0.43	5.31	0.5207	0.66	Algorithm converged.	0.19	2.33
Infections and infestations	Hordeolum	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Infection	n/a	435	100.0	8	1.8	438	100.0	4	0.9	2.03	Convergence criterion (GCONV=1E-8) satisfied.	0.61	6.80	0.009	Algorithm converged.	-0.006	0.025	2.01	Algorithm converged.	0.61	6.64	0.2501	0.50	Algorithm converged.	0.15	1.64
Infections and infestations	Influenza	n/a	435	100.0	8	1.8	438	100.0	3	0.7	2.72	Convergence criterion (GCONV=1E-8) satisfied.	0.72	10.31	0.012	Algorithm converged.	-0.003	0.026	2.69	Algorithm converged.	0.72	10.05	0.1426	0.37	Algorithm converged.	0.10	1.39
Infections and infestations	Intervertebral discitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Keratitis viral	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Klebsiella sepsis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Large intestine infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Laryngitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Localised infection	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Infections and infestations	Lower respiratory tract infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Lymph gland infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Mediastinitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Mycobacterial infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Infections and infestations	Nail infection	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89	
Infections and infestations	Nasopharyngitis	n/a	435	100.0	18	4.1	438	100.0	18	4.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.52	1.96	0.000	Algorithm converged.	-0.026	0.027	1.01	Algorithm converged.	0.53	1.91	0.9832	0.99	Algorithm converged.	0.52	1.88	
Infections and infestations	Neutropenic sepsis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46	
Infections and infestations	Oesophageal candidiasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Onychomycosis	n/a	435	100.0	4	0.9	438	100.0	6	1.4	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.19	2.38	-0.005	Algorithm converged.	-0.019	0.010	0.67	Algorithm converged.	0.19	2.36	0.5347	1.49	Algorithm converged.	0.42	5.24	

Infections and infestations	Oral candidiasis	n/a	435	100.0	8	1.8	438	100.0	9	2.1	0.89	Convergence criterion (GCONV=1E-8) satisfied.	0.34	2.34	-0.002	Algorithm converged.	-0.020	0.016	0.90	Algorithm converged.	0.35	2.30	0.8177	1.12	Algorithm converged.	0.44	2.87
Infections and infestations	Oral fungal infection	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Infections and infestations	Oral herpes	n/a	435	100.0	7	1.6	438	100.0	7	1.6	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.35	2.90	0.000	Algorithm converged.	-0.017	0.017	1.01	Algorithm converged.	0.36	2.85	0.9897	0.99	Algorithm converged.	0.35	2.81
Infections and infestations	Osteomyelitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Otitis media	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Infections and infestations	Papilloma viral infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Paronychia	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83

Infections and infestations	Periodontitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Peritonitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Pharyngitis	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Infections and infestations	Pneumonia	n/a	435	100.0	32	7.4	438	100.0	28	6.4	1.16	Convergence criterion (GCONV=1E-8) satisfied.	0.69	1.97	0.010	Algorithm converged.	-0.024	0.043	1.15	Algorithm converged.	0.71	1.88	0.5740	0.87	Algorithm converged.	0.53	1.42
Infections and infestations	Pneumonia bacterial	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Infections and infestations	Pneumonia viral	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Postoperative wound infection	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Proctitis fungal	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Prostate infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Pseudomonas infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Rectal abscess	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Respiratory tract infection	n/a	435	100.0	8	1.8	438	100.0	5	1.1	1.62	Convergence criterion (GCONV=1E-8) satisfied.	0.53	5.00	0.007		Algorithm converged.	-0.009	0.023	1.61	Algorithm converged.	0.53	4.89	0.3995	0.62	Algorithm converged.	0.20	1.88
Infections and infestations	Rhinitis	n/a	435	100.0	17	3.9	438	100.0	11	2.5	1.58	Convergence criterion (GCONV=1E-8) satisfied.	0.73	3.41	0.014		Algorithm converged.	-0.009	0.037	1.56	Algorithm converged.	0.74	3.28	0.2458	0.64	Algorithm converged.	0.30	1.36
Infections and infestations	Scrotal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Sepsis	n/a	435	100.0	5	1.1	438	100.0	8	1.8	0.63	Convergence criterion (GCONV=1E-8) satisfied.	0.20	1.93	-0.007		Algorithm converged.	-0.023	0.009	0.63	Algorithm converged.	0.21	1.91	0.4133	1.59	Algorithm converged.	0.52	4.82
Infections and infestations	Septic shock	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Sialoadenitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Sinusitis	n/a	435	100.0	6	1.4	438	100.0	3	0.7	2.03	Convergence criterion (GCONV=1E-8) satisfied.	0.50	8.16	0.007		Algorithm converged.	-0.006	0.020	2.01	Algorithm converged.	0.51	8.00	0.3200	0.50	Algorithm converged.	0.12	1.97

Infections and infestations	Sinusitis bacterial	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Skin infection	n/a	435	100.0	8	1.8	438	100.0	3	0.7	2.72	Convergence criterion (GCONV=1E-8) satisfied.	0.72	10.31	0.012		Algorithm converged.	-0.003	0.026	2.69	Algorithm converged.	0.72	10.05	0.1426	0.37	Algorithm converged.	0.10	1.39
Infections and infestations	Soft tissue infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932836 3 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Staphylococcal infection	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Infections and infestations	Staphylococcal sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Stenotrophomonas infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Stoma site infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Systemic candida	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Infections and infestations	Tinea cruris	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Infections and infestations	Tinea pedis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Tongue fungal infection	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Infections and infestations	Tonsillitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Tooth abscess	n/a	435	100.0	4	0.9	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Tooth infection	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Infections and infestations	Tracheitis	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Tracheobronchitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Tuberculosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Upper respiratory tract infection	n/a	435	100.0	31	7.1	438	100.0	39	8.9	0.79	Convergence criterion (GCONV=1E-8) satisfied.	0.48	1.28	-0.018	Algorithm converged.	-0.054	0.018	0.80	Algorithm converged.	0.51	1.26	0.3348	1.25	Algorithm converged.	0.79	1.96
Infections and infestations	Upper respiratory tract infection bacterial	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Urethritis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Urinary tract infection	n/a	435	100.0	35	8.0	438	100.0	24	5.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.88	2.58	0.026	Algorithm converged.	-0.008	0.059	1.47	Algorithm converged.	0.89	2.43	0.1338	0.68	Algorithm converged.	0.41	1.13

Infections and infestations	Urinary tract infection bacterial	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Urinary tract infection enterococcal	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Vaginal infection	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50		Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Infections and infestations	Vascular device infection	n/a	435	100.0	4	0.9	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Viraemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Viral infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Vulvovaginal mycotic infection	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03		Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17

Infections and infestations	Wound infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Wound infection bacterial	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications		n/a	435	100.0	42	9.7	438	100.0	51	11.6	0.81	Convergence criterion (GCONV=1E-8) satisfied.	0.53	1.25	-0.020		Algorithm converged.	-0.061	0.021	0.83	Algorithm converged.	0.56	1.22	0.3419	1.21	Algorithm converged.	0.82	1.77
Injury, poisoning and procedural complications	Chest injury	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Compression fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Concussion	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Contusion	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000		Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Injury, poisoning and procedural complications	Corneal abrasion	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Injury, poisoning and procedural complications	Eschar	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Eye contusion	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Eye injury	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Fall	n/a	435	100.0	5	1.1	438	100.0	13	3.0	0.38	Convergence criterion (GCONV=1E-8) satisfied.	0.13	1.08	-0.018		Algorithm converged.	-0.037	0.001	0.39	Algorithm converged.	0.14	1.08	0.0691	2.58	Algorithm converged.	0.93	7.18
Injury, poisoning and procedural complications	Foot fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Injury, poisoning and procedural complications	Head injury	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Hip fracture	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005	Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53	
Injury, poisoning and procedural complications	Incision site swelling	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Infusion related reaction	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02	
Injury, poisoning and procedural complications	Injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Joint dislocation	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Ligament sprain	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83	
Injury, poisoning and procedural complications	Limb injury	n/a	435	100.0	3	0.7	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Injury, poisoning and procedural complications	Lip injury	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Lower limb fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Lumbar vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Meningitis chemical	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Meniscus injury	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Muscle rupture	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Penis injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Peroneal nerve injury	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Injury, poisoning and procedural complications	Post lumbar puncture syndrome	n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005	Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Injury, poisoning and procedural complications	Procedural pain	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Injury, poisoning and procedural complications	Rib fracture	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Injury, poisoning and procedural complications	Scratch	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Seroma	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Skin abrasion	n/a	435	100.0	4	0.9	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Skin laceration	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Spinal column injury	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Spinal compression fracture	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Injury, poisoning and procedural complications	Spinal fracture	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Injury, poisoning and procedural complications	Stoma site extravasation	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Subcutaneous haematoma	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Subdural haematoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Thermal burn	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Thoracic vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Tooth fracture	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46

Injury, poisoning and procedural complications	Traumatic fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Vascular access complication	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Injury, poisoning and procedural complications	Venous injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Wound	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Wound complication	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations		n/a	435	100.0	161	37.0	438	100.0	150	34.2	1.13	Convergence criterion (GCONV=1E-8) satisfied.	0.86	1.49	0.028		Algorithm converged.	-0.036	0.091	1.08	Algorithm converged.	0.90	1.29	0.3940	0.93	Algorithm converged.	0.77	1.11
Investigations	Activated partial thromboplastin time prolonged	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Alanine aminotransferase increased	n/a	435	100.0	20	4.6	438	100.0	22	5.0	0.91	Convergence criterion (GCONV=1E-8) satisfied.	0.49	1.70	-0.004		Algorithm converged.	-0.033	0.024	0.92	Algorithm converged.	0.51	1.65	0.7692	1.09	Algorithm converged.	0.61	1.97
Investigations	Amylase increased	n/a	435	100.0	2	0.5	438	100.0	9	2.1	0.22	Convergence criterion (GCONV=1E-8) satisfied.	0.05	1.02	-0.016		Algorithm converged.	-0.031	-0.001	0.22	Algorithm converged.	0.05	1.03	0.0545	4.47	Algorithm converged.	0.97	20.57

Investigations	Aspartate aminotransferase increased	n/a	435	100.0	18	4.1	438	100.0	18	4.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.52	1.96	0.000	Algorithm converged.	-0.026	0.027	1.01	Algorithm converged.	0.53	1.91	0.9832	0.99	Algorithm converged.	0.52	1.88
Investigations	Bacterial test positive	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Investigations	Beta 2 microglobulin increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Blood albumin decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood alkaline phosphatase increased	n/a	435	100.0	5	1.1	438	100.0	9	2.1	0.55	Convergence criterion (GCONV=1E-8) satisfied.	0.18	1.67	-0.009	Algorithm converged.	-0.026	0.008	0.56	Algorithm converged.	0.19	1.66	0.2941	1.79	Algorithm converged.	0.60	5.29
Investigations	Blood bilirubin increased	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Investigations	Blood creatine increased	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Blood creatinine increased	n/a	435	100.0	2	0.5	438	100.0	5	1.1	0.40	Convergence criterion (GCONV=1E-8) satisfied.	0.08	2.07	-0.007	Algorithm converged.	-0.019	0.005	0.40	Algorithm converged.	0.08	2.06	0.2755	2.48	Algorithm converged.	0.48	12.73
Investigations	Blood culture positive	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Investigations	Blood folate decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood glucose increased	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Investigations	Blood immunoglobulin G decreased	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood immunoglobulin M decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood lactate dehydrogenase increased	n/a	435	100.0	2	0.5	438	100.0	5	1.1	0.40	Convergence criterion (GCONV=1E-8) satisfied.	0.08	2.07	-0.007		Algorithm converged.	-0.019	0.005	0.40	Algorithm converged.	0.08	2.06	0.2755	2.48	Algorithm converged.	0.48	12.73
Investigations	Blood lactic acid increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Investigations	Blood magnesium decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood potassium increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Blood pressure decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood pressure increased	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Investigations	Blood uric acid increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Body temperature increased	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83

Investigations	C-reactive protein increased	n/a	435	100.0	7	1.6	438	100.0	1	0.2	7.15	Convergence criterion (GCONV=1E-8) satisfied.	0.88	58.33	0.014	Algorithm converged.	0.001	0.026	7.05	Algorithm converged.	0.87	57.05	0.0672	0.14	Algorithm converged.	0.02	1.15
Investigations	Cardiac murmur	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Coronavirus test positive	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Corynebacterium test positive	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Ejection fraction decreased	n/a	435	100.0	9	2.1	438	100.0	5	1.1	1.83	Convergence criterion (GCONV=1E-8) satisfied.	0.61	5.50	0.009	Algorithm converged.	-0.007	0.026	1.81	Algorithm converged.	0.61	5.36	0.2828	0.55	Algorithm converged.	0.19	1.63
Investigations	Electrocardiogram QT prolonged	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Gamma-glutamyltransferase increased	n/a	435	100.0	7	1.6	438	100.0	6	1.4	1.18	Convergence criterion (GCONV=1E-8) satisfied.	0.39	3.53	0.002	Algorithm converged.	-0.014	0.018	1.17	Algorithm converged.	0.40	3.47	0.7706	0.85	Algorithm converged.	0.29	2.51
Investigations	Haemoglobin decreased	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Investigations	Heart rate increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Hepatic enzyme abnormal	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Hepatic enzyme increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Human rhinovirus test positive	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Investigations	Immunoglobulins decreased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Influenza A virus test positive	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Lipase increased	n/a	435	100.0	1	0.2	438	100.0	11	2.5	0.09	Convergence criterion (GCONV=1E-8) satisfied.	0.01	0.70	-0.023		Algorithm converged.	-0.038	-0.007	0.09	Algorithm converged.	0.01	0.71	0.0218	10.92	Algorithm converged.	1.42	84.25
Investigations	Liver function test increased	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Lymphocyte count decreased	n/a	435	100.0	19	4.4	438	100.0	23	5.3	0.82	Convergence criterion (GCONV=1E-8) satisfied.	0.44	1.54	-0.009		Algorithm converged.	-0.037	0.020	0.83	Algorithm converged.	0.46	1.50	0.5427	1.20	Algorithm converged.	0.66	2.18
Investigations	N-terminal prohormone brain natriuretic peptide increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Neutrophil count decreased	n/a	435	100.0	36	8.3	438	100.0	33	7.5	1.11	Convergence criterion (GCONV=1E-8) satisfied.	0.68	1.81	0.007		Algorithm converged.	-0.028	0.043	1.10	Algorithm converged.	0.70	1.73	0.6848	0.91	Algorithm converged.	0.58	1.43
Investigations	Neutrophil count increased	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Investigations	Oxygen saturation decreased	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005		Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
Investigations	Platelet count	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Platelet count decreased	n/a	435	100.0	19	4.4	438	100.0	18	4.1	1.07	Convergence criterion (GCONV=1E-8) satisfied.	0.55	2.06	0.003		Algorithm converged.	-0.024	0.029	1.06	Algorithm converged.	0.57	2.00	0.8498	0.94	Algorithm converged.	0.50	1.77

Investigations	Platelet count increased	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Investigations	Red blood cell count decreased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Red blood cell sedimentation rate increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Transaminases increased	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Troponin I increased	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Troponin T increased	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Investigations	Troponin increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Vitamin D decreased	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Investigations	Weight decreased	n/a	435	100.0	55	12.6	438	100.0	52	11.9	1.07	Convergence criterion (GCONV=1E-8) satisfied.	0.72	1.61	0.008	Algorithm converged.	-0.036	0.051	1.06	Algorithm converged.	0.75	1.52	0.7282	0.94	Algorithm converged.	0.66	1.34
Investigations	Weight increased	n/a	435	100.0	10	2.3	438	100.0	13	3.0	0.77	Convergence criterion (GCONV=1E-8) satisfied.	0.33	1.77	-0.007	Algorithm converged.	-0.028	0.015	0.77	Algorithm converged.	0.34	1.75	0.5383	1.29	Algorithm converged.	0.57	2.91
Investigations	White blood cell count decreased	n/a	435	100.0	27	6.2	438	100.0	21	4.8	1.31	Convergence criterion (GCONV=1E-8) satisfied.	0.73	2.36	0.014	Algorithm converged.	-0.016	0.044	1.29	Algorithm converged.	0.74	2.25	0.3616	0.77	Algorithm converged.	0.44	1.35

Investigations	White blood cell count increased	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Metabolism and nutrition disorders		n/a	435	100.0	160	36.8	438	100.0	161	36.8	1.00	Convergence criterion (GCONV=1E-8) satisfied.	0.76	1.32	0.000	Algorithm converged.	-0.064	0.064	1.00	Algorithm converged.	0.84	1.19	0.9942	1.00	Algorithm converged.	0.84	1.19
Metabolism and nutrition disorders	Abnormal loss of weight	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Decreased appetite	n/a	435	100.0	71	16.3	438	100.0	62	14.2	1.18	Convergence criterion (GCONV=1E-8) satisfied.	0.82	1.71	0.022	Algorithm converged.	-0.026	0.069	1.15	Algorithm converged.	0.84	1.58	0.3737	0.87	Algorithm converged.	0.63	1.19
Metabolism and nutrition disorders	Dehydration	n/a	435	100.0	15	3.4	438	100.0	19	4.3	0.79	Convergence criterion (GCONV=1E-8) satisfied.	0.39	1.57	-0.009	Algorithm converged.	-0.035	0.017	0.79	Algorithm converged.	0.41	1.54	0.4980	1.26	Algorithm converged.	0.65	2.44
Metabolism and nutrition disorders	Diabetes mellitus	n/a	435	100.0	2	0.5	438	100.0	5	1.1	0.40	Convergence criterion (GCONV=1E-8) satisfied.	0.08	2.07	-0.007	Algorithm converged.	-0.019	0.005	0.40	Algorithm converged.	0.08	2.06	0.2755	2.48	Algorithm converged.	0.48	12.73
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Fluid overload	n/a	435	100.0	1	0.2	438	100.0	4	0.9	0.25	Convergence criterion (GCONV=1E-8) satisfied.	0.03	2.25	-0.007	Algorithm converged.	-0.017	0.003	0.25	Algorithm converged.	0.03	2.24	0.2164	3.97	Algorithm converged.	0.45	35.40
Metabolism and nutrition disorders	Fluid retention	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Metabolism and nutrition disorders	Glucose tolerance impaired	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Gout	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Metabolism and nutrition disorders	Hypercalcaemia	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Metabolism and nutrition disorders	Hypercholesterolaemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Hyperglycaemia	n/a	435	100.0	18	4.1	438	100.0	17	3.9	1.07	Convergence criterion (GCONV=1E-8) satisfied.	0.54	2.10	0.003	Algorithm converged.	-0.023	0.029	1.07	Algorithm converged.	0.56	2.04	0.8468	0.94	Algorithm converged.	0.49	1.80
Metabolism and nutrition disorders	Hyperkalaemia	n/a	435	100.0	5	1.1	438	100.0	8	1.8	0.63	Convergence criterion (GCONV=1E-8) satisfied.	0.20	1.93	-0.007	Algorithm converged.	-0.023	0.009	0.63	Algorithm converged.	0.21	1.91	0.4133	1.59	Algorithm converged.	0.52	4.82
Metabolism and nutrition disorders	Hyperlipidaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hypernatraemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Hyperphagia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Metabolism and nutrition disorders	Hyperphosphataemia	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46	
Metabolism and nutrition disorders	Hyperuricaemia	n/a	435	100.0	11	2.5	438	100.0	7	1.6	1.60	Convergence criterion (GCONV=1E-8) satisfied.	0.61	4.16	0.009		Algorithm converged.	-0.010	0.028	1.58	Algorithm converged.	0.62	4.04	0.3378	0.63	Algorithm converged.	0.25	1.62	
Metabolism and nutrition disorders	Hypoalbuminaemia	n/a	435	100.0	9	2.1	438	100.0	11	2.5	0.82	Convergence criterion (GCONV=1E-8) satisfied.	0.34	2.00	-0.004		Algorithm converged.	-0.024	0.015	0.82	Algorithm converged.	0.34	1.97	0.6627	1.21	Algorithm converged.	0.51	2.90	
Metabolism and nutrition disorders	Hypocalcaemia	n/a	435	100.0	7	1.6	438	100.0	10	2.3	0.70	Convergence criterion (GCONV=1E-8) satisfied.	0.26	1.86	-0.007		Algorithm converged.	-0.025	0.012	0.70	Algorithm converged.	0.27	1.83	0.4736	1.42	Algorithm converged.	0.55	3.69	
Metabolism and nutrition disorders	Hypochloraemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Hypoglycaemia	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87	
Metabolism and nutrition disorders	Hypokalaemia	n/a	435	100.0	36	8.3	438	100.0	39	8.9	0.92	Convergence criterion (GCONV=1E-8) satisfied.	0.57	1.48	-0.006		Algorithm converged.	-0.043	0.031	0.93	Algorithm converged.	0.60	1.43	0.7406	1.08	Algorithm converged.	0.70	1.66	
Metabolism and nutrition disorders	Hypomagnesaemia	n/a	435	100.0	22	5.1	438	100.0	12	2.7	1.89	Convergence criterion (GCONV=1E-8) satisfied.	0.92	3.87	0.023		Algorithm converged.	-0.002	0.049	1.85	Algorithm converged.	0.93	3.68	0.0820	0.54	Algorithm converged.	0.27	1.08	
Metabolism and nutrition disorders	Hyponatraemia	n/a	435	100.0	10	2.3	438	100.0	16	3.7	0.62	Convergence criterion (GCONV=1E-8) satisfied.	0.28	1.38	-0.014		Algorithm converged.	-0.036	0.009	0.63	Algorithm converged.	0.29	1.37	0.2438	1.59	Algorithm converged.	0.73	3.46	

Metabolism and nutrition disorders	Hypophagia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hypophosphataemia	n/a	435	100.0	21	4.8	438	100.0	12	2.7	1.80	Convergence criterion (GCONV=1E-8) satisfied.	0.87	3.71	0.021	*	Algorithm converged.	-0.004	0.046	1.76	Algorithm converged.	0.88	3.54	0.1110	0.57	Algorithm converged.	0.28	1.14
Metabolism and nutrition disorders	Hypoproteinaemia	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Hypovitaminosis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	*	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Hypovolaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Iron deficiency	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	*	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Metabolism and nutrition disorders	Lactic acidosis	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Malnutrition	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	*	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17

Metabolism and nutrition disorders	Mineral deficiency	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Salt craving	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	435	100.0	2	0.5	438	100.0	4	0.9	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.09	2.75	-0.005		Algorithm converged.	-0.015	0.006	0.50	Algorithm converged.	0.09	2.73	0.4267	1.99	Algorithm converged.	0.37	10.79
Metabolism and nutrition disorders	Type 2 diabetes mellitus	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Vitamin B1 deficiency	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Vitamin D deficiency	n/a	435	100.0	4	0.9	438	100.0	8	1.8	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.15	1.67	-0.009		Algorithm converged.	-0.024	0.006	0.50	Algorithm converged.	0.15	1.66	0.2595	1.99	Algorithm converged.	0.60	6.55

Musculoskeletal and connective tissue disorders		n/a	435	100.0	124	28.5	438	100.0	144	32.9	0.81	Convergence criterion (GCONV=1E-8) satisfied.	0.61	1.09	-0.044	Algorithm converged.	-0.105	0.017	0.87	Algorithm converged.	0.71	1.06	0.1624	1.15	Algorithm converged.	0.94	1.41
Musculoskeletal and connective tissue disorders	Arthralgia	n/a	435	100.0	26	6.0	438	100.0	37	8.4	0.69	Convergence criterion (GCONV=1E-8) satisfied.	0.41	1.16	-0.025	Algorithm converged.	-0.059	0.010	0.71	Algorithm converged.	0.44	1.15	0.1610	1.41	Algorithm converged.	0.87	2.29
Musculoskeletal and connective tissue disorders	Back pain	n/a	435	100.0	41	9.4	438	100.0	48	11.0	0.85	Convergence criterion (GCONV=1E-8) satisfied.	0.54	1.31	-0.015	Algorithm converged.	-0.055	0.025	0.86	Algorithm converged.	0.58	1.28	0.4546	1.16	Algorithm converged.	0.78	1.73
Musculoskeletal and connective tissue disorders	Bone pain	n/a	435	100.0	20	4.6	438	100.0	31	7.1	0.63	Convergence criterion (GCONV=1E-8) satisfied.	0.35	1.13	-0.025	Algorithm converged.	-0.056	0.006	0.65	Algorithm converged.	0.38	1.12	0.1217	1.54	Algorithm converged.	0.89	2.66
Musculoskeletal and connective tissue disorders	Clubbing	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Musculoskeletal and connective tissue disorders	Dupuytren's contracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Musculoskeletal and connective tissue disorders	Flank pain	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005	Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
Musculoskeletal and connective tissue disorders	Groin pain	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Inguinal mass	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*			WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Musculoskeletal and connective tissue disorders	Joint stiffness	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Musculoskeletal and connective tissue disorders	Joint swelling	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83

Musculoskeletal and connective tissue disorders	Limb discomfort	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Mobility decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Muscle contracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Muscle oedema	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Muscle spasms	n/a	435	100.0	20	4.6	438	100.0	24	5.5	0.83	Convergence criterion (GCONV=1E-8) satisfied.	0.45	1.53	-0.009		Algorithm converged.	-0.038	0.020	0.84	Algorithm converged.	0.47	1.50	0.5522	1.19	Algorithm converged.	0.67	2.13
Musculoskeletal and connective tissue disorders	Muscle tightness	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Musculoskeletal and connective tissue disorders	Muscular weakness	n/a	435	100.0	8	1.8	438	100.0	12	2.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.27	1.64	-0.009	Algorithm converged.	-0.029	0.011	0.67	Algorithm converged.	0.28	1.63	0.3772	1.49	Algorithm converged.	0.62	3.61	
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89	
Musculoskeletal and connective tissue disorders	Musculoskeletal pain	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005	Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53	
Musculoskeletal and connective tissue disorders	Musculoskeletal stiffness	n/a	435	100.0	4	0.9	438	100.0	3	0.7	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.30	6.05	0.002	Algorithm converged.	-0.009	0.014	1.34	Algorithm converged.	0.30	5.96	0.6986	0.74	Algorithm converged.	0.17	3.31	
Musculoskeletal and connective tissue disorders	Myalgia	n/a	435	100.0	18	4.1	438	100.0	12	2.7	1.53	Convergence criterion (GCONV=1E-8) satisfied.	0.73	3.22	0.014	Algorithm converged.	-0.010	0.038	1.51	Algorithm converged.	0.74	3.10	0.2605	0.66	Algorithm converged.	0.32	1.36	
Musculoskeletal and connective tissue disorders	Neck pain	n/a	435	100.0	12	2.8	438	100.0	6	1.4	2.04	Convergence criterion (GCONV=1E-8) satisfied.	0.76	5.49	0.014	Algorithm converged.	-0.005	0.033	2.01	Algorithm converged.	0.76	5.32	0.1576	0.50	Algorithm converged.	0.19	1.31	
Musculoskeletal and connective tissue disorders	Osteoarthritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Musculoskeletal and connective tissue disorders	Osteoporosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	435	100.0	16	3.7	438	100.0	18	4.1	0.89	Convergence criterion (GCONV=1E-8) satisfied.	0.45	1.77	-0.004	Algorithm converged.	-0.030	0.021	0.90	Algorithm converged.	0.46	1.73	0.7420	1.12	Algorithm converged.	0.58	2.16	
Musculoskeletal and connective tissue disorders	Pain in jaw	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87	
Musculoskeletal and connective tissue disorders	Patellofemoral pain syndrome	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Pathological fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Musculoskeletal and connective tissue disorders	Periarthritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Plantar fasciitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Sjogren's syndrome	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Spinal pain	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50		Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Musculoskeletal and connective tissue disorders	Spondylolisthesis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Musculoskeletal and connective tissue disorders	Synovial cyst	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Musculoskeletal and connective tissue disorders	Tendonitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										
---	------------	-----	-----	-------	---	-----	-----	-------	---	-----	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Cancer pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Colorectal cancer	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hodgkin's disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lipoma	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Lung neoplasm	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Malignant melanoma in situ	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Meningioma	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary renal cell carcinoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Seborrheic keratosis	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Skin papilloma	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders		n/a	435	100.0	286	65.7	438	100.0	301	68.7	0.87	Convergence criterion (GCONV=1E-8) satisfied.	0.66	1.16	-0.030	Algorithm converged.	-0.092	0.032	0.96	Algorithm converged.	0.87	1.05	0.3495	1.05	Algorithm converged.	0.95	1.15
Nervous system disorders	Ageusia	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Nervous system disorders	Altered state of consciousness	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Amnesia	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Nervous system disorders	Aphasia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Nervous system disorders	Ataxia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Nervous system disorders	Balance disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Carotid artery stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Cerebellar ataxia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Nervous system disorders	Cerebral haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Cerebral infarction	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Cerebral ischaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Cerebrospinal fluid leakage	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Nervous system disorders	Cerebrovascular accident	n/a	435	100.0	0	0.0	438	100.0	4	0.9	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	

Nervous system disorders	Cervicobrachial syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Cognitive disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Disturbance in attention	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Dizziness	n/a	435	100.0	28	6.4	438	100.0	31	7.1	0.90	Convergence criterion (GCONV=1E-8) satisfied.	0.53	1.53	-0.006		Algorithm converged.	-0.040	0.027	0.91	Algorithm converged.	0.56	1.49	0.7062	1.10	Algorithm converged.	0.67	1.80
Nervous system disorders	Dizziness exertional	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Dizziness postural	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Dysaesthesia	n/a	435	100.0	5	1.1	438	100.0	2	0.5	2.53	Convergence criterion (GCONV=1E-8) satisfied.	0.49	13.14	0.007		Algorithm converged.	-0.005	0.019	2.52	Algorithm converged.	0.49	12.90	0.2683	0.40	Algorithm converged.	0.08	2.04
Nervous system disorders	Dysgeusia	n/a	435	100.0	49	11.3	438	100.0	57	13.0	0.85	Convergence criterion (GCONV=1E-8) satisfied.	0.56	1.28	-0.017		Algorithm converged.	-0.061	0.026	0.87	Algorithm converged.	0.61	1.24	0.4294	1.16	Algorithm converged.	0.81	1.65

Nervous system disorders	Epilepsy	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Extrapyramidal disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Head discomfort	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Headache	n/a	435	100.0	56	12.9	438	100.0	57	13.0	0.99	Convergence criterion (GCONV=1E-8) satisfied.	0.67	1.47	-0.001	Algorithm converged.	-0.046	0.043	0.99	Algorithm converged.	0.70	1.40	0.9508	1.01	Algorithm converged.	0.72	1.43
Nervous system disorders	Hemiparesis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Hyperaesthesia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Hypoaesthesia	n/a	435	100.0	16	3.7	438	100.0	14	3.2	1.16	Convergence criterion (GCONV=1E-8) satisfied.	0.56	2.40	0.005	Algorithm converged.	-0.019	0.029	1.15	Algorithm converged.	0.57	2.33	0.6962	0.87	Algorithm converged.	0.43	1.76
Nervous system disorders	Hyporeflexia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Nervous system disorders	Hypotonia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Nervous system disorders	Lethargy	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Nervous system disorders	Memory impairment	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Nervous system disorders	Migraine	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Nervous system disorders	Neuralgia	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Nervous system disorders	Neurological symptom	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Neuromyopathy	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Neuropathy peripheral	n/a	435	100.0	105	24.1	438	100.0	99	22.6	1.09	Convergence criterion (GCONV=1E-8) satisfied.	0.80	1.49	0.015	Algorithm converged.	-0.041	0.071	1.07	Algorithm converged.	0.84	1.36	0.5921	0.94	Algorithm converged.	0.74	1.19
Nervous system disorders	Ophthalmic migraine	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Nervous system disorders	Paraesthesia	n/a	435	100.0	29	6.7	438	100.0	20	4.6	1.49	Convergence criterion (GCONV=1E-8) satisfied.	0.83	2.68	0.021	Algorithm converged.	-0.010	0.052	1.46	Algorithm converged.	0.84	2.54	0.1806	0.68	Algorithm converged.	0.39	1.19
Nervous system disorders	Paralysis recurrent laryngeal nerve	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Parosmia	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Nervous system disorders	Peripheral motor neuropathy	n/a	435	100.0	3	0.7	438	100.0	10	2.3	0.30	Convergence criterion (GCONV=1E-8) satisfied.	0.08	1.09	-0.016	Algorithm converged.	-0.032	0.000	0.30	Algorithm converged.	0.08	1.09	0.0675	3.31	Algorithm converged.	0.92	11.95
Nervous system disorders	Peripheral sensorimotor neuropathy	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Nervous system disorders	Peripheral sensory neuropathy	n/a	435	100.0	85	19.5	438	100.0	94	21.5	0.89	Convergence criterion (GCONV=1E-8) satisfied.	0.64	1.23	-0.019	Algorithm converged.	-0.073	0.034	0.91	Algorithm converged.	0.70	1.18	0.4824	1.10	Algorithm converged.	0.85	1.43
Nervous system disorders	Peroneal nerve palsy	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Nervous system disorders	Piriformis syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Polyneuropathy	n/a	435	100.0	6	1.4	438	100.0	11	2.5	0.54	Convergence criterion (GCONV=1E-8) satisfied.	0.20	1.48	-0.011		Algorithm converged.	-0.030	0.007	0.55	Algorithm converged.	0.20	1.47	0.2335	1.82	Algorithm converged.	0.68	4.88
Nervous system disorders	Post herpetic neuralgia	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000		Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Nervous system disorders	Presyncope	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000		Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Nervous system disorders	Restless legs syndrome	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000		Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Nervous system disorders	Sciatica	n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005		Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Nervous system disorders	Seizure	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Speech disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Spinal cord compression	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Nervous system disorders	Subdural hygroma	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Syncope	n/a	435	100.0	10	2.3	438	100.0	11	2.5	0.91	Convergence criterion (GCONV=1E-8) satisfied.	0.38	2.17	-0.002	Algorithm converged.	-0.022	0.018	0.92	Algorithm converged.	0.39	2.13	0.8377	1.09	Algorithm converged.	0.47	2.55
Nervous system disorders	Taste disorder	n/a	435	100.0	11	2.5	438	100.0	9	2.1	1.24	Convergence criterion (GCONV=1E-8) satisfied.	0.51	3.01	0.005	Algorithm converged.	-0.015	0.025	1.23	Algorithm converged.	0.52	2.94	0.6404	0.81	Algorithm converged.	0.34	1.94
Nervous system disorders	Transient ischaemic attack	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Tremor	n/a	435	100.0	9	2.1	438	100.0	7	1.6	1.30	Convergence criterion (GCONV=1E-8) satisfied.	0.48	3.52	0.005	Algorithm converged.	-0.013	0.023	1.29	Algorithm converged.	0.49	3.45	0.6051	0.77	Algorithm converged.	0.29	2.06
Nervous system disorders	Vith nerve disorder	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Product issues		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Product issues	Device occlusion	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Psychiatric disorders		n/a	435	100.0	78	17.9	438	100.0	72	16.4	1.11		Convergence criterion (GCONV=1E-8) satisfied.	0.78	1.58	0.015		Algorithm converged.	-0.035	0.065	1.09		Algorithm converged.	0.81	1.46	0.5590	0.92		Algorithm converged.	0.68	1.23
Psychiatric disorders	Adjustment disorder	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01		Algorithm converged.	0.06	16.05	0.9961	0.99		Algorithm converged.	0.06	15.83
Psychiatric disorders	Adjustment disorder with anxiety	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Psychiatric disorders	Affect lability	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99		Algorithm converged.	0.00	NE
Psychiatric disorders	Agitation	n/a	435	100.0	4	0.9	438	100.0	3	0.7	1.35		Convergence criterion (GCONV=1E-8) satisfied.	0.30	6.05	0.002		Algorithm converged.	-0.009	0.014	1.34		Algorithm converged.	0.30	5.96	0.6986	0.74		Algorithm converged.	0.17	3.31

Psychiatric disorders	Agoraphobia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Anxiety	n/a	435	100.0	16	3.7	438	100.0	16	3.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.50	2.04	0.000		Algorithm converged.	-0.025	0.025	1.01	Algorithm converged.	0.51	1.99	0.9842	0.99	Algorithm converged.	0.50	1.96
Psychiatric disorders	Confusional state	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69	Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005		Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
Psychiatric disorders	Delirium	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Psychiatric disorders	Depression	n/a	435	100.0	8	1.8	438	100.0	6	1.4	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.46	3.92	0.005		Algorithm converged.	-0.012	0.021	1.34	Algorithm converged.	0.47	3.84	0.5825	0.74	Algorithm converged.	0.26	2.13
Psychiatric disorders	Disorientation	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Emotional distress	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Psychiatric disorders	Insomnia	n/a	435	100.0	41	9.4	438	100.0	43	9.8	0.96	Convergence criterion (GCONV=1E-8) satisfied.	0.61	1.50	-0.004		Algorithm converged.	-0.043	0.035	0.96	Algorithm converged.	0.64	1.44	0.8443	1.04	Algorithm converged.	0.69	1.56
Psychiatric disorders	Irritability	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94

Psychiatric disorders	Libido decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Mental disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Mental status changes	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Mixed anxiety and depressive disorder	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Psychiatric disorders	Mood altered	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Mood swings	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Psychiatric disorders	Panic disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Psychiatric disorders	Personality change	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Poor quality sleep	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Restlessness	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Psychiatric disorders	Sleep disorder	n/a	435	100.0	2	0.5	438	100.0	4	0.9	0.50		Convergence criterion (GCONV=1E-8) satisfied.	0.09	2.75	-0.005		Algorithm converged.	-0.015	0.006	0.50	Algorithm converged.	0.09	2.73	0.4267	1.99	Algorithm converged.	0.37	10.79
Psychiatric disorders	Stress	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Psychiatric disorders	Suicidal ideation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders		n/a	435	100.0	51	11.7	438	100.0	38	8.7	1.40	Convergence criterion (GCONV=1E-8) satisfied.	0.90	2.18	0.030		Algorithm converged.	-0.010	0.071	1.35	Algorithm converged.	0.91	2.01	0.1386	0.74	Algorithm converged.	0.50	1.10
Renal and urinary disorders	Acute kidney injury	n/a	435	100.0	11	2.5	438	100.0	3	0.7	3.76	Convergence criterion (GCONV=1E-8) satisfied.	1.04	13.58	0.018		Algorithm converged.	0.002	0.035	3.69	Algorithm converged.	1.04	13.14	0.0438	0.27	Algorithm converged.	0.08	0.96
Renal and urinary disorders	Atonic urinary bladder	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932836 3 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders	Bladder spasm	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Renal and urinary disorders	Chromaturia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders	Chronic kidney disease	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Renal and urinary disorders	Cystitis haemorrhagic	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Cystitis noninfective	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Renal and urinary disorders	Dysuria	n/a	435	100.0	15	3.4	438	100.0	10	2.3	1.53	Convergence criterion (GCONV=1E-8) satisfied.	0.68	3.44	0.012		Algorithm converged.	-0.010	0.034	1.51	Algorithm converged.	0.69	3.32	0.3057	0.66	Algorithm converged.	0.30	1.46
Renal and urinary disorders	Haematuria	n/a	435	100.0	4	0.9	438	100.0	4	0.9	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.25	4.05	0.000		Algorithm converged.	-0.013	0.013	1.01	Algorithm converged.	0.25	4.00	0.9922	0.99	Algorithm converged.	0.25	3.95
Renal and urinary disorders	Hydronephrosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Renal and urinary disorders	Micturition urgency	n/a	435	100.0	5	1.1	438	100.0	1	0.2	5.08	Convergence criterion (GCONV=1E-8) satisfied.	0.59	43.67	0.009	Algorithm converged.	-0.002	0.020	5.03	Algorithm converged.	0.59	42.92	0.1393	0.20	Algorithm converged.	0.02	1.69
Renal and urinary disorders	Nephrolithiasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders	Nocturia	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Renal and urinary disorders	Oliguria	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Pollakiuria	n/a	435	100.0	3	0.7	438	100.0	4	0.9	0.75	Convergence criterion (GCONV=1E-8) satisfied.	0.17	3.39	-0.002	Algorithm converged.	-0.014	0.010	0.76	Algorithm converged.	0.17	3.35	0.7120	1.32	Algorithm converged.	0.30	5.88
Renal and urinary disorders	Polyuria	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Renal and urinary disorders	Renal colic	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Renal failure	n/a	435	100.0	2	0.5	438	100.0	4	0.9	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.09	2.75	-0.005	Algorithm converged.	-0.015	0.006	0.50	Algorithm converged.	0.09	2.73	0.4267	1.99	Algorithm converged.	0.37	10.79
Renal and urinary disorders	Renal impairment	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Renal and urinary disorders	Renal pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Urge incontinence	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders	Urinary incontinence	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Renal and urinary disorders	Urinary retention	n/a	435	100.0	3	0.7	438	100.0	6	1.4	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.12	2.01	-0.007		Algorithm converged.	-0.020	0.007	0.50	Algorithm converged.	0.13	2.00	0.3296	1.99	Algorithm converged.	0.50	7.89
Renal and urinary disorders	Urinary tract disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Urinary tract obstruction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Urinary tract pain	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Renal and urinary disorders	Urine flow decreased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Reproductive system and breast disorders		n/a	435	100.0	16	3.7	438	100.0	16	3.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.50	2.04	0.000		Algorithm converged.	-0.025	0.025	1.01	Algorithm converged.	0.51	1.99	0.9842	0.99	Algorithm converged.	0.50	1.96
Reproductive system and breast disorders	Amenorrhoea	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Reproductive system and breast disorders	Benign prostatic hyperplasia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Reproductive system and breast disorders	Breast pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders	Erectile dysfunction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Reproductive system and breast disorders	Female genital tract fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders	Genital discharge	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Reproductive system and breast disorders	Genital haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Reproductive system and breast disorders	Intermenstrual bleeding	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders	Menopausal symptoms	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Reproductive system and breast disorders	Menstruation irregular	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Reproductive system and breast disorders	Pelvic pain	n/a	435	100.0	3	0.7	438	100.0	4	0.9	0.75	Convergence criterion (GCONV=1E-8) satisfied.	0.17	3.39	-0.002	Algorithm converged.	-0.014	0.010	0.76	Algorithm converged.	0.17	3.35	0.7120	1.32	Algorithm converged.	0.30	5.88	
Reproductive system and breast disorders	Perineal rash	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders	Prostatitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	

Reproductive system and breast disorders	Pruritus genital	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Reproductive system and breast disorders	Scrotal pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE			
Reproductive system and breast disorders	Uterine pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.	NE		NE	NE	NE	NE	Algorithm converged.	NE	NE			
Reproductive system and breast disorders	Vaginal fistula	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE			
Reproductive system and breast disorders	Vaginal haemorrhage	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01		Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Reproductive system and breast disorders	Vulvovaginal dryness	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01		Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46

Reproductive system and breast disorders	Vulvovaginal inflammation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders	Vulvovaginal pruritus	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005		Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
Respiratory, thoracic and mediastinal disorders		n/a	435	100.0	183	42.1	438	100.0	167	38.1	1.18	Convergence criterion (GCONV=1E-8) satisfied.	0.90	1.55	0.039		Algorithm converged.	-0.026	0.104	1.10	Algorithm converged.	0.94	1.30	0.2353	0.91	Algorithm converged.	0.77	1.07
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Allergic cough	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Aphonia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Asthma	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Respiratory, thoracic and mediastinal disorders	Atelectasis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Respiratory, thoracic and mediastinal disorders	Bronchospasm	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Respiratory, thoracic and mediastinal disorders	Catarrh	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Cough	n/a	435	100.0	56	12.9	438	100.0	53	12.1	1.07	Convergence criterion (GCONV=1E-8) satisfied.	0.72	1.60	0.008	Algorithm converged.	-0.036	0.052	1.06	Algorithm converged.	0.75	1.51	0.7298	0.94	Algorithm converged.	0.66	1.34
Respiratory, thoracic and mediastinal disorders	Dry throat	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Dysphonia	n/a	435	100.0	5	1.1	438	100.0	7	1.6	0.72	Convergence criterion (GCONV=1E-8) satisfied.	0.23	2.27	-0.004	Algorithm converged.	-0.020	0.011	0.72	Algorithm converged.	0.23	2.25	0.5709	1.39	Algorithm converged.	0.44	4.35
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	435	100.0	48	11.0	438	100.0	36	8.2	1.38	Convergence criterion (GCONV=1E-8) satisfied.	0.88	2.18	0.028	Algorithm converged.	-0.011	0.067	1.34	Algorithm converged.	0.89	2.03	0.1604	0.74	Algorithm converged.	0.49	1.12
Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional	n/a	435	100.0	9	2.1	438	100.0	9	2.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.40	2.56	0.000	Algorithm converged.	-0.019	0.019	1.01	Algorithm converged.	0.40	2.51	0.9882	0.99	Algorithm converged.	0.40	2.48
Respiratory, thoracic and mediastinal disorders	Epistaxis	n/a	435	100.0	11	2.5	438	100.0	6	1.4	1.87	Convergence criterion (GCONV=1E-8) satisfied.	0.68	5.10	0.012	Algorithm converged.	-0.007	0.030	1.85	Algorithm converged.	0.69	4.95	0.2229	0.54	Algorithm converged.	0.20	1.45
Respiratory, thoracic and mediastinal disorders	Hiccups	n/a	435	100.0	6	1.4	438	100.0	10	2.3	0.60	Convergence criterion (GCONV=1E-8) satisfied.	0.22	1.66	-0.009	Algorithm converged.	-0.027	0.009	0.60	Algorithm converged.	0.22	1.65	0.3249	1.66	Algorithm converged.	0.61	4.51

Respiratory, thoracic and mediastinal disorders	Hydrothorax	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Hypoxia	n/a	435	100.0	12	2.8	438	100.0	4	0.9	3.08	Convergence criterion (GCONV=1E-8) satisfied.	0.98	9.62	0.018		Algorithm converged.	0.001	0.036	3.02	Algorithm converged.	0.98	9.29	0.0538	0.33	Algorithm converged.	0.11	1.02
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Respiratory, thoracic and mediastinal disorders	Laryngeal obstruction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Laryngeal oedema	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Lower respiratory tract congestion	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Respiratory, thoracic and mediastinal disorders	Lung cyst	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE		NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Lung disorder	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99		Algorithm converged.	0.06	15.83
Respiratory, thoracic and mediastinal disorders	Lung infiltration	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE		NE		Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Lung opacity	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99		Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Nasal congestion	n/a	435	100.0	15	3.4	438	100.0	10	2.3	1.53		Convergence criterion (GCONV=1E-8) satisfied.	0.68	3.44	0.012		Algorithm converged.	-0.010	0.034	1.51	Algorithm converged.	0.69	3.32	0.3057	0.66		Algorithm converged.	0.30	1.46
Respiratory, thoracic and mediastinal disorders	Nasal discomfort	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE		NE		Algorithm converged.	NE	NE

Respiratory, thoracic and mediastinal disorders	Nasal dryness	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Nasal mucosal disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Nasal mucosal hypertrophy	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Nasal obstruction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Oropharyngeal discomfort	n/a	435	100.0	7	1.6	438	100.0	2	0.5	3.56	Convergence criterion (GCONV=1E-8) satisfied.	0.74	17.25	0.012		Algorithm converged.	-0.002	0.025	3.52	Algorithm converged.	0.74	16.87	0.1149	0.28	Algorithm converged.	0.06	1.36
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	n/a	435	100.0	21	4.8	438	100.0	25	5.7	0.84	Convergence criterion (GCONV=1E-8) satisfied.	0.46	1.52	-0.009		Algorithm converged.	-0.038	0.021	0.85	Algorithm converged.	0.48	1.49	0.5611	1.18	Algorithm converged.	0.67	2.08

Respiratory, thoracic and mediastinal disorders	Orthopnoea	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Paranasal sinus hypersecretion	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Respiratory, thoracic and mediastinal disorders	Pharyngeal erythema	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pharyngeal inflammation	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Pharyngeal oedema	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Pharyngeal paraesthesia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Respiratory, thoracic and mediastinal disorders	Pharyngeal swelling	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	435	100.0	6	1.4	438	100.0	4	0.9	1.52		Convergence criterion (GCONV=1E-8) satisfied.	0.43	5.41	0.005		Algorithm converged.	-0.009	0.019	1.51	Algorithm converged.	0.43	5.31	0.5207	0.66	Algorithm converged.	0.19	2.33

Respiratory, thoracic and mediastinal disorders	Pleuritic pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pneumomediastinum	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69	Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005	Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48	
Respiratory, thoracic and mediastinal disorders	Pneumothorax	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Productive cough	n/a	435	100.0	10	2.3	438	100.0	10	2.3	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.41	2.44	0.000	Algorithm converged.	-0.020	0.020	1.01	Algorithm converged.	0.42	2.39	0.9876	0.99	Algorithm converged.	0.42	2.36	
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	435	100.0	5	1.1	438	100.0	4	0.9	1.26	Convergence criterion (GCONV=1E-8) satisfied.	0.34	4.73	0.002	Algorithm converged.	-0.011	0.016	1.26	Algorithm converged.	0.34	4.66	0.7304	0.79	Algorithm converged.	0.21	2.94	
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17	

Respiratory, thoracic and mediastinal disorders	Pulmonary pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Respiratory failure	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17	
Respiratory, thoracic and mediastinal disorders	Rhinitis allergic	n/a	435	100.0	10	2.3	438	100.0	4	0.9	2.55	Convergence criterion (GCONV=1E-8) satisfied.	0.79	8.20	0.014	Algorithm converged.	-0.003	0.031	2.52	Algorithm converged.	0.80	7.97	0.1162	0.40	Algorithm converged.	0.13	1.26	
Respiratory, thoracic and mediastinal disorders	Rhinorrhoea	n/a	435	100.0	16	3.7	438	100.0	19	4.3	0.84	Convergence criterion (GCONV=1E-8) satisfied.	0.43	1.66	-0.007	Algorithm converged.	-0.033	0.019	0.85	Algorithm converged.	0.44	1.63	0.6198	1.18	Algorithm converged.	0.61	2.26	
Respiratory, thoracic and mediastinal disorders	Sinus congestion	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89	
Respiratory, thoracic and mediastinal disorders	Sinus pain	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Sleep apnoea syndrome	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Respiratory, thoracic and mediastinal disorders	Sneezing	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Respiratory, thoracic and mediastinal disorders	Stridor	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Tachypnoea	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00			Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Throat irritation	n/a	435	100.0	11	2.5	438	100.0	8	1.8	1.39	Convergence criterion (GCONV=1E-8) satisfied.	0.56	3.50	0.007		Algorithm converged.	-0.012	0.026	1.38	Algorithm converged.	0.56	3.41	0.4791	0.72	Algorithm converged.	0.29	1.78
Respiratory, thoracic and mediastinal disorders	Throat tightness	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract congestion	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Upper respiratory tract inflammation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00			Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Upper-airway cough syndrome	n/a	435	100.0	2	0.5	438	100.0	4	0.9	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.09	2.75	-0.005		Algorithm converged.	-0.015	0.006	0.50	Algorithm converged.	0.09	2.73	0.4267	1.99	Algorithm converged.	0.37	10.79
Respiratory, thoracic and mediastinal disorders	Wheezing	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94

													Convergen e criterion (GCONV=1E- 8) satisfied.																						
Skin and subcutaneous tissue disorders		n/a	435	100.0	211	48.5	438	100.0	193	44.1	1.20			0.92	1.56	0.044		Algorithm converged.	-0.022	0.111	1.10		Algorithm converged.	0.95	1.27	0.1887	0.91		Algorithm converged.	0.79	1.05				
Skin and subcutaneous tissue disorders	Acanthosis nigricans	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi- complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.9 9		Algorithm converged.	0.00	NE				
Skin and subcutaneous tissue disorders	Acne	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi- complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.9 9		Algorithm converged.	0.00	NE				
Skin and subcutaneous tissue disorders	Actinic keratosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi- complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionabl e.			NE		Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE				
Skin and subcutaneous tissue disorders	Alopecia	n/a	435	100.0	106	24.4	438	100.0	105	24.0	1.02		Convergen e criterion (GCONV=1E- 8) satisfied.	0.75	1.39	0.004		Algorithm converged.	-0.053	0.061	1.02		Algorithm converged.	0.80	1.29	0.8915	0.98		Algorithm converged.	0.78	1.24				
Skin and subcutaneous tissue disorders	Angioedema	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi- complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.9 9		Algorithm converged.	0.00	NE				
Skin and subcutaneous tissue disorders	Blister	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi- complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionabl e.			NE		Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE					

Skin and subcutaneous tissue disorders	Bullous haemorrhagic dermatosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Cold sweat	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Skin and subcutaneous tissue disorders	Cutaneous vasculitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Decubitus ulcer	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Skin and subcutaneous tissue disorders	Dermal cyst	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Skin and subcutaneous tissue disorders	Dermatitis	n/a	435	100.0	0	0.0	438	100.0	3	0.7		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Dermatitis acneiform	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000		Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Skin and subcutaneous tissue disorders	Dermatitis allergic	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Skin and subcutaneous tissue disorders	Dermatitis bullous	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Skin and subcutaneous tissue disorders	Dermatitis contact	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Dermatitis diaper	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Dermatitis exfoliative generalised	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Drug eruption	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Dry skin	n/a	435	100.0	24	5.5	438	100.0	9	2.1	2.78	Convergence criterion (GCONV=1E-8) satisfied.	1.28	6.06	0.035	Algorithm converged.	0.009	0.060	2.69	Algorithm converged.	1.26	5.71	0.0103	0.37	Algorithm converged.	0.18	0.79
Skin and subcutaneous tissue disorders	Dyshidrotic eczema	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Ecchymosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Skin and subcutaneous tissue disorders	Eczema	n/a	435	100.0	7	1.6	438	100.0	4	0.9	1.77	Convergence criterion (GCONV=1E-8) satisfied.	0.52	6.11	0.007	Algorithm converged.	-0.008	0.022	1.76	Algorithm converged.	0.52	5.98	0.3633	0.57	Algorithm converged.	0.17	1.92
Skin and subcutaneous tissue disorders	Eosinophilic cellulitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Erythema	n/a	435	100.0	12	2.8	438	100.0	8	1.8	1.52	Convergence criterion (GCONV=1E-8) satisfied.	0.62	3.77	0.009	Algorithm converged.	-0.011	0.029	1.51	Algorithm converged.	0.62	3.66	0.3610	0.66	Algorithm converged.	0.27	1.60
Skin and subcutaneous tissue disorders	Erythema multiforme	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Hyperhidrosis	n/a	435	100.0	8	1.8	438	100.0	8	1.8	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.37	2.71	0.000	Algorithm converged.	-0.018	0.018	1.01	Algorithm converged.	0.38	2.66	0.9889	0.99	Algorithm converged.	0.38	2.62
Skin and subcutaneous tissue disorders	Hyperkeratosis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Skin and subcutaneous tissue disorders	Ingrowing nail	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Ingrown hair	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Skin and subcutaneous tissue disorders	Melanoderma	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Skin and subcutaneous tissue disorders	Nail discolouration	n/a	435	100.0	12	2.8	438	100.0	11	2.5	1.10	Convergence criterion (GCONV=1E-8) satisfied.	0.48	2.52	0.002	Algorithm converged.	-0.019	0.024	1.10	Algorithm converged.	0.49	2.46	0.8197	0.91	Algorithm converged.	0.41	2.04
Skin and subcutaneous tissue disorders	Nail disorder	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Skin and subcutaneous tissue disorders	Nail pigmentation	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Skin and subcutaneous tissue disorders	Nail ridging	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Skin and subcutaneous tissue disorders	Nail toxicity	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Skin and subcutaneous tissue disorders	Night sweats	n/a	435	100.0	18	4.1	438	100.0	11	2.5	1.68	Convergence criterion (GCONV=1E-8) satisfied.	0.78	3.59	0.016	Algorithm converged.	-0.008	0.040	1.65	Algorithm converged.	0.79	3.45	0.1849	0.61	Algorithm converged.	0.29	1.27
Skin and subcutaneous tissue disorders	Onychalgia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Skin and subcutaneous tissue disorders	Onychoclasia	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87

Skin and subcutaneous tissue disorders	Onycholysis	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Onychomadesis	n/a	435	100.0	6	1.4	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Onychomalacia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Pain of skin	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Papule	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Perivascular dermatitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Petechiae	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Pigmentation disorder	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Skin and subcutaneous tissue disorders	Prurigo	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Pruritus	n/a	435	100.0	35	8.0	438	100.0	27	6.2	1.33	Convergence criterion (GCONV=1E-8) satisfied.	0.79	2.24	0.019	Algorithm converged.	-0.015	0.053	1.31	Algorithm converged.	0.80	2.12	0.2809	0.77	Algorithm converged.	0.47	1.24	
Skin and subcutaneous tissue disorders	Pruritus allergic	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Skin and subcutaneous tissue disorders	Psoriasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Rash	n/a	435	100.0	32	7.4	438	100.0	23	5.3	1.43	Convergence criterion (GCONV=1E-8) satisfied.	0.82	2.49	0.021	Algorithm converged.	-0.011	0.053	1.40	Algorithm converged.	0.83	2.35	0.2031	0.71	Algorithm converged.	0.42	1.20	
Skin and subcutaneous tissue disorders	Rash erythematous	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02	
Skin and subcutaneous tissue disorders	Rash macular	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	

Skin and subcutaneous tissue disorders	Rash maculo-papular	n/a	435	100.0	11	2.5	438	100.0	13	3.0	0.85	Convergence criterion (GCONV=1E-8) satisfied.	0.38	1.91	-0.004	Algorithm converged.	-0.026	0.017	0.85	Algorithm converged.	0.39	1.88	0.6918	1.17	Algorithm converged.	0.53	2.59
Skin and subcutaneous tissue disorders	Rash papular	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Rash pruritic	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000	Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Skin and subcutaneous tissue disorders	Rosacea	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Sarcoid-like reaction	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932836 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Scar pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Skin and subcutaneous tissue disorders	Seborrhoeic dermatitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
																* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												

Skin and subcutaneous tissue disorders	Skin lesion	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Skin plaque	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Skin and subcutaneous tissue disorders	Skin striae	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Skin and subcutaneous tissue disorders	Skin ulcer	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06		Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Skin and subcutaneous tissue disorders	Toxic skin eruption	n/a	435	100.0	2	0.5	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Skin and subcutaneous tissue disorders	Trichodynia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932836 3 is greater than the limit of 0.0001. The convergence is questionable.	NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	

Skin and subcutaneous tissue disorders	Urticaria	n/a	435	100.0	6	1.4	438	100.0	15	3.4	0.39	Convergence criterion (GCONV=1E-8) satisfied.	0.15	1.03	-0.020	Algorithm converged.	-0.041	0.000	0.40	Algorithm converged.	0.16	1.03	0.0572	2.48	Algorithm converged.	0.97	6.34
Skin and subcutaneous tissue disorders	Vitiligo	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders		n/a	435	100.0	68	15.6	438	100.0	79	18.0	0.84	Convergence criterion (GCONV=1E-8) satisfied.	0.59	1.20	-0.024	Algorithm converged.	-0.074	0.026	0.87	Algorithm converged.	0.64	1.17	0.3432	1.15	Algorithm converged.	0.86	1.55
Vascular disorders	Aortic aneurysm	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Circulatory collapse	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Deep vein thrombosis	n/a	435	100.0	5	1.1	438	100.0	5	1.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.29	3.50	0.000	Algorithm converged.	-0.014	0.014	1.01	Algorithm converged.	0.29	3.45	0.9913	0.99	Algorithm converged.	0.29	3.41
Vascular disorders	Embolism	n/a	435	100.0	1	0.2	438	100.0	3	0.7	0.33	Convergence criterion (GCONV=1E-8) satisfied.	0.03	3.22	-0.005	Algorithm converged.	-0.013	0.004	0.34	Algorithm converged.	0.04	3.21	0.3436	2.98	Algorithm converged.	0.31	28.53
Vascular disorders	Flushing	n/a	435	100.0	4	0.9	438	100.0	9	2.1	0.44	Convergence criterion (GCONV=1E-8) satisfied.	0.14	1.45	-0.011	Algorithm converged.	-0.027	0.005	0.45	Algorithm converged.	0.14	1.44	0.1781	2.23	Algorithm converged.	0.69	7.20
Vascular disorders	Haematoma	n/a	435	100.0	5	1.1	438	100.0	2	0.5	2.53	Convergence criterion (GCONV=1E-8) satisfied.	0.49	13.14	0.007	Algorithm converged.	-0.005	0.019	2.52	Algorithm converged.	0.49	12.90	0.2683	0.40	Algorithm converged.	0.08	2.04
Vascular disorders	Haemorrhage	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Hot flush	n/a	435	100.0	6	1.4	438	100.0	10	2.3	0.60	Convergence criterion (GCONV=1E-8) satisfied.	0.22	1.66	-0.009	Algorithm converged.	-0.027	0.009	0.60	Algorithm converged.	0.22	1.65	0.3249	1.66	Algorithm converged.	0.61	4.51

Vascular disorders	Hypertension	n/a	435	100.0	9	2.1	438	100.0	18	4.1	0.49	Convergence criterion (GCONV=1E-8) satisfied.	0.22	1.11	-0.020	Algorithm converged.	-0.043	0.002	0.50	Algorithm converged.	0.23	1.11	0.0883	1.99	Algorithm converged.	0.90	4.37
Vascular disorders	Hypertensive crisis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Hypotension	n/a	435	100.0	18	4.1	438	100.0	19	4.3	0.95	Convergence criterion (GCONV=1E-8) satisfied.	0.49	1.84	-0.002	Algorithm converged.	-0.029	0.025	0.95	Algorithm converged.	0.51	1.79	0.8834	1.05	Algorithm converged.	0.56	1.97
Vascular disorders	Hypovolaemic shock	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Jugular vein thrombosis	n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005	Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Vascular disorders	Lymphoedema	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Orthostatic hypotension	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Pallor	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Vascular disorders	Pelvic venous thrombosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Peripheral coldness	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Peripheral embolism	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Peripheral ischaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Peripheral venous disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Phlebitis	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Vascular disorders	Subgaleal haematoma	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Vascular disorders	Systolic hypertension	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Thrombophlebitis	n/a	435	100.0	3	0.7	438	100.0	4	0.9	0.75		Convergence criterion (GCONV=1E-8) satisfied.	0.17	3.39	-0.002		Algorithm converged.	-0.014	0.010	0.76	Algorithm converged.	0.17	3.35	0.7120	1.32	Algorithm converged.	0.30	5.88
Vascular disorders	Thrombophlebitis superficial	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Thrombosis	n/a	435	100.0	4	0.9	438	100.0	3	0.7	1.35		Convergence criterion (GCONV=1E-8) satisfied.	0.30	6.05	0.002		Algorithm converged.	-0.009	0.014	1.34	Algorithm converged.	0.30	5.96	0.6986	0.74	Algorithm converged.	0.17	3.31
Vascular disorders	Varicose vein	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Vascular pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Vasculitis	n/a	435	100.0	4	0.9	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Vascular disorders	Vein disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Venous thrombosis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	*	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Venous thrombosis limb	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
 * indicates convergence problem. Result is uninterpretable.
 Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw_soc.sas
 Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_soc_AE_SE_GLOBAL_28JUN2021_39942.xls
 08MAR2022 12:15

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 3
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

All

			Polatuzumab Vedotin				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin			
			Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	435	100.0	85	19.5	438	100.0	68	15.5	1.32	Convergence criterion (GCONV=1E-8) satisfied.	0.93	1.88	0.040	Algorithm converged.	-0.010	0.091	1.26	Algorithm converged.	0.94	1.68	0.1200	0.79	Algorithm converged.	0.59	1.06	
Blood and lymphatic system disorders	Anaemia	n/a	435	100.0	50	11.5	438	100.0	36	8.2	1.45	Convergence criterion (GCONV=1E-8) satisfied.	0.92	2.28	0.033	Algorithm converged.	-0.007	0.072	1.40	Algorithm converged.	0.93	2.10	0.1066	0.72	Algorithm converged.	0.48	1.07	
Blood and lymphatic system disorders	Febrile bone marrow aplasia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	435	100.0	45	10.3	438	100.0	25	5.7	1.91	Convergence criterion (GCONV=1E-8) satisfied.	1.15	3.17	0.046	Algorithm converged.	0.010	0.082	1.81	Algorithm converged.	1.13	2.90	0.0133	0.55	Algorithm converged.	0.34	0.88	
Blood and lymphatic system disorders	Hypofibrinogenaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Blood and lymphatic system disorders	Leukopenia	n/a	435	100.0	11	2.5	438	100.0	16	3.7	0.68	Convergence criterion (GCONV=1E-8) satisfied.	0.31	1.49	-0.011	Algorithm converged.	-0.034	0.012	0.69	Algorithm converged.	0.32	1.47	0.3404	1.44	Algorithm converged.	0.68	3.08	
Blood and lymphatic system disorders	Lymphopenia	n/a	435	100.0	5	1.1	438	100.0	7	1.6	0.72	Convergence criterion (GCONV=1E-8) satisfied.	0.23	2.27	-0.004	Algorithm converged.	-0.020	0.011	0.72	Algorithm converged.	0.23	2.25	0.5709	1.39	Algorithm converged.	0.44	4.35	
Blood and lymphatic system disorders	Neutropenia	n/a	435	100.0	38	8.7	438	100.0	43	9.8	0.88	Convergence criterion (GCONV=1E-8) satisfied.	0.56	1.39	-0.011	Algorithm converged.	-0.049	0.028	0.89	Algorithm converged.	0.59	1.35	0.5821	1.12	Algorithm converged.	0.74	1.70	

Blood and lymphatic system disorders	Pancytopenia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.		NE	NE	NE	NE	Algorithm converged.		NE	NE
Blood and lymphatic system disorders	Thrombocytopenia	n/a	435	100.0	5	1.1	438	100.0	9	2.1	0.55	Convergence criterion (GCONV=1E-8) satisfied.	0.18	1.67	-0.009		Algorithm converged.	-0.026	0.008	0.56	Algorithm converged.	0.19	1.66	0.2941	1.79	Algorithm converged.		0.60	5.29	
Cardiac disorders		n/a	435	100.0	5	1.1	438	100.0	5	1.1	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.29	3.50	0.000		Algorithm converged.	-0.014	0.014	1.01	Algorithm converged.	0.29	3.45	0.9913	0.99	Algorithm converged.		0.29	3.41	
Cardiac disorders	Atrial fibrillation	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.		0.06	15.83	
Cardiac disorders	Cardiac failure congestive	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.		0.00	NE	
Cardiac disorders	Cardiopulmonary failure	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.		NE	NE	NE	NE	Algorithm converged.		NE	NE
Cardiac disorders	Left ventricular dysfunction	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.		0.06	15.83	

Cardiac disorders	Myocardial infarction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Cardiac disorders	Sinus tachycardia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01		Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Cardiac disorders	Tachycardia	n/a	435	100.0	0	0.0	438	100.0	2	0.5		Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Congenital, familial and genetic disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Congenital, familial and genetic disorders	Pyloric stenosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Ear and labyrinth disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Ear and labyrinth disorders	Hypoacusis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					*	WARNING: Negative of Hessian not positive definite.				0.00		Algorithm converged .	0.00	NE	0.9999	>999.99		Algorithm converged .	0.00	NE
Eye disorders		n/a	435	100.0	3	0.7	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					*	WARNING: Negative of Hessian not positive definite.				NE		Algorithm converged .	NE	NE	NE	NE		Algorithm converged .	NE	NE
Eye disorders	Angle closure glaucoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE		Algorithm converged .	NE	NE	NE	NE		Algorithm converged .	NE	NE
Eye disorders	Cataract	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE		Algorithm converged .	NE	NE	NE	NE		Algorithm converged .	NE	NE
Eye disorders	Rhegmatogenous retinal detachment	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.				NE		Algorithm converged .	NE	NE	NE	NE		Algorithm converged .	NE	NE
Gastrointestinal disorders		n/a	435	100.0	37	8.5	438	100.0	28	6.4	1.36	Convergence criterion (GCONV=1E-8) satisfied .	0.82	2.27	0.021			Algorithm converged.	-0.014	0.056	1.33			Algorithm converged .	0.83	2.13	0.2363	0.75		Algorithm converged .	0.47	1.21

Gastrointestinal disorders	Abdominal distension	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Abdominal pain	n/a	435	100.0	4	0.9	438	100.0	6	1.4	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.19	2.38	-0.005	Algorithm converged.	-0.019	0.010	0.67	Algorithm converged.	0.19	2.36	0.5347	1.49	Algorithm converged.	0.42	5.24
Gastrointestinal disorders	Abdominal pain upper	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Anal fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Anal stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Colitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Constipation	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007	Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Gastrointestinal disorders	Diarrhoea	n/a	435	100.0	17	3.9	438	100.0	8	1.8	2.19	Convergence criterion (GCONV=1E-8) satisfied.	0.93	5.12	0.021	Algorithm converged.	-0.001	0.043	2.14	Algorithm converged.	0.93	4.91	0.0724	0.47	Algorithm converged.	0.20	1.07
Gastrointestinal disorders	Dysphagia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Enteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Epigastric discomfort	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastrointestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Gastrooesophageal reflux disease	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	

Gastrointestinal disorders	Haemorrhoidal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Ileus	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Impaired gastric emptying	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Gastrointestinal disorders	Intestinal obstruction	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Intestinal perforation	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Large intestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Nausea	n/a	435	100.0	5	1.1	438	100.0	2	0.5	2.53	Convergence criterion (GCONV=1E-8) satisfied.	0.49	13.14	0.007		Algorithm converged.	-0.005	0.019	2.52	Algorithm converged.	0.49	12.90	0.2683	0.40	Algorithm converged.	0.08	2.04
Gastrointestinal disorders	Neutropenic colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Pancreatitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Small intestinal obstruction	n/a	435	100.0	0	0.0	438	100.0	5	1.1		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Small intestinal perforation	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Stomatitis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Gastrointestinal disorders	Subileus	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Tooth loss	n/a	435	100.0	0	0.0	438	100.0	1	0.2			Quasi-complete separation of data points detected.							WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Upper gastrointestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0			Quasi-complete separation of data points detected.							WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Vomiting	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69		Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005				Algorithm converged.	-0.008	0.017	1.68		Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
General disorders and administration site conditions		n/a	435	100.0	23	5.3	438	100.0	23	5.3	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.56	1.82	0.000				Algorithm converged.	-0.029	0.030	1.01		Algorithm converged.	0.57	1.77	0.9809	0.99	Algorithm converged.	0.57	1.74
General disorders and administration site conditions	Asthenia	n/a	435	100.0	7	1.6	438	100.0	2	0.5	3.56		Convergence criterion (GCONV=1E-8) satisfied.	0.74	17.25	0.012				Algorithm converged.	-0.002	0.025	3.52		Algorithm converged.	0.74	16.87	0.1149	0.28	Algorithm converged.	0.06	1.36
General disorders and administration site conditions	Catheter site haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2			Quasi-complete separation of data points detected.							WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Chest discomfort	n/a	435	100.0	0	0.0	438	100.0	1	0.2			Quasi-complete separation of data points detected.							WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Chest pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000				Algorithm converged.	-0.006	0.006	1.01		Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
General disorders and administration site conditions	Chills	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50		Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002				Algorithm converged.	-0.010	0.005	0.50		Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	Device related thrombosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2			Quasi-complete separation of data points detected.							WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

General disorders and administration site conditions	Fatigue	n/a	435	100.0	4	0.9	438	100.0	11	2.5	0.36	Convergence criterion (GCONV=1E-8) satisfied.	0.11	1.14	-0.016	Algorithm converged.	-0.033	0.001	0.37	Algorithm converged.	0.12	1.14	0.0832	2.73	Algorithm converged.	0.88	8.51
General disorders and administration site conditions	General physical health deterioration	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*				WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Ill-defined disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*				WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Infusion site extravasation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*				WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.		NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Injection site extravasation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*				WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Malaise	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*				WARNING: Negative of Hessian not positive definite.		0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Mucosal inflammation	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
General disorders and administration site conditions	Oedema peripheral	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
General disorders and administration site conditions	Pain	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*				WARNING: Negative of Hessian not positive definite.		NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Pyrexia	n/a	435	100.0	5	1.1	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*				WARNING: Negative of Hessian not positive definite.		NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

General disorders and administration site conditions	Ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Vascular stent thrombosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Hepatobiliary disorders		n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Hepatobiliary disorders	Bile duct stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Hepatobiliary disorders	Biliary obstruction	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.					* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Cholangitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.					* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Hepatobiliary disorders	Cholestasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Hepatic function abnormal	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Immune system disorders		n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Immune system disorders	Haemophagocytic lymphohistiocytosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Immune system disorders	Hypogammaglobulin aemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations		n/a	435	100.0	55	12.6	438	100.0	43	9.8	1.33	Convergence criterion (GCONV=1E-8) satisfied.	0.87	2.03	0.028	Algorithm converged.	-0.014	0.070	1.29	Algorithm converged.	0.88	1.88	0.1875	0.78	Algorithm converged.	0.53	1.13

Infections and infestations	Abdominal abscess	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Abdominal infection	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Abscess	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Actinomycotic abdominal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Appendicitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Aspergillus infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Atypical pneumonia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Infections and infestations	Bacteraemia	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied .	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged .	0.32	28.93	0.3375	0.33	Algorithm converged .	0.03	3.17
Infections and infestations	Bronchitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Infections and infestations	Bronchitis bacterial	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Infections and infestations	Bronchopulmonary aspergillosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Infections and infestations	Campylobacter gastroenteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE

Infections and infestations	Cellulitis	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Infections and infestations	Clostridium difficile colitis	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Clostridium difficile infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Coronavirus infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Device related infection	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Infections and infestations	Device related sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Diarrhoea infectious	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Enterobacter infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Erysipelas	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia bacteraemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia sepsis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Fungal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Gastroenteritis viral	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Herpes simplex	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Herpes zoster	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Infection	n/a	435	100.0	5	1.1	438	100.0	1	0.2	5.08	Convergence criterion (GCONV=1E-8) satisfied.	0.59	43.67	0.009		Algorithm converged.	-0.002	0.020	5.03	Algorithm converged.	0.59	42.92	0.1393	0.20	Algorithm converged.	0.02	1.69
Infections and infestations	Influenza	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Intervertebral discitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Mediastinitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Nail infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Neutropenic sepsis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Infections and infestations	Oral herpes	n/a	435	100.0	1	0.2	438	100.0	0	0.0				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Infections and infestations	Papilloma viral infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0				*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Infections and infestations	Peritonitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2				*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02				Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50		Algorithm converged.	0.05	5.46
Infections and infestations	Pneumonia	n/a	435	100.0	13	3.0	438	100.0	16	3.7	0.81				Convergence criterion (GCONV=1E-8) satisfied.	0.39	1.71	-0.007		Algorithm converged.	-0.030	0.017	0.82	Algorithm converged.	0.40	1.68	0.5846	1.22		Algorithm converged.	0.60	2.51
Infections and infestations	Pneumonia bacterial	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02				Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50		Algorithm converged.	0.05	5.46

Infections and infestations	Pneumonia viral	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Rectal abscess	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Respiratory tract infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Scrotal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Sepsis	n/a	435	100.0	4	0.9	438	100.0	4	0.9	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.25	4.05	0.000	Algorithm converged.	-0.013	0.013	1.01	Algorithm converged.	0.25	4.00	0.9922	0.99	Algorithm converged.	0.25	3.95
Infections and infestations	Septic shock	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Skin infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Staphylococcal infection	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	

Infections and infestations	Wound infection bacterial	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications		n/a	435	100.0	5	1.1	438	100.0	4	0.9	1.26	Convergence criterion (GCONV=1E-8) satisfied.	0.34	4.73	0.002		Algorithm converged.	-0.011	0.016	1.26		Algorithm converged.	0.34	4.66	0.7304	0.79	Algorithm converged.	0.21	2.94
Injury, poisoning and procedural complications	Compression fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Hip fracture	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50		Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Injury, poisoning and procedural complications	Infusion related reaction	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Lumbar vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Peroneal nerve injury	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Injury, poisoning and procedural complications	Post lumbar puncture syndrome	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Thoracic vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Traumatic fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations		n/a	435	100.0	30	6.9	438	100.0	27	6.2	1.13	Convergence criterion (GCONV=1E-8) satisfied.	0.66	1.93	0.007	Algorithm converged.	-0.025	0.040	1.12	Algorithm converged.	0.68	1.85	0.6617	0.89	Algorithm converged.	0.54	1.48
Investigations	Alanine aminotransferase increased	n/a	435	100.0	3	0.7	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.		NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Amylase increased	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Investigations	Aspartate aminotransferase increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood creatinine increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Blood culture positive	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	C-reactive protein increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Coronavirus test positive	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Ejection fraction decreased	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	*	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.8

Investigations	Gamma-glutamyltransferase increased	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Investigations	Lipase increased	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Investigations	Liver function test increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.				NE	NE	NE	NE	NE	NE	NE	NE
Investigations	Lymphocyte count decreased	n/a	435	100.0	11	2.5	438	100.0	8	1.8	1.39	Convergence criterion (GCONV=1E-8) satisfied.	0.56	3.50	0.007	Algorithm converged.	-0.012	0.026	1.38	Algorithm converged.	0.56	3.41	0.4791	0.72	Algorithm converged.	0.29	1.78
Investigations	Neutrophil count decreased	n/a	435	100.0	6	1.4	438	100.0	8	1.8	0.75	Convergence criterion (GCONV=1E-8) satisfied.	0.26	2.18	-0.004	Algorithm converged.	-0.021	0.012	0.76	Algorithm converged.	0.26	2.16	0.6002	1.32	Algorithm converged.	0.46	3.78
Investigations	Oxygen saturation decreased	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Platelet count decreased	n/a	435	100.0	6	1.4	438	100.0	2	0.5	3.05	Convergence criterion (GCONV=1E-8) satisfied.	0.61	15.19	0.009	Algorithm converged.	-0.003	0.022	3.02	Algorithm converged.	0.61	14.88	0.1743	0.33	Algorithm converged.	0.07	1.63
Investigations	Transaminases increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Troponin I increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Metabolism and nutrition disorders	Dehydration	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Glucose tolerance impaired	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.		NE		NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hyperglycaemia	n/a	435	100.0	7	1.6	438	100.0	5	1.1	1.42	Convergence criterion (GCONV=1E-8) satisfied.	0.45	4.50	0.005	Algorithm converged.	-0.011	0.020	1.41	Algorithm converged.	0.45	4.41	0.5550	0.71	Algorithm converged.	0.23	2.22
Metabolism and nutrition disorders	Hyperkalaemia	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Hyperuricaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.		NE		NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hypoalbuminaemia	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		NE		NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hypocalcaemia	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83

Metabolism and nutrition disorders	Hypoglycaemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Hypokalaemia	n/a	435	100.0	7	1.6	438	100.0	7	1.6	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.35	2.90	0.000	Algorithm converged.	-0.017	0.017	1.01	Algorithm converged.	0.36	2.85	0.9897	0.99	Algorithm converged.	0.35	2.81
Metabolism and nutrition disorders	Hypomagnesaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hyponatraemia	n/a	435	100.0	6	1.4	438	100.0	8	1.8	0.75	Convergence criterion (GCONV=1E-8) satisfied.	0.26	2.18	-0.004	Algorithm converged.	-0.021	0.012	0.76	Algorithm converged.	0.26	2.16	0.6002	1.32	Algorithm converged.	0.46	3.78
Metabolism and nutrition disorders	Hypophosphataemia	n/a	435	100.0	8	1.8	438	100.0	6	1.4	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.46	3.92	0.005	Algorithm converged.	-0.012	0.021	1.34	Algorithm converged.	0.47	3.84	0.5825	0.74	Algorithm converged.	0.26	2.13
Metabolism and nutrition disorders	Hypovolaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Metabolism and nutrition disorders	Malnutrition	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	*				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.		Algorithm converged.		-0.012	0.008	0.67		Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Metabolism and nutrition disorders	Vitamin B1 deficiency	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.	*				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders		n/a	435	100.0	2	0.5	438	100.0	9	2.1	0.22	Convergence criterion (GCONV=1E-8) satisfied.		Algorithm converged.		-0.031	-0.001	0.22		Algorithm converged.	0.05	1.03	0.0545	4.47	Algorithm converged.	0.97	20.57
Musculoskeletal and connective tissue disorders	Back pain	n/a	435	100.0	1	0.2	438	100.0	5	1.1	0.20	Convergence criterion (GCONV=1E-8) satisfied.		Algorithm converged.		-0.020	0.002	0.20		Algorithm converged.	0.02	1.72	0.1427	4.97	Algorithm converged.	0.58	42.33
Musculoskeletal and connective tissue disorders	Bone pain	n/a	435	100.0	0	0.0	438	100.0	3	0.7		Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	*			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.	0.00			Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.	0.00			Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma of colon	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Colorectal cancer	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hodgkin's disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary renal cell carcinoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Nervous system disorders		n/a	435	100.0	17	3.9	438	100.0	22	5.0	0.77	Convergence criterion (GCONV=1E-8) satisfied .	0.40	1.47	-0.011		Algorithm converged.	-0.039	0.016	0.78	Algorithm converged .	0.42	1.44	0.4267	1.29	Algorithm converged .	0.69	2.39
Nervous system disorders	Aphasia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Nervous system disorders	Carotid artery stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Nervous system disorders	Cerebellar ataxia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Nervous system disorders	Cerebral infarction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Nervous system disorders	Cerebrovascular accident	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE

Nervous system disorders	Dizziness	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Nervous system disorders	Epilepsy	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Headache	n/a	435	100.0	1	0.2	438	100.0	4	0.9	0.25	Convergence criterion (GCONV=1E-8) satisfied.	0.03	2.25	-0.007	Algorithm converged.	-0.017	0.003	0.25	Algorithm converged.	0.03	2.24	0.2164	3.97	Algorithm converged.	0.45	35.40
Nervous system disorders	Hypoaesthesia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Hypotonia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Neuropathy peripheral	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Nervous system disorders	Paralysis recurrent laryngeal nerve	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Peripheral motor neuropathy	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Peripheral sensory neuropathy	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Nervous system disorders	Peroneal nerve palsy	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Polyneuropathy	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Presyncope	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Nervous system disorders	Spinal cord compression	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Syncope	n/a	435	100.0	8	1.8	438	100.0	8	1.8	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.37	2.71	0.000		Algorithm converged.	-0.018	0.018	1.01	Algorithm converged.	0.38	2.66	0.9889	0.99	Algorithm converged.	0.38	2.62
Psychiatric disorders		n/a	435	100.0	6	1.4	438	100.0	2	0.5	3.05		Convergence criterion (GCONV=1E-8) satisfied.	0.61	15.19	0.009		Algorithm converged.	-0.003	0.022	3.02	Algorithm converged.	0.61	14.88	0.1743	0.33	Algorithm converged.	0.07	1.62

Psychiatric disorders	Mental status changes	n/a	435	100.0	1	0.2	438	100.0	0	0.0			* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders		n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005		Algorithm converged.	-0.006	0.016	2.01		Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Renal and urinary disorders	Acute kidney injury	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03		Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02		Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Renal and urinary disorders	Cystitis noninfective	n/a	435	100.0	0	0.0	438	100.0	1	0.2			* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Renal failure	n/a	435	100.0	1	0.2	438	100.0	0	0.0			* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders	Urinary retention	n/a	435	100.0	1	0.2	438	100.0	0	0.0			* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Reproductive system and breast disorders		n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Reproductive system and breast disorders	Female genital tract fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Reproductive system and breast disorders	Uterine pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Respiratory, thoracic and mediastinal disorders		n/a	435	100.0	14	3.2	438	100.0	9	2.1	1.59	Convergence criterion (GCONV=1E-8) satisfied .	0.68	3.70	0.012		Algorithm converged.	-0.010	0.033	1.57	Algorithm converged .	0.69	3.58	0.2875	0.64	Algorithm converged .	0.28	1.46
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.9 9	Algorithm converged .	0.00	NE
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.9 9	Algorithm converged .	0.00	NE
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied .	0.20	5.02	0.000		Algorithm converged.	-0.011	0.011	1.01	Algorithm converged .	0.20	4.96	0.9933	0.99	Algorithm converged .	0.20	4.89
Respiratory, thoracic and mediastinal disorders	Hypoxia	n/a	435	100.0	5	1.1	438	100.0	1	0.2	5.08	Convergence criterion (GCONV=1E-8) satisfied .	0.59	43.67	0.009		Algorithm converged.	-0.002	0.020	5.03	Algorithm converged .	0.59	42.92	0.1393	0.20	Algorithm converged .	0.02	1.69

Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Tachypnoea	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Skin and subcutaneous tissue disorders		n/a	435	100.0	6	1.4	438	100.0	4	0.9	1.52	Convergence criterion (GCONV=1E-8) satisfied.	0.43	5.41	0.005	Algorithm converged.	-0.009	0.019	1.51	Algorithm converged.	0.43	5.31	0.5207	0.66	Algorithm converged.	0.19	2.33
Skin and subcutaneous tissue disorders	Alopecia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Bullous haemorrhagic dermatosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Hyperhidrosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Nail discolouration	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Pruritus	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Psoriasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Rash	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Skin and subcutaneous tissue disorders	Rash maculopapular	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Skin and subcutaneous tissue disorders	Urticaria	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders		n/a	435	100.0	13	3.0	438	100.0	14	3.2	0.93	Convergence criterion (GCONV=1E-8) satisfied.	0.43	2.01	-0.002	Algorithm converged.	-0.025	0.021	0.93	Algorithm converged.	0.44	1.97	0.8593	1.07	Algorithm converged.	0.51	2.25
Vascular disorders	Deep vein thrombosis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Embolism	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Hypertension	n/a	435	100.0	6	1.4	438	100.0	10	2.3	0.60	Convergence criterion (GCONV=1E-8) satisfied.	0.22	1.66	-0.009	Algorithm converged.	-0.027	0.009	0.60	Algorithm converged.	0.22	1.65	0.3249	1.66	Algorithm converged.	0.61	4.51
Vascular disorders	Hypotension	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Pallor	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Vascular disorders	Peripheral coldness	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.				0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	

Vascular disorders	Peripheral embolism	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Peripheral ischaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Vascular disorders	Systolic hypertension	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE		NE	NE	NE	NE	Algorithm converged.	NE	NE		
Vascular disorders	Thrombosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.	NE		NE	NE	NE	NE	Algorithm converged.	NE	NE		

Vascular disorders	Venous thrombosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
--------------------	-------------------	-----	-----	-------	---	-----	-----	-------	---	-----	---	--	---	---	----	----------------------	----	----	----	----	----------------------	----	----

```
Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw_soc.sas
Output: root/clinical studies/RO5541077/CDPT7884/G039942/data analysis/ACE PRIMARY CSR Pooled/prod/output global/t ae raw soc WGR3AE SE GLOBAL 28JUN2021 39942.xls
08MAR2022 12:28
```

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 4
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

All

			Polatuzumab Vedotin +				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
			Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	435	100.0	98	22.5	438	100.0	106	24.2	0.91	Convergence criterion (GCONV=1E-8) satisfied.	0.67	1.25	-0.017	Algorithm converged.	-0.073	0.039	0.93	Algorithm converged.	0.73	1.18	0.5595	1.07	Algorithm converged.	0.84	1.37	
Blood and lymphatic system disorders	Agranulocytosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Blood and lymphatic system disorders	Anaemia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46	
Blood and lymphatic system disorders	Aplasia pure red cell	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Blood and lymphatic system disorders	Cytopenia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Blood and lymphatic system disorders	Febrile bone marrow aplasia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	435	100.0	15	3.4	438	100.0	10	2.3	1.53	Convergence criterion (GCONV=1E-8) satisfied.	0.68	3.44	0.012	Algorithm converged.	-0.010	0.034	1.51	Algorithm converged.	0.69	3.32	0.3057	0.66	Algorithm converged.	0.30	1.46	

Blood and lymphatic system disorders	Leukopenia	n/a	435	100.0	14	3.2	438	100.0	14	3.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.47	2.14	0.000	Algorithm converged.	-0.023	0.024	1.01	Algorithm converged.	0.49	2.09	0.9853	0.99	Algorithm converged.	0.48	2.06
Blood and lymphatic system disorders	Lymphopenia	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Blood and lymphatic system disorders	Neutropenia	n/a	435	100.0	85	19.5	438	100.0	92	21.0	0.91	Convergence criterion (GCONV=1E-8) satisfied.	0.66	1.27	-0.015	Algorithm converged.	-0.068	0.039	0.93	Algorithm converged.	0.71	1.21	0.5907	1.07	Algorithm converged.	0.83	1.40
Blood and lymphatic system disorders	Thrombocytopenia	n/a	435	100.0	9	2.1	438	100.0	10	2.3	0.90	Convergence criterion (GCONV=1E-8) satisfied.	0.36	2.25	-0.002	Algorithm converged.	-0.021	0.017	0.91	Algorithm converged.	0.37	2.21	0.8284	1.10	Algorithm converged.	0.45	2.69
Cardiac disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Atrial fibrillation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Ear and labyrinth disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Ear and labyrinth disorders	Deafness	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders		n/a	435	100.0	4	0.9	438	100.0	8	1.8	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.15	1.67	-0.009	Algorithm converged.	-0.024	0.006	0.50	Algorithm converged.	0.15	1.66	0.2595	1.99	Algorithm converged.	0.60	6.55

Gastrointestinal disorders	Constipation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastric ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastrointestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Gastrointestinal disorders	Ileus	n/a	435	100.0	0	0.0	438	100.0	2	0.5		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Intestinal perforation	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Intra-abdominal haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Gastrointestinal disorders	Necrotising colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Obstruction gastric	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Gastrointestinal disorders	Pancreatic disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Gastrointestinal disorders	Stomatitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.	NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
General disorders and administration site conditions		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE		Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	

General disorders and administration site conditions	Pyrexia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE
Hepatobiliary disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE
Hepatobiliary disorders	Cholecystitis acute	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE
Infections and infestations		n/a	435	100.0	6	1.4	438	100.0	6	1.4	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.32	3.15	0.000		Algorithm converged.	-0.015	0.016	1.01	Algorithm converged.	0.33	3.10	0.9904	0.99		Algorithm converged.	0.32	3.06

Infections and infestations	Cytomegalovirus enteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Cytomegalovirus infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Escherichia bacteraemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Escherichia infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia sepsis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Klebsiella sepsis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Neutropenic sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Pneumonia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Sepsis	n/a	435	100.0	0	0.0	438	100.0	3	0.7		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Staphylococcal infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Systemic candida	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications		n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Injury, poisoning and procedural complications	Lower limb fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Spinal column injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Investigations		n/a	435	100.0	29	6.7	438	100.0	33	7.5	0.88	Convergence criterion (GCONV=1E-8) satisfied.	0.52	1.47	-0.009	Algorithm converged.	-0.043	0.025	0.88	Algorithm converged.	0.55	1.43	0.6181	1.13	Algorithm converged.	0.70	1.83
Investigations	Amylase increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Lipase increased	n/a	435	100.0	0	0.0	438	100.0	4	0.9	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Lymphocyte count decreased	n/a	435	100.0	2	0.5	438	100.0	7	1.6	0.28	Convergence criterion (GCONV=1E-8) satisfied.	0.06	1.38	-0.011	Algorithm converged.	-0.025	0.002	0.29	Algorithm converged.	0.06	1.38	0.1189	3.48	Algorithm converged.	0.73	16.64
Investigations	Neutrophil count decreased	n/a	435	100.0	24	5.5	438	100.0	20	4.6	1.22	Convergence criterion (GCONV=1E-8) satisfied.	0.66	2.24	0.010	Algorithm converged.	-0.020	0.039	1.21	Algorithm converged.	0.68	2.15	0.5214	0.83	Algorithm converged.	0.46	1.48
Investigations	Platelet count decreased	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Investigations	White blood cell count decreased	n/a	435	100.0	9	2.1	438	100.0	10	2.3	0.90	Convergence criterion (GCONV=1E-8) satisfied.	0.36	2.25	-0.002	Algorithm converged.	-0.021	0.017	0.91	Algorithm converged.	0.37	2.21	0.8284	1.10	Algorithm converged.	0.45	2.69
Metabolism and nutrition disorders		n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005	Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Metabolism and nutrition disorders	Hypercalcaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hyperuricaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hypokalaemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Hyponatraemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma pancreas	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Nervous system disorders	Syncope	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Psychiatric disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Personality change	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders		n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Renal and urinary disorders	Acute kidney injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Renal failure	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders		n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Respiratory, thoracic and mediastinal disorders	Lung disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Respiratory failure	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Hypotension	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier. Only AEs of highest severity are counted.

* indicates convergence problem. Result is uninterpretable.

Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw_soc.sas

Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_soc_WGR4AE_SE_GLOBAL_28JUN2021_39942.xls

08MAR2022 12:34

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

			Polatuzumab Vedotin +				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin +			
			Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk					
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	435	100.0	183	42.1	438	100.0	174	39.7	1.10	Convergence criterion (GCONV=1E-8) satisfied.	0.84	1.44	0.023	Algorithm converged.	-0.042	0.089	1.06	Algorithm converged.	0.90	1.24	0.4816	0.94	Algorithm converged.	0.81	1.11	
Blood and lymphatic system disorders	Agranulocytosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Blood and lymphatic system disorders	Anaemia	n/a	435	100.0	52	12.0	438	100.0	37	8.4	1.47	Convergence criterion (GCONV=1E-8) satisfied.	0.94	2.29	0.035	Algorithm converged.	-0.005	0.075	1.42	Algorithm converged.	0.95	2.11	0.0890	0.71	Algorithm converged.	0.47	1.05	
Blood and lymphatic system disorders	Aplasia pure red cell	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Blood and lymphatic system disorders	Cytopenia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Blood and lymphatic system disorders	Febrile bone marrow aplasia	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	435	100.0	60	13.8	438	100.0	35	8.0	1.84	Convergence criterion (GCONV=1E-8) satisfied.	1.19	2.86	0.058	Algorithm converged.	0.017	0.099	1.73	Algorithm converged.	1.16	2.56	0.0068	0.58	Algorithm converged.	0.39	0.86	

Blood and lymphatic system disorders	Hypofibrinogenaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Blood and lymphatic system disorders	Leukopenia	n/a	435	100.0	25	5.7	438	100.0	30	6.8	0.83	Convergence criterion (GCONV=1E-8) satisfied.	0.48	1.43	-0.011	Algorithm converged.	-0.043	0.021	0.84	Algorithm converged.	0.50	1.40	0.5034	1.19	Algorithm converged.	0.71	1.99
Blood and lymphatic system disorders	Lymphopenia	n/a	435	100.0	7	1.6	438	100.0	10	2.3	0.70	Convergence criterion (GCONV=1E-8) satisfied.	0.26	1.86	-0.007	Algorithm converged.	-0.025	0.012	0.70	Algorithm converged.	0.27	1.83	0.4736	1.42	Algorithm converged.	0.55	3.69
Blood and lymphatic system disorders	Neutropenia	n/a	435	100.0	123	28.3	438	100.0	135	30.8	0.88	Convergence criterion (GCONV=1E-8) satisfied.	0.66	1.18	-0.025	Algorithm converged.	-0.086	0.035	0.92	Algorithm converged.	0.75	1.13	0.4101	1.09	Algorithm converged.	0.89	1.34
Blood and lymphatic system disorders	Pancytopenia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Blood and lymphatic system disorders	Thrombocytopenia	n/a	435	100.0	14	3.2	438	100.0	19	4.3	0.73	Convergence criterion (GCONV=1E-8) satisfied.	0.36	1.48	-0.011	Algorithm converged.	-0.036	0.014	0.74	Algorithm converged.	0.38	1.46	0.3878	1.35	Algorithm converged.	0.68	2.65
Cardiac disorders		n/a	435	100.0	5	1.1	438	100.0	7	1.6	0.72	Convergence criterion (GCONV=1E-8) satisfied.	0.23	2.27	-0.004	Algorithm converged.	-0.020	0.011	0.72	Algorithm converged.	0.23	2.25	0.5709	1.39	Algorithm converged.	0.44	4.35
Cardiac disorders	Atrial fibrillation	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Cardiac disorders	Atrioventricular block complete	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Cardiac disorders	Cardiac failure congestive	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Cardiopulmonary failure	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Left ventricular dysfunction	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Cardiac disorders	Myocardial infarction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Sinus tachycardia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Cardiac disorders	Tachycardia	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Congenital, familial and genetic disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Congenital, familial and genetic disorders	Pyloric stenosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Ear and labyrinth disorders		n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Ear and labyrinth disorders	Deafness	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Ear and labyrinth disorders	Hypoacusis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Eye disorders		n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE

Eye disorders	Angle closure glaucoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Eye disorders	Cataract	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Eye disorders	Rhegmatogenous retinal detachment	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Gastrointestinal disorders		n/a	435	100.0	42	9.7	438	100.0	36	8.2	1.19	Convergence criterion (GCONV=1E-8) satisfied.	0.75	1.90	0.014	Algorithm converged.	-0.023	0.052	1.17	Algorithm converged.	0.77	1.80	0.4577	0.85	Algorithm converged.	0.56	1.30
Gastrointestinal disorders	Abdominal distension	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Gastrointestinal disorders	Abdominal pain	n/a	435	100.0	4	0.9	438	100.0	6	1.4	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.19	2.38	-0.005	Algorithm converged.	-0.019	0.010	0.67	Algorithm converged.	0.19	2.36	0.5347	1.49	Algorithm converged.	0.42	5.24

Gastrointestinal disorders	Abdominal pain upper	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Anal fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Anal stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Colitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Constipation	n/a	435	100.0	5	1.1	438	100.0	1	0.2	5.08	Convergence criterion (GCONV=1E-8) satisfied.	0.59	43.67	0.009		Algorithm converged.	-0.002	0.020	5.03	Algorithm converged.	0.59	42.92	0.1393	0.20	Algorithm converged.	0.02	1.69
Gastrointestinal disorders	Diarrhoea	n/a	435	100.0	17	3.9	438	100.0	8	1.8	2.19	Convergence criterion (GCONV=1E-8) satisfied.	0.93	5.12	0.021		Algorithm converged.	-0.001	0.043	2.14	Algorithm converged.	0.93	4.91	0.0724	0.47	Algorithm converged.	0.20	1.07
Gastrointestinal disorders	Dysphagia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Enteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Epigastric discomfort	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastric ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastrointestinal haemorrhage	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Gastrointestinal disorders	Gastroesophageal reflux disease	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Haemorrhoidal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Gastrointestinal disorders	Ileus	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Gastrointestinal disorders	Impaired gastric emptying	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Gastrointestinal disorders	Intestinal obstruction	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Intestinal perforation	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Gastrointestinal disorders	Intra-abdominal haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Gastrointestinal disorders	Large intestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Gastrointestinal disorders	Nausea	n/a	435	100.0	5	1.1	438	100.0	2	0.5	2.53	Convergence criterion (GCONV=1E-8) satisfied.	0.49	13.14	0.007	Algorithm converged.	-0.005	0.019	2.52	Algorithm converged.	0.49	12.90	0.2683	0.40	Algorithm converged.	0.08	2.04

Gastrointestinal disorders	Necrotising colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Neutropenic colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Obstruction gastric	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Pancreatic disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Pancreatitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Small intestinal obstruction	n/a	435	100.0	0	0.0	438	100.0	5	1.1	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Small intestinal perforation	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Stomatitis	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17

Gastrointestinal disorders	Subileus	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Tooth loss	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Upper gastrointestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Vomiting	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69	Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005		Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
General disorders and administration site conditions		n/a	435	100.0	29	6.7	438	100.0	25	5.7	1.18	Convergence criterion (GCONV=1E-8) satisfied.	0.68	2.05	0.010		Algorithm converged.	-0.022	0.042	1.17	Algorithm converged.	0.70	1.96	0.5570	0.86	Algorithm converged.	0.51	1.44
General disorders and administration site conditions	Asthenia	n/a	435	100.0	7	1.6	438	100.0	2	0.5	3.56	Convergence criterion (GCONV=1E-8) satisfied.	0.74	17.25	0.012		Algorithm converged.	-0.002	0.025	3.52	Algorithm converged.	0.74	16.87	0.1149	0.28	Algorithm converged.	0.06	1.36
General disorders and administration site conditions	Cardiac death	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Catheter site haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

General disorders and administration site conditions	Chest discomfort	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Chest pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
General disorders and administration site conditions	Chills	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	Death	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
General disorders and administration site conditions	Device related thrombosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Fatigue	n/a	435	100.0	4	0.9	438	100.0	11	2.5	0.36	Convergence criterion (GCONV=1E-8) satisfied.	0.11	1.14	-0.016		Algorithm converged.	-0.033	0.001	0.37	Algorithm converged.	0.12	1.14	0.0832	2.73	Algorithm converged.	0.88	8.51
General disorders and administration site conditions	General physical health deterioration	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Ill-defined disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Infusion site extravasation	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Injection site extravasation	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	

General disorders and administration site conditions	Malaise	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Mucosal inflammation	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Oedema peripheral	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
General disorders and administration site conditions	Pain	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Pyrexia	n/a	435	100.0	6	1.4	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Vascular stent thrombosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Hepatobiliary disorders		n/a	435	100.0	3	0.7	438	100.0	3	0.7	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.20	5.02	0.000		Algorithm converged.	-0.011	0.011	1.01	Algorithm converged.	0.20	4.96	0.9933	0.99	Algorithm converged.	0.20	4.89
Hepatobiliary disorders	Bile duct stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Hepatobiliary disorders	Biliary obstruction	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Cholangitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Hepatobiliary disorders	Cholecystitis acute	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Cholestasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932787 7 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Hepatic function abnormal	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Immune system disorders		n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	

Immune system disorders	Haemophagocytic lymphohistiocytosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Immune system disorders	Hypogammaglobulin aemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations		n/a	435	100.0	66	15.2	438	100.0	55	12.6	1.25	Convergence criterion (GCONV=1E-8) satisfied.	0.85	1.83	0.026		Algorithm converged.	-0.020	0.072	1.21	Algorithm converged.	0.87	1.68	0.2645	0.83	Algorithm converged.	0.59	1.15
Infections and infestations	Abdominal abscess	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Abdominal infection	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Abscess	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Actinomycotic abdominal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Appendicitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Aspergillus infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Atypical pneumonia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Bacteraemia	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17	
Infections and infestations	Bronchitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Infections and infestations	Bronchitis bacterial	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Bronchopulmonary aspergillosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Campylobacter gastroenteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Cellulitis	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Infections and infestations	Clostridium difficile colitis	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Clostridium difficile infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Coronavirus infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Cytomegalovirus enteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Cytomegalovirus infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Infections and infestations	Device related infection	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005	Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17	
Infections and infestations	Device related sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Diarrhoea infectious	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Enterobacter infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Erysipelas	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia bacteraemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Escherichia infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia sepsis	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Fungal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Gastroenteritis viral	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932836 3 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Herpes simplex	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Herpes zoster	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Infection	n/a	435	100.0	5	1.1	438	100.0	1	0.2	5.08	Convergence criterion (GCONV=1E-8) satisfied.	0.59	43.67	0.009		Algorithm converged.	-0.002	0.020	5.03	Algorithm converged.	0.59	42.92	0.1393	0.20	Algorithm converged.	0.02	1.69
Infections and infestations	Influenza	n/a	435	100.0	2	0.5	438	100.0	0	0.0		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Intervertebral discitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Klebsiella sepsis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Mediastinitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Nail infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Neutropenic sepsis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Infections and infestations	Oral herpes	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Papilloma viral infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Peritonitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Infections and infestations	Pneumonia	n/a	435	100.0	18	4.1	438	100.0	20	4.6	0.90	Convergence criterion (GCONV=1E-8) satisfied.	0.47	1.73	-0.004	Algorithm converged.	-0.031	0.023	0.91	Algorithm converged.	0.49	1.69	0.7566	1.10	Algorithm converged.	0.59	2.06
Infections and infestations	Pneumonia bacterial	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46

Infections and infestations	Pneumonia viral	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Infections and infestations	Rectal abscess	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Infections and infestations	Respiratory tract infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Infections and infestations	Scrotal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Infections and infestations	Sepsis	n/a	435	100.0	5	1.1	438	100.0	8	1.8	0.63	Convergence criterion (GCONV=1E-8) satisfied.	0.20	1.93	-0.007	Algorithm converged.	-0.023	0.009	0.63	Algorithm converged.	0.21	1.91	0.4133	1.59	Algorithm converged.	0.52	4.82
Infections and infestations	Septic shock	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Infections and infestations	Skin infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Staphylococcal infection	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02

Infections and infestations	Staphylococcal sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Infections and infestations	Systemic candida	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Infections and infestations	Tracheobronchitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Infections and infestations	Tuberculosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Infections and infestations	Upper respiratory tract infection	n/a	435	100.0	2	0.5	438	100.0	2	0.5	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.14	7.18	0.000	Algorithm converged.	-0.009	0.009	1.01	Algorithm converged.	0.14	7.12	0.9945	0.99	Algorithm converged.	0.14	7.02
Infections and infestations	Urinary tract infection	n/a	435	100.0	8	1.8	438	100.0	5	1.1	1.62	Convergence criterion (GCONV=1E-8) satisfied.	0.53	5.00	0.007	Algorithm converged.	-0.009	0.023	1.61	Algorithm converged.	0.53	4.89	0.3995	0.62	Algorithm converged.	0.20	1.88

Infections and infestations	Viral infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Infections and infestations	Wound infection bacterial	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Injury, poisoning and procedural complications		n/a	435	100.0	6	1.4	438	100.0	6	1.4	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.32	3.15	0.000	Algorithm converged.	-0.015	0.016	1.01	Algorithm converged.	0.33	3.10	0.9904	0.99	Algorithm converged.	0.32	3.06
Injury, poisoning and procedural complications	Compression fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Injury, poisoning and procedural complications	Hip fracture	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Injury, poisoning and procedural complications	Infusion related reaction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Injury, poisoning and procedural complications	Injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				

Injury, poisoning and procedural complications	Lower limb fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Lumbar vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Peroneal nerve injury	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Post lumbar puncture syndrome	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932836 3 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Injury, poisoning and procedural complications	Spinal column injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Thoracic vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Injury, poisoning and procedural complications	Traumatic fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations		n/a	435	100.0	59	13.6	438	100.0	60	13.7	0.99	Convergence criterion (GCONV=1E-8) satisfied.	0.67	1.46	-0.001		Algorithm converged.	-0.047	0.044	0.99	Algorithm converged.	0.71	1.38	0.9535	1.01	Algorithm converged.	0.72	1.41
Investigations	Alanine aminotransferase increased	n/a	435	100.0	3	0.7	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Amylase increased	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Aspartate aminotransferase increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Blood creatinine increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Blood culture positive	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Investigations	C-reactive protein increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE
Investigations	Coronavirus test positive	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE
Investigations	Ejection fraction decreased	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99		Algorithm converged.	0.06	15.83
Investigations	Gamma-glutamyltransferase increased	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66		Algorithm converged.	0.11	3.94
Investigations	Lipase increased	n/a	435	100.0	1	0.2	438	100.0	6	1.4	0.17	Convergence criterion (GCONV=1E-8) satisfied.	0.02	1.38	-0.011		Algorithm converged.	-0.023	0.000	0.17	Algorithm converged.	0.02	1.39	0.0978	5.96		Algorithm converged.	0.72	49.29
Investigations	Liver function test increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE

Investigations	Lymphocyte count decreased	n/a	435	100.0	13	3.0	438	100.0	15	3.4	0.87	Convergence criterion (GCONV=1E-8) satisfied.	0.41	1.85	-0.004	Algorithm converged.	-0.028	0.019	0.87	Algorithm converged.	0.42	1.81	0.7148	1.15	Algorithm converged.	0.55	2.38
Investigations	Neutrophil count decreased	n/a	435	100.0	30	6.9	438	100.0	28	6.4	1.08	Convergence criterion (GCONV=1E-8) satisfied.	0.64	1.85	0.005	Algorithm converged.	-0.028	0.038	1.08	Algorithm converged.	0.66	1.77	0.7651	0.93	Algorithm converged.	0.56	1.52
Investigations	Oxygen saturation decreased	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Platelet count decreased	n/a	435	100.0	9	2.1	438	100.0	3	0.7	3.06	Convergence criterion (GCONV=1E-8) satisfied.	0.82	11.39	0.014	Algorithm converged.	-0.002	0.029	3.02	Algorithm converged.	0.82	11.08	0.0955	0.33	Algorithm converged.	0.09	1.21
Investigations	Transaminases increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Troponin I increased	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	Troponin T increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Weight decreased	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007	Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Investigations	Weight increased	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Investigations	White blood cell count decreased	n/a	435	100.0	18	4.1	438	100.0	14	3.2	1.31	Convergence criterion (GCONV=1E-8) satisfied.	0.64	2.66	0.009	Algorithm converged.	-0.016	0.034	1.29	Algorithm converged.	0.65	2.57	0.4605	0.77	Algorithm converged.	0.39	1.53
Investigations	White blood cell count increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders		n/a	435	100.0	40	9.2	438	100.0	34	7.8	1.20	Convergence criterion (GCONV=1E-8) satisfied.	0.75	1.94	0.014	Algorithm converged.	-0.023	0.051	1.18	Algorithm converged.	0.76	1.83	0.4480	0.84	Algorithm converged.	0.55	1.31
Metabolism and nutrition disorders	Decreased appetite	n/a	435	100.0	5	1.1	438	100.0	3	0.7	1.69	Convergence criterion (GCONV=1E-8) satisfied.	0.40	7.10	0.005	Algorithm converged.	-0.008	0.017	1.68	Algorithm converged.	0.40	6.98	0.4765	0.60	Algorithm converged.	0.14	2.48
Metabolism and nutrition disorders	Dehydration	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Metabolism and nutrition disorders	Diabetes mellitus inadequate control	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Glucose tolerance impaired	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Metabolism and nutrition disorders	Hypercalcaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Metabolism and nutrition disorders	Hyperglycaemia	n/a	435	100.0	7	1.6	438	100.0	5	1.1	1.42	Convergence criterion (GCONV=1E-8) satisfied.	0.45	4.50	0.005	Algorithm converged.	-0.011	0.020	1.41	Algorithm converged.	0.45	4.41	0.5550	0.71	Algorithm converged.	0.23	2.22
Metabolism and nutrition disorders	Hyperkalaemia	n/a	435	100.0	0	0.0	438	100.0	2	0.5		* Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Metabolism and nutrition disorders	Hypertriglyceridaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Metabolism and nutrition disorders	Hyperuricaemia	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Metabolism and nutrition disorders	Hypoalbuminaemia	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Metabolism and nutrition disorders	Hypocalcaemia	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Metabolism and nutrition disorders	Hypoglycaemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Metabolism and nutrition disorders	Hypokalaemia	n/a	435	100.0	8	1.8	438	100.0	8	1.8	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.37	2.71	0.000	Algorithm converged.	-0.018	0.018	1.01	Algorithm converged.	0.38	2.66	0.9889	0.99	Algorithm converged.	0.38	2.62
Metabolism and nutrition disorders	Hypomagnesaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Hyponatraemia	n/a	435	100.0	6	1.4	438	100.0	9	2.1	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.24	1.89	-0.007	Algorithm converged.	-0.024	0.010	0.67	Algorithm converged.	0.24	1.87	0.4457	1.49	Algorithm converged.	0.53	4.15
Metabolism and nutrition disorders	Hypophosphataemia	n/a	435	100.0	8	1.8	438	100.0	6	1.4	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.46	3.92	0.005	Algorithm converged.	-0.012	0.021	1.34	Algorithm converged.	0.47	3.84	0.5825	0.74	Algorithm converged.	0.26	2.13
Metabolism and nutrition disorders	Hypovolaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Metabolism and nutrition disorders	Malnutrition	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Metabolism and nutrition disorders	Vitamin B1 deficiency	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders		n/a	435	100.0	2	0.5	438	100.0	9	2.1	0.22	Convergence criterion (GCONV=1E-8) satisfied.	0.05	1.02	-0.016	Algorithm converged.	-0.031	-0.001	0.22	Algorithm converged.	0.05	1.03	0.0545	4.47	Algorithm converged.	0.97	20.57
Musculoskeletal and connective tissue disorders	Back pain	n/a	435	100.0	1	0.2	438	100.0	5	1.1	0.20	Convergence criterion (GCONV=1E-8) satisfied.	0.02	1.71	-0.009	Algorithm converged.	-0.020	0.002	0.20	Algorithm converged.	0.02	1.72	0.1427	4.97	Algorithm converged.	0.58	42.33
Musculoskeletal and connective tissue disorders	Bone pain	n/a	435	100.0	0	0.0	438	100.0	3	0.7		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Musculoskeletal and connective tissue disorders	Pain in extremity	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005	Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma of colon	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma pancreas	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Colorectal cancer	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hodgkin's disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary renal cell carcinoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0			Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	*				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders		n/a	435	100.0	17	3.9	438	100.0	23	5.3	0.73		Convergence criterion (GCONV=1E-8) satisfied.	0.39	1.39	-0.013	Algorithm converged.	-0.041	0.014	0.74	Algorithm converged.	0.40	1.37	0.3447	1.34	Algorithm converged.	0.73	2.48
Nervous system disorders	Aphasia	n/a	435	100.0	0	0.0	438	100.0	1	0.2			Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	*			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Carotid artery stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2			Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	*			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Cerebellar ataxia	n/a	435	100.0	1	0.2	438	100.0	0	0.0			Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	*				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Cerebral infarction	n/a	435	100.0	0	0.0	438	100.0	1	0.2			Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	*			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Cerebrovascular accident	n/a	435	100.0	0	0.0	438	100.0	2	0.5			Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	*			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Nervous system disorders	Dizziness	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.8

Nervous system disorders	Epilepsy	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99		Algorithm converged.	0.00	NE
Nervous system disorders	Headache	n/a	435	100.0	1	0.2	438	100.0	4	0.9	0.25	Convergence criterion (GCONV=1E-8) satisfied.	0.03	2.25	-0.007	Algorithm converged.	-0.017	0.003	0.25	Algorithm converged.	0.03	2.24	0.2164	3.97		Algorithm converged.	0.45	35.40
Nervous system disorders	Hypoaesthesia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99		Algorithm converged.	0.00	NE
Nervous system disorders	Hypotonia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99		Algorithm converged.	0.00	NE
Nervous system disorders	Neuropathy peripheral	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49		Algorithm converged.	0.25	8.87
Nervous system disorders	Paralysis recurrent laryngeal nerve	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE
Nervous system disorders	Peripheral motor neuropathy	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE
Nervous system disorders	Peripheral sensory neuropathy	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE		Algorithm converged.	NE	NE

Nervous system disorders	Peroneal nerve palsy	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Nervous system disorders	Polyneuropathy	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Nervous system disorders	Presyncope	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Nervous system disorders	Spinal cord compression	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Nervous system disorders	Syncope	n/a	435	100.0	8	1.8	438	100.0	9	2.1	0.89	Convergence criterion (GCONV=1E-8) satisfied.	0.34	2.34	-0.002	Algorithm converged.	-0.020	0.016	0.90	Algorithm converged.	0.35	2.30	0.8177	1.12	Algorithm converged.	0.44	2.87

Psychiatric disorders		n/a	435	100.0	7	1.6	438	100.0	2	0.5	3.56	Convergence criterion (GCONV=1E-8) satisfied.	0.74	17.25	0.012	Algorithm converged.	-0.002	0.025	3.52	Algorithm converged.	0.74	16.87	0.1149	0.28	Algorithm converged.	0.06	1.36
Psychiatric disorders	Agitation	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Confusional state	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Psychiatric disorders	Depression	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Disorientation	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Psychiatric disorders	Insomnia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Psychiatric disorders	Mental status changes	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Psychiatric disorders	Personality change	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Renal and urinary disorders		n/a	435	100.0	5	1.1	438	100.0	4	0.9	1.26	Convergence criterion (GCONV=1E-8) satisfied.	0.34	4.73	0.002	Algorithm converged.	-0.011	0.016	1.26	Algorithm converged.	0.34	4.66	0.7304	0.79	Algorithm converged.	0.21	2.94
Renal and urinary disorders	Acute kidney injury	n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005	Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Renal and urinary disorders	Cystitis noninfective	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Renal and urinary disorders	Renal failure	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Renal and urinary disorders	Urinary retention	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders		n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders	Female genital tract fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Reproductive system and breast disorders	Uterine pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders		n/a	435	100.0	17	3.9	438	100.0	12	2.7	1.44	Convergence criterion (GCONV=1E-8) satisfied.	0.68	3.06	0.012		Algorithm converged.	-0.012	0.035	1.43	Algorithm converged.	0.69	2.95	0.3383	0.70	Algorithm converged.	0.34	1.45
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	435	100.0	4	0.9	438	100.0	4	0.9	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.25	4.05	0.000	Algorithm converged.	-0.013	0.013	1.01	Algorithm converged.	0.25	4.00	0.9922	0.99	Algorithm converged.	0.25	3.95
Respiratory, thoracic and mediastinal disorders	Hypoxia	n/a	435	100.0	5	1.1	438	100.0	1	0.2	5.08	Convergence criterion (GCONV=1E-8) satisfied.	0.59	43.67	0.009	Algorithm converged.	-0.002	0.020	5.03	Algorithm converged.	0.59	42.92	0.1393	0.20	Algorithm converged.	0.02	1.69
Respiratory, thoracic and mediastinal disorders	Lung disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51	Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002	Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE				
Respiratory, thoracic and mediastinal disorders	Respiratory failure	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Respiratory, thoracic and mediastinal disorders	Tachypnoea	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				
Skin and subcutaneous tissue disorders		n/a	435	100.0	6	1.4	438	100.0	4	0.9	1.52	Convergence criterion (GCONV=1E-8) satisfied.	0.43	5.41	0.005	Algorithm converged.	-0.009	0.019	1.51	Algorithm converged.	0.43	5.31	0.5207	0.66	Algorithm converged.	0.19	2.33
Skin and subcutaneous tissue disorders	Alopecia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE				

Skin and subcutaneous tissue disorders	Bullous haemorrhagic dermatosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Hyperhidrosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Nail discolouration	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Pruritus	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Psoriasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Skin and subcutaneous tissue disorders	Rash	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Skin and subcutaneous tissue disorders	Rash maculo-papular	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE		
Skin and subcutaneous tissue disorders	Urticaria	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders		n/a	435	100.0	13	3.0	438	100.0	15	3.4	0.87	Convergence criterion (GCONV=1E-8) satisfied.	0.41	1.85	-0.004	Algorithm converged.	-0.028	0.019	0.87	Algorithm converged.	0.42	1.81	0.7148	1.15	Algorithm converged.	0.55	2.38
Vascular disorders	Deep vein thrombosis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Embolism	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Hypertension	n/a	435	100.0	6	1.4	438	100.0	10	2.3	0.60	Convergence criterion (GCONV=1E-8) satisfied.	0.22	1.66	-0.009	Algorithm converged.	-0.027	0.009	0.60	Algorithm converged.	0.22	1.65	0.3249	1.66	Algorithm converged.	0.61	4.51
Vascular disorders	Hypotension	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Vascular disorders	Pallor	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Vascular disorders	Peripheral coldness	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		

Vascular disorders	Peripheral embolism	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Peripheral ischaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.	*	WARNING: Negative of Hessian not positive definite.	0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Systolic hypertension	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Thrombosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Vascular disorders	Venous thrombosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.				NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
--------------------	-------------------	-----	-----	-------	---	-----	-----	-------	---	-----	--	---	--	--	--	--	---	---	--	--	--	----	----------------------	----	----	----	----	----------------------	----	----

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier. Only AEs of highest severity are counted.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

```
Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw_soc.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_soc_WGR35AE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:21
```

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: AEs Grade 5 (AEs leading to Death)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

All

			Polatuzumab Vedotin +				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin			
			Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
Cardiac disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Cardiac disorders	Atrioventricular block complete	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Gastrointestinal disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
Gastrointestinal disorders	Intestinal perforation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE	
General disorders and administration site conditions		n/a	435	100.0	5	1.1	438	100.0	2	0.5	2.53	Convergence criterion (GCONV=1E-8) satisfied.	0.49	13.14	0.007	Algorithm converged.	-0.005	0.019	2.52	Algorithm converged.	0.49	12.90	0.2683	0.40	Algorithm converged.	0.08	2.04	

General disorders and administration site conditions	Cardiac death	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Death	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations		n/a	435	100.0	5	1.1	438	100.0	6	1.4	0.84	Convergence criterion (GCONV=1E-8) satisfied.	0.25	2.76	-0.002		Algorithm converged.	-0.017	0.013	0.84	Algorithm converged.	0.26	2.73	0.7706	1.19	Algorithm converged.	0.37	3.88
Infections and infestations	Pneumonia	n/a	435	100.0	4	0.9	438	100.0	3	0.7	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.30	6.05	0.002		Algorithm converged.	-0.009	0.014	1.34	Algorithm converged.	0.30	5.96	0.6986	0.74	Algorithm converged.	0.17	3.31
Infections and infestations	Sepsis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Septic shock	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications		n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Renal and urinary disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders	Acute kidney injury	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Respiratory failure	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Only AEs of highest severity are counted.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw_soc.sas

Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_soc_WGR5AE_SE_GLOBAL_28JUN2021_39942.xls

08MAR2022 12:43

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Any SAEs
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

All

			Polatuzumab Vedotin				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin			
			Patients		Patients		Patients		Patients		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk			
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
Blood and lymphatic system disorders		n/a	435	100.0	50	11.5	438	100.0	40	9.1	1.29	Convergence criterion (GCONV=1E-8) satisfied.	0.83	2.00	0.024	Algorithm converged.	-0.017	0.064	1.26	Algorithm converged.	0.85	1.87	0.2526	0.79	Algorithm converged.	0.54	1.18	
Blood and lymphatic system disorders	Agranulocytosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Blood and lymphatic system disorders	Anaemia	n/a	435	100.0	4	0.9	438	100.0	6	1.4	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.19	2.38	-0.005	Algorithm converged.	-0.019	0.010	0.67	Algorithm converged.	0.19	2.36	0.5347	1.49	Algorithm converged.	0.42	5.24	
Blood and lymphatic system disorders	Febrile bone marrow aplasia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Blood and lymphatic system disorders	Febrile neutropenia	n/a	435	100.0	43	9.9	438	100.0	28	6.4	1.61	Convergence criterion (GCONV=1E-8) satisfied.	0.98	2.64	0.035	Algorithm converged.	-0.001	0.071	1.55	Algorithm converged.	0.98	2.44	0.0616	0.65	Algorithm converged.	0.41	1.02	
Blood and lymphatic system disorders	Leukopenia	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE	
Blood and lymphatic system disorders	Neutropenia	n/a	435	100.0	4	0.9	438	100.0	6	1.4	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.19	2.38	-0.005	Algorithm converged.	-0.019	0.010	0.67	Algorithm converged.	0.19	2.36	0.5347	1.49	Algorithm converged.	0.42	5.24	
Blood and lymphatic system disorders	Thrombocytopenia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83	
Cardiac disorders		n/a	435	100.0	3	0.7	438	100.0	8	1.8	0.37	Convergence criterion (GCONV=1E-8) satisfied.	0.10	1.42	-0.011	Algorithm converged.	-0.026	0.003	0.38	Algorithm converged.	0.10	1.41	0.1482	2.65	Algorithm converged.	0.71	9.92	

Cardiac disorders	Atrial fibrillation	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Cardiac disorders	Atrial flutter	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Cardiac disorders	Atrioventricular block complete	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Cardiac failure congestive	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Left ventricular dysfunction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Cardiac disorders	Myocardial infarction	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Cardiac disorders	Tachycardia	n/a	435	100.0	0	0.0	438	100.0	3	0.7	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Eye disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Eye disorders	Rhegmatogenous retinal detachment	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders		n/a	435	100.0	31	7.1	438	100.0	26	5.9	1.22	Convergence criterion (GCONV=1E-8) satisfied.	0.71	2.08	0.012		Algorithm converged.	-0.021	0.045	1.20	Algorithm converged.	0.73	1.99	0.4773	0.83	Algorithm converged.	0.50	1.38
Gastrointestinal disorders	Abdominal distension	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Abdominal pain	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Gastrointestinal disorders	Anal fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Anal stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Colitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Constipation	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Gastrointestinal disorders	Diarrhoea	n/a	435	100.0	11	2.5	438	100.0	2	0.5	5.66	Convergence criterion (GCONV=1E-8) satisfied.	1.25	25.67	0.021	Algorithm converged.	0.005	0.037	5.54	Algorithm converged.	1.23	24.84	0.0254	0.18	Algorithm converged.	0.04	0.81
Gastrointestinal disorders	Epigastric discomfort	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Faeces discoloured	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastric ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Gastrointestinal haemorrhage	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002	Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87

Gastrointestinal disorders	Haemorrhoidal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Ileus	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
Gastrointestinal disorders	Impaired gastric emptying	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Intestinal obstruction	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Intestinal perforation	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Gastrointestinal disorders	Intra-abdominal haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.					WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Nausea	n/a	435	100.0	4	0.9	438	100.0	2	0.5	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.37	11.10	0.005		Algorithm converged.	-0.006	0.016	2.01	Algorithm converged.	0.37	10.94	0.4175	0.50	Algorithm converged.	0.09	2.70
Gastrointestinal disorders	Necrotising colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.					WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Gastrointestinal disorders	Neutropenic colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Obstruction gastric	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Pancreatitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Gastrointestinal disorders	Rectal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Small intestinal obstruction	n/a	435	100.0	0	0.0	438	100.0	5	1.1		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Small intestinal perforation	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Gastrointestinal disorders	Stomatitis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Gastrointestinal disorders	Subileus	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	

Gastrointestinal disorders	Upper gastrointestinal haemorrhage	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932787 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Gastrointestinal disorders	Vomiting	n/a	435	100.0	5	1.1	438	100.0	2	0.5	2.53	Convergence criterion (GCONV=1E-8) satisfied.	0.49	13.14	0.007		Algorithm converged.	-0.005	0.019	2.52	Algorithm converged.	0.49	12.90	0.2683	0.40	Algorithm converged.	0.08	2.04
General disorders and administration site conditions		n/a	435	100.0	26	6.0	438	100.0	20	4.6	1.33	Convergence criterion (GCONV=1E-8) satisfied.	0.73	2.42	0.014		Algorithm converged.	-0.016	0.044	1.31	Algorithm converged.	0.74	2.31	0.3526	0.76	Algorithm converged.	0.43	1.35
General disorders and administration site conditions	Asthenia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
General disorders and administration site conditions	Cardiac death	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Catheter site haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Chest pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

General disorders and administration site conditions	Chills	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Death	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
General disorders and administration site conditions	Fatigue	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002		Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	General physical health deterioration	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
General disorders and administration site conditions	Hypothermia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Ill-defined disorder	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

General disorders and administration site conditions	Infusion site extravasation	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Malaise	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	*	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83
General disorders and administration site conditions	Mucosal inflammation	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Multiple organ dysfunction syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
General disorders and administration site conditions	Non-cardiac chest pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	*	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
General disorders and administration site conditions	Oedema peripheral	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Pyrexia	n/a	435	100.0	8	1.8	438	100.0	8	1.8	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.37	2.71	0.000	*	Algorithm converged.	-0.018	0.018	1.01	Algorithm converged.	0.38	2.66	0.9889	0.99	Algorithm converged.	0.38	2.62

General disorders and administration site conditions	Ulcer	n/a	435	100.0	1	0.2	438	100.0	0	0.0			*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
General disorders and administration site conditions	Vascular stent thrombosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2			*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Hepatobiliary disorders		n/a	435	100.0	3	0.7	438	100.0	2	0.5	1.51			Convergence criterion (GCONV=1E-8) satisfied.	0.25	9.10	0.002		Algorithm converged.	-0.008	0.012	1.51	Algorithm converged.	0.25	8.99	0.6506	0.66	Algorithm converged.	0.11	3.94
Hepatobiliary disorders	Bile duct stenosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2			*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Hepatobiliary disorders	Bile duct stone	n/a	435	100.0	1	0.2	438	100.0	0	0.0			*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Biliary obstruction	n/a	435	100.0	1	0.2	438	100.0	0	0.0			*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Hepatobiliary disorders	Cholangitis	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Hepatobiliary disorders	Cholecystitis acute	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Hepatobiliary disorders	Cholestasis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations		n/a	435	100.0	61	14.0	438	100.0	45	10.3	1.42	Convergence criterion (GCONV=1E-8) satisfied.	0.94	2.15	0.037	Algorithm converged.	-0.006	0.081	1.36	Algorithm converged.	0.95	1.96	0.0917	0.73	Algorithm converged.	0.51	1.05
Infections and infestations	Abdominal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Actinomycotic abdominal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Appendicitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Aspergillus infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Atypical pneumonia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Bacteraemia	n/a	435	100.0	4	0.9	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Bronchitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Bronchopulmonary aspergillosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Campylobacter gastroenteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Cellulitis	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Infections and infestations	Clostridium difficile colitis	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Clostridium difficile infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Coronavirus infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Infections and infestations	Cytomegalovirus enteritis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.		NE	NE	NE	NE	Algorithm converged.		NE	NE
Infections and infestations	Cytomegalovirus infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83		
Infections and infestations	Device related infection	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.		NE	NE	NE	NE	Algorithm converged.		NE	NE
Infections and infestations	Device related sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.		NE	NE	NE	NE	Algorithm converged.		NE	NE
Infections and infestations	Diarrhoea infectious	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Infections and infestations	Enterobacter infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		

Infections and infestations	Erysipelas	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia bacteraemia	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Infections and infestations	Escherichia infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932799 9 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Escherichia sepsis	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Fungal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Gastroenteritis viral	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932836 3 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Infections and infestations	Herpes simplex	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Infections and infestations	Herpes zoster	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Infections and infestations	Infection	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied .	0.45	36.43	0.007	Algorithm converged.	-0.003	0.017	4.03	Algorithm converged .	0.45	35.89	0.2119	0.25	Algorithm converged .	0.03	2.21
Infections and infestations	Influenza	n/a	435	100.0	2	0.5	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Infections and infestations	Intervertebral discitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Infections and infestations	Klebsiella sepsis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Infections and infestations	Mediastinitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		* Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Infections and infestations	Neutropenic sepsis	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied .	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged .	0.18	22.13	0.5670	0.50	Algorithm converged .	0.05	5.46
Infections and infestations	Peritonitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		* Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Infections and infestations	Pneumocystis jirovecii pneumonia	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied .	0.18	22.34	0.002	Algorithm converged.	-0.005	0.010	2.01	Algorithm converged .	0.18	22.13	0.5670	0.50	Algorithm converged .	0.05	5.46

Infections and infestations	Pneumonia	n/a	435	100.0	18	4.1	438	100.0	17	3.9	1.07	Convergence criterion (GCONV=1E-8) satisfied.	0.54	2.10	0.003	Algorithm converged.	-0.023	0.029	1.07	Algorithm converged.	0.56	2.04	0.8468	0.94	Algorithm converged.	0.49	1.80
Infections and infestations	Pneumonia bacterial	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Prostate infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Respiratory tract infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Scrotal infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Sepsis	n/a	435	100.0	5	1.1	438	100.0	7	1.6	0.72	Convergence criterion (GCONV=1E-8) satisfied.	0.23	2.27	-0.004	Algorithm converged.	-0.020	0.011	0.72	Algorithm converged.	0.23	2.25	0.5709	1.39	Algorithm converged.	0.44	4.35
Infections and infestations	Septic shock	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Skin infection	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Infections and infestations	Staphylococcal infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Staphylococcal sepsis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Systemic candida	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Tracheobronchitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Tuberculosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Infections and infestations	Upper respiratory tract infection	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46

Infections and infestations	Urinary tract infection	n/a	435	100.0	8	1.8	438	100.0	3	0.7	2.72	Convergence criterion (GCONV=1E-8) satisfied.	0.72	10.31	0.012	Algorithm converged.	-0.003	0.026	2.69	Algorithm converged.	0.72	10.05	0.1426	0.37	Algorithm converged.	0.10	1.39
Infections and infestations	Urinary tract infection bacterial	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932799 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Viral infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0		Quasi-complete separation of data points detected.				WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Infections and infestations	Wound infection bacterial	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications		n/a	435	100.0	3	0.7	438	100.0	7	1.6	0.43	Convergence criterion (GCONV=1E-8) satisfied.	0.11	1.66	-0.009	Algorithm converged.	-0.023	0.005	0.43	Algorithm converged.	0.11	1.66	0.2210	2.32	Algorithm converged.	0.60	8.90
Injury, poisoning and procedural complications	Concussion	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Fall	n/a	435	100.0	0	0.0	438	100.0	1	0.2		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Injury, poisoning and procedural complications	Hip fracture	n/a	435	100.0	0	0.0	438	100.0	2	0.5		Quasi-complete separation of data points detected.				WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Injury, poisoning and procedural complications	Infusion related reaction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Injury, poisoning and procedural complications	Injury	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Injury, poisoning and procedural complications	Lower limb fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Injury, poisoning and procedural complications	Lumbar vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Injury, poisoning and procedural complications	Post lumbar puncture syndrome	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328363 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Injury, poisoning and procedural complications	Thoracic vertebral fracture	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE

Injury, poisoning and procedural complications	Traumatic fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations		n/a	435	100.0	9	2.1	438	100.0	5	1.1	1.83	Convergence criterion (GCONV=1E-8) satisfied.	0.61	5.50	0.009		Algorithm converged.	-0.007	0.026	1.81	Algorithm converged.	0.61	5.36	0.2828	0.55	Algorithm converged.	0.19	1.63
Investigations	Blood culture positive	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Investigations	C-reactive protein increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Coronavirus test positive	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Investigations	Troponin T increased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	Weight decreased	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Investigations	White blood cell count decreased	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00			Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders		n/a	435	100.0	5	1.1	438	100.0	8	1.8	0.63	Convergence criterion (GCONV=1E-8) satisfied.	0.20	1.93	-0.007		Algorithm converged.	-0.023	0.009	0.63	Algorithm converged.	0.21	1.91	0.4133	1.59	Algorithm converged.	0.52	4.82
Metabolism and nutrition disorders	Decreased appetite	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Metabolism and nutrition disorders	Dehydration	n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied.	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged.	0.11	4.00	0.6615	1.49	Algorithm converged.	0.25	8.87
Metabolism and nutrition disorders	Hypoglycaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00			Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Metabolism and nutrition disorders	Hypokalaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.	0.00			Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Metabolism and nutrition disorders	Hyponatraemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Metabolism and nutrition disorders	Hypovolaemia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327877 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Metabolism and nutrition disorders	Tumour lysis syndrome	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied .	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged .	0.06	16.05	0.9961	0.99	Algorithm converged .	0.06	15.83
Musculoskeletal and connective tissue disorders		n/a	435	100.0	2	0.5	438	100.0	3	0.7	0.67	Convergence criterion (GCONV=1E-8) satisfied .	0.11	4.03	-0.002		Algorithm converged.	-0.012	0.008	0.67	Algorithm converged .	0.11	4.00	0.6615	1.49	Algorithm converged .	0.25	8.87
Musculoskeletal and connective tissue disorders	Back pain	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Musculoskeletal and connective tissue disorders	Bone pain	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied .	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged .	0.06	16.05	0.9961	0.99	Algorithm converged .	0.06	15.83
Musculoskeletal and connective tissue disorders	Pathological fracture	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied .	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged .	0.32	28.93	0.3375	0.33	Algorithm converged .	0.03	3.17

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Adenocarcinoma pancreas	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Colorectal cancer	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Papillary renal cell carcinoma	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged .	NE	NE	NE	NE	Algorithm converged .	NE	NE
Nervous system disorders		n/a	435	100.0	7	1.6	438	100.0	10	2.3	0.70	Convergence criterion (GCONV=1E-8) satisfied .	0.26	1.86	-0.007		Algorithm converged.	-0.025	0.012	0.70	Algorithm converged .	0.27	1.83	0.4736	1.42	Algorithm converged .	0.55	3.69
Nervous system disorders	Aphasia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged .	0.00	NE	0.9999	>999.99	Algorithm converged .	0.00	NE

Nervous system disorders	Cerebellar ataxia	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Cerebral haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Nervous system disorders	Cerebral infarction	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Nervous system disorders	Cerebral ischaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Nervous system disorders	Cerebrovascular accident	n/a	435	100.0	0	0.0	438	100.0	2	0.5	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Nervous system disorders	Dizziness	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.			*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Epilepsy	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Nervous system disorders	Headache	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		
Nervous system disorders	Hypotonia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.			*	WARNING: Negative of Hessian not positive definite.	0.00		0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		

Nervous system disorders	Peripheral sensory neuropathy	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Presyncope	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Nervous system disorders	Syncope	n/a	435	100.0	3	0.7	438	100.0	1	0.2	3.03	Convergence criterion (GCONV=1E-8) satisfied.	0.31	29.28	0.005		Algorithm converged.	-0.004	0.014	3.02	Algorithm converged.	0.32	28.93	0.3375	0.33	Algorithm converged.	0.03	3.17
Nervous system disorders	Transient ischaemic attack	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Psychiatric disorders		n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Psychiatric disorders	Confusional state	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02	Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Psychiatric disorders	Disorientation	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Psychiatric disorders	Personality change	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Renal and urinary disorders		n/a	435	100.0	4	0.9	438	100.0	3	0.7	1.35	Convergence criterion (GCONV=1E-8) satisfied.	0.30	6.05	0.002		Algorithm converged.	-0.009	0.014	1.34	Algorithm converged.	0.30	5.96	0.6986	0.74	Algorithm converged.	0.17	3.31
Renal and urinary disorders	Acute kidney injury	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06	Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Renal and urinary disorders	Cystitis noninfective	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Renal and urinary disorders	Renal failure	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Reproductive system and breast disorders		n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932824 2 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Reproductive system and breast disorders	Female genital tract fistula	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders		n/a	435	100.0	17	3.9	438	100.0	10	2.3	1.74		Convergence criterion (GCONV=1E-8) satisfied.	0.79	3.85	0.016		Algorithm converged.	-0.007	0.039	1.71	Algorithm converged.	0.79	3.70	0.1711	0.58	Algorithm converged.	0.27	1.26
Respiratory, thoracic and mediastinal disorders	Acute respiratory distress syndrome	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Acute respiratory failure	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Chronic obstructive pulmonary disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Cough	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	435	100.0	4	0.9	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	ERROR: The mean parameter is either invalid or at a limit of its range for some observations.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Hypoxia	n/a	435	100.0	3	0.7	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	ERROR: Error in computing the link function, its derivatives, or the variance function.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Respiratory, thoracic and mediastinal disorders	Laryngeal obstruction	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239327999 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Lung disorder	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pleural effusion	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01		Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000		Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83

Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Pneumothorax	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	n/a	435	100.0	4	0.9	438	100.0	1	0.2	4.06		Convergence criterion (GCONV=1E-8) satisfied.	0.45	36.43	0.007		Algorithm converged.	-0.003	0.017	4.03	Algorithm converged.	0.45	35.89	0.2119	0.25	Algorithm converged.	0.03	2.21
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	435	100.0	1	0.2	438	100.0	0	0.0		*	Quasi-complete separation of data points detected.				*	WARNING: The relative Hessian convergence criterion of 37.239328242 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Respiratory, thoracic and mediastinal disorders	Respiratory failure	n/a	435	100.0	2	0.5	438	100.0	1	0.2	2.02		Convergence criterion (GCONV=1E-8) satisfied.	0.18	22.34	0.002		Algorithm converged.	-0.005	0.010	2.01	Algorithm converged.	0.18	22.13	0.5670	0.50	Algorithm converged.	0.05	5.46
Respiratory, thoracic and mediastinal disorders	Tachypnoea	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Skin and subcutaneous tissue disorders	Decubitus ulcer	n/a	435	100.0	0	0.0	438	100.0	1	0.2		*	Quasi-complete separation of data points detected.				*	WARNING: Negative of Hessian not positive definite.		0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE

Vascular disorders		n/a	435	100.0	6	1.4	438	100.0	6	1.4	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.32	3.15	0.000	Algorithm converged.	-0.015	0.016	1.01	Algorithm converged.	0.33	3.10	0.9904	0.99	Algorithm converged.	0.32	3.06
Vascular disorders	Deep vein thrombosis	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Embolism	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Hypertension	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Hypotension	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000	Algorithm converged.	-0.006	0.006	1.01	Algorithm converged.	0.06	16.05	0.9961	0.99	Algorithm converged.	0.06	15.83
Vascular disorders	Hypovolaemic shock	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Peripheral embolism	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
Vascular disorders	Peripheral ischaemia	n/a	435	100.0	0	0.0	438	100.0	1	0.2	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			0.00	Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE
Vascular disorders	Thrombosis	n/a	435	100.0	2	0.5	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.				* WARNING: Negative of Hessian not positive definite.			NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE

Vascular disorders	Venous thrombosis	n/a	435	100.0	1	0.2	438	100.0	0	0.0	*	Quasi-complete separation of data points detected.	*	WARNING: The relative Hessian convergence criterion of 37.23932812 is greater than the limit of 0.0001. The convergence is questionable.	NE	Algorithm converged.	NE	NE	NE	NE	Algorithm converged.	NE	NE
--------------------	-------------------	-----	-----	-------	---	-----	-----	-------	---	-----	---	--	---	--	----	----------------------	----	----	----	----	----------------------	----	----

```
Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw_soc.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_soc_SAE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:50
```

POPULATION: Global Population, Safety-Evaluable Population
 ENDPOINT: AEs leading to any Study Treatment Discontinuation
 MODEL: Unstratified analysis
 STUDY: GO39942
 Dichotomous Analysis (Safety)

All

			Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)			
			Patients		Patients with Event		Patients		Patients with	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%	n	%	n	%
Blood and lymphatic system disorders		n/a	435	100.0	3	0.7	438	100.0	0	0.0
Blood and lymphatic system disorders	Neutropenia	n/a	435	100.0	2	0.5	438	100.0	0	0.0
Blood and lymphatic system disorders	Thrombocytopenia	n/a	435	100.0	1	0.2	438	100.0	0	0.0
Cardiac disorders		n/a	435	100.0	0	0.0	438	100.0	1	0.2
Cardiac disorders	Left ventricular dysfunction	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Gastrointestinal disorders		n/a	435	100.0	2	0.5	438	100.0	3	0.7
Gastrointestinal disorders	Intestinal obstruction	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Gastrointestinal disorders	Intestinal perforation	n/a	435	100.0	1	0.2	438	100.0	0	0.0
Gastrointestinal disorders	Intra-abdominal haemorrhage	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Gastrointestinal disorders	Nausea	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Gastrointestinal disorders	Necrotising colitis	n/a	435	100.0	1	0.2	438	100.0	0	0.0
General disorders and administration site conditions		n/a	435	100.0	5	1.1	438	100.0	2	0.5
General disorders and administration site conditions	Cardiac death	n/a	435	100.0	1	0.2	438	100.0	0	0.0
General disorders and administration site conditions	Chest pain	n/a	435	100.0	0	0.0	438	100.0	1	0.2
General disorders and administration site conditions	Death	n/a	435	100.0	3	0.7	438	100.0	1	0.2
General disorders and administration site conditions	Fatigue	n/a	435	100.0	1	0.2	438	100.0	0	0.0
Infections and infestations		n/a	435	100.0	7	1.6	438	100.0	10	2.3
Infections and infestations	Intervertebral discitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Infections and infestations	Peritonitis	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Infections and infestations	Pneumonia	n/a	435	100.0	5	1.1	438	100.0	6	1.4
Infections and infestations	Prostate infection	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Infections and infestations	Sepsis	n/a	435	100.0	1	0.2	438	100.0	1	0.2
Infections and infestations	Vulvovaginal mycotic infection	n/a	435	100.0	1	0.2	438	100.0	0	0.0
Investigations		n/a	435	100.0	0	0.0	438	100.0	1	0.2
Investigations	Ejection fraction decreased	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Nervous system disorders		n/a	435	100.0	3	0.7	438	100.0	11	2.5
Nervous system disorders	Cerebral infarction	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Nervous system disorders	Hypoaesthesia	n/a	435	100.0	0	0.0	438	100.0	1	0.2
Nervous system disorders	Neuropathy peripheral	n/a	435	100.0	1	0.2	438	100.0	4	0.9
Nervous system disorders	Peripheral motor neuropathy	n/a	435	100.0	0	0.0	438	100.0	2	0.5
Nervous system disorders	Peripheral sensorimotor neuropathy	n/a	435	100.0	1	0.2	438	100.0	1	0.2
Nervous system disorders	Peripheral sensory neuropathy	n/a	435	100.0	0	0.0	438	100.0	2	0.5
Nervous system disorders	Polyneuropathy	n/a	435	100.0	1	0.2	438	100.0	0	0.0
Renal and urinary disorders		n/a	435	100.0	1	0.2	438	100.0	1	0.2
Renal and urinary disorders	Acute kidney injury	n/a	435	100.0	1	0.2	438	100.0	1	0.2
Respiratory, thoracic and mediastinal disorders		n/a	435	100.0	6	1.4	438	100.0	1	0.2
Respiratory, thoracic and mediastinal disorders	Dyspnoea	n/a	435	100.0	1	0.2	438	100.0	1	0.2
Respiratory, thoracic and mediastinal disorders	Interstitial lung disease	n/a	435	100.0	1	0.2	438	100.0	0	0.0
Respiratory, thoracic and mediastinal disorders	Pneumonitis	n/a	435	100.0	2	0.5	438	100.0	0	0.0
Respiratory, thoracic and mediastinal disorders	Pulmonary oedema	n/a	435	100.0	1	0.2	438	100.0	0	0.0

Respiratory, thoracic and mediastinal disorders	Respiratory failure	n/a	435	100.0	1	0.2	438	100.0	0	0.0

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_soc_descriptive.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_soc_descriptive_WDSTAE_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 12:56

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: All Patients
MODEL: descriptive
STUDY: GO39942
Outcome of Adverse Events

	Polatuzumab Vedotin + R-CHP (N=435)															R-CHOP (N=438)																
	Total	RECOVERED/RESOLVED			RECOVERED/RESOLVED WITH SEQUELAE			NOT RECOVERED/NOT RESOLVED			FATAL		RECOVERING/RESOLVING		UNKNOWN	MISSING	Total	RECOVERED/RESOLVED			RECOVERED/RESOLVED WITH SEQUELAE			NOT RECOVERED/NOT RESOLVED			FATAL		RECOVERING/RESOLVING		UNKNOWN	MISSING
Category of Adverse Events Grade	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	n	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Any AEs																																
All	5470	4600	84.1	25	0.5	680	12.4	13	0.2	144	2.6	8	0.1	0	0.0	5189	4288	82.6	30	0.6	734	14.1	10	0.2	116	2.2	11	0.2	0	0.0	0	
Grade 1	2729	2229	81.7	7	0.3	398	14.6	0	0.0	95	3.5	0	0.0	0	0.0	2615	2070	79.2	10	0.4	467	17.9	0	0.0	64	2.4	4	0.2	0	0.0	0	
Grade 2	1711	1427	83.4	6	0.4	234	13.7	0	0.0	41	2.4	3	0.2	0	0.0	1631	1353	83.0	7	0.4	228	14.0	0	0.0	43	2.6	0	0.0	0	0.0	0	
Grade 3	696	632	90.8	8	1.1	45	6.5	0	0.0	7	1.0	4	0.6	0	0.0	590	541	91.7	10	1.7	29	4.9	0	0.0	5	0.8	5	0.8	0	0.0	0	
Grade 4	321	312	97.2	4	1.2	3	0.9	0	0.0	1	0.3	1	0.3	0	0.0	340	322	94.7	3	0.9	9	2.6	0	0.0	4	1.2	2	0.6	0	0.0	0	
Grade 5	13	0	0.0	0	0.0	0	0.0	13	100.0	0	0.0	0	0.0	0	0.0	10	0	0.0	0	0.0	0	0.0	10	100.0	0	0.0	0	0.0	0	0.0	0	
Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	2	66.7	0	0.0	1	33.3	0	0.0	0	0.0	0	0.0	0	0.0	0	
Any SAEs																																
All	313	276	88.2	9	2.9	11	3.5	13	4.2	3	1.0	1	0.3	0	0.0	251	215	85.7	7	2.8	10	4.0	10	4.0	4	1.6	5	2.0	0	0.0	0	
Grade 1	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	8	6	75.0	0	0.0	2	25.0	0	0.0	0	0.0	0	0.0	0	0.0	0	
Grade 2	40	36	90.0	2	5.0	2	5.0	0	0.0	0	0.0	0	0.0	0	0.0	29	27	93.1	1	3.4	1	3.4	0	0.0	0	0.0	0	0.0	0	0.0	0	
Grade 3	205	187	91.2	7	3.4	8	3.9	0	0.0	3	1.5	0	0.0	0	0.0	149	133	89.3	5	3.4	5	3.4	0	0.0	3	2.0	3	2.0	0	0.0	0	
Grade 4	47	45	95.7	0	0.0	1	2.1	0	0.0	0	0.0	1	2.1	0	0.0	55	49	89.1	1	1.8	2	3.6	0	0.0	1	1.8	2	3.6	0	0.0	0	
Grade 5	13	0	0.0	0	0.0	0	0.0	13	100.0	0	0.0	0	0.0	0	0.0	10	0	0.0	0	0.0	0	0.0	10	100.0	0	0.0	0	0.0	0	0.0	0	
Any AESI																																
All	1238	1080	87.2	11	0.9	125	10.1	5	0.4	17	1.4	0	0.0	0	0.0	1139	996	87.4	4	0.4	114	10.0	7	0.6	13	1.1	5	0.4	0	0.0	0	
Grade 1	393	304	77.4	4	1.0	70	17.8	0	0.0	15	3.8	0	0.0	0	0.0	349	261	74.8	1	0.3	79	22.6	0	0.0	8	2.3	0	0.0	0	0.0	0	
Grade 2	331	284	85.8	2	0.6	43	13.0	0	0.0	2	0.6	0	0.0	0	0.0	324	289	89.2	1	0.3	29	9.0	0	0.0	5	1.5	0	0.0	0	0.0	0	
Grade 3	277	263	94.9	3	1.1	11	4.0	0	0.0	0	0.0	0	0.0	0	0.0	220	210	95.5	1	0.5	5	2.3	0	0.0	0	0.0	4	1.8	0	0.0	0	
Grade 4	232	229	98.7	2	0.9	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	238	235	98.7	1	0.4	1	0.4	0	0.0	0	0.0	1	0.4	0	0.0	0	
Grade 5	5	0	0.0	0	0.0	0	0.0	5	100.0	0	0.0	0	0.0	0	0.0	7	0	0.0	0	0.0	0	0.0	7	100.0	0	0.0	0	0.0	0	0.0	0	
Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse macros/current/prod/program/t ae resolved.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_resolved_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:01

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: DILI (potential drug-induced liver injury)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-				
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_DILI_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:14

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: DILI (potential drug-induced liver injury) Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk					
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	435	100.0	1	0.2	438	100.0	2	0.5	0.50	Convergence criterion (GCONV=1E-8) satisfied.	0.05	5.56	-0.002	Algorithm converged.	-0.010	0.005	0.50	Algorithm converged.	0.05	5.53	0.5747	1.99	Algorithm converged.	0.18	21.83	

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_DILIGR35_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:15

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Serious DILI (potential drug-induced liver injury)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-					
		Patients		Patients with		Patients		Patients with		Odds Ratio						Absolute Risk Difference						Relative Risk						Relative Risk			
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio			Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		95% Lower CL	95% Upper CL	Relative Risk		95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk		95% Lower CL	95% Upper CL			
All	n/a	435	100.0	0	0	438	100.0	1	0.2		*		Quasi-complete separation of data points detected.				*			0.00		Algorithm converged.	0.00	NE	0.9999	>999.99	Algorithm converged.	0.00	NE		

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDEPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_DILIS_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:17

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Hepatic Toxicity
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients with		Patients		Patients with				Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk					
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL		
All	n/a	435	100.0	46	10.6	438	100.0	32	7.3	1.50		Convergence criterion (GCONV=1E-8) satisfied.	0.94	2.41	0.033	Algorithm converged.	-0.005	0.070	1.45	Algorithm converged.	0.94	2.23	0.0928	0.69	Algorithm converged.	0.45	1.06		

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_HEPT_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:41

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Hepatic Toxicity Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-				
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk								Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason		95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason		95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL
											Convergence criterion (GCONV=1E-8) satisfied.					Algorithm converged.					Algorithm converged.									
All	n/a	435	100.0	8	1.8	438	100.0	4	0.9	2.03	Convergence criterion (GCONV=1E-8) satisfied.		0.61	6.80	0.009	Algorithm converged.		-0.006	0.025	2.01	Algorithm converged.		0.61	6.64	0.2501	0.50	Algorithm converged.		0.15	1.64

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_HEPTGR35_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:43

Dichotomous Analysis (Safety)

```

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_HEPTS_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:44

```

08MAR2022 11:44

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Infections
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk								Relative Risk																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																											
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_INF_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:36

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Infections Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk									
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	435	100.0	66	15.2	438	100.0	55	12.6	1.25	Convergence criterion (GCONV=1E-8) satisfied.	0.85	1.83	0.026	Algorithm converged.	-0.020	0.072	1.21	Algorithm converged.	0.87	1.68	0.2645	0.83	Algorithm converged.	0.59	1.15	

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_INFGR35_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:37

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Serious Infections
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk					
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	435	100.0	61	14.0	438	100.0	45	10.3	1.42	Convergence criterion (GCONV=1E-8) satisfied.	0.94	2.15	0.037	Algorithm converged.	-0.006	0.081	1.36	Algorithm converged.	0.95	1.96	0.0917	0.73	Algorithm converged.	0.51	1.05	

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_INFS_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:39

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Serious Infections Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-												
Patients				Patients with				Patients				Patients with				Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk						
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason			95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason			95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason			95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason			95% Lower CL	95% Upper CL
											Convergence criterion (GCONV=1E-8) satisfied.						Algorithm converged.						Algorithm converged.							Algorithm converged.				
All	n/a	435	100.0	56	12.9	438	100.0	43	9.8	1.36	Convergence criterion (GCONV=1E-8) satisfied.			0.89	2.07	0.031	Algorithm converged.			-0.011	0.073	1.31	Algorithm converged.			0.90	1.91	0.1562	0.76	Algorithm converged.			0.52	1.11

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_INFSGR35_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:24

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Neutropenia incl. Febrile Neutropenia
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-									
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk									
Nam e	Leve l	n	%	n	%	n	%	n	%	Odds Rati o	Convergence Reason			95% Lowe r CL	95% Uppe r CL	Absolu te Risk	Convergence Reason		95% Lower CL	95% Upper CL	Relati ve Risk	Convergence Reason		95% Lowe r CL	95% Uppe r CL	p- value (Wald)	Relati ve Risk	Convergence Reason		95% Lowe r CL	95% Uppe r CL
All	n/a	435	100.0	200	46.0	438	100.0	187	42.7	1.14	Convergence criterion (GCONV=1E-8) satisfied.			0.87	1.49	0.033	Algorithm converged.		-0.033	0.099	1.08	Algorithm converged.		0.93	1.25	0.3292	0.93	Algorithm converged.		0.80	1.08

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_NEUT_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:25

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Neutropenia incl. Febrile Neutropenia Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-			
		Patients		Patients with		Patients		Patients with		Odds Ratio	Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk				
Name	Level	n	%	n	%	n	%	n	%		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	
All	n/a	435	100.0	182	41.8	438	100.0	176	40.2	1.07	Convergence criterion (GCONV=1E-8) satisfied.	0.82	1.40	0.017	Algorithm converged.	-0.049	0.082	1.04	Algorithm converged.	0.89	1.22	0.6189	0.96	Algorithm converged.	0.82	1.13	

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_NEUTGR35_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:27

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Serious Neutropenia incl. Febrile Neutropenia
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-				
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk		Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk		Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	435	100.0	50	11.5	438	100.0	37	8.4	1.41		Convergence criterion (GCONV=1E-8) satisfied.	0.90	2.20	0.030		Algorithm converged.	-0.009	0.070	1.36		Algorithm converged.	0.91	2.04	0.1349	0.73		Algorithm converged.	0.49	1.10

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_NEUTS_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:58

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Peripheral Neuropathy (sensory and/or motor)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP																R-CHOP vs. Polatuzumab Vedotin + R-								
		Patients		Patients with		Patients		Patients with			Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk											
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason			95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason			95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason			95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason			95% Lower CL	95% Upper CL
											Convergence criterion (GCONV=1E-8) satisfied.						Algorithm converged.						Algorithm converged.						Algorithm converged.					
All	n/a	435	100.0	230	52.9	438	100.0	236	53.9	0.96	Convergence criterion (GCONV=1E-8) satisfied.			0.74	1.25	-0.010	Algorithm converged.			-0.076	0.056	0.98	Algorithm converged.			0.87	1.11	0.7654	1.02	Algorithm converged.			0.90	1.15

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_PERN_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:31

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Peripheral Neuropathy (sensory and/or motor) Grade 2-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-								
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk								
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason		95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason		95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason		95% Lower CL	95% Upper CL
											Convergence criterion (GCONV=1E-8) satisfied.					Algorithm converged.					Algorithm converged.									
All	n/a	435	100.0	60	13.8	438	100.0	73	16.7	0.80	Convergence criterion (GCONV=1E-8) satisfied.		0.55	1.16	-0.029	Algorithm converged.		-0.076	0.019	0.83	Algorithm converged.		0.60	1.13	0.2386	1.21	Algorithm converged.		0.88	1.66

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_PERNGR25_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:20

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Peripheral Neuropathy (sensory and/or motor) Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-				
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk				Relative Risk				
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio	Convergence Reason	95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL
All	n/a	435	100.0	7	1.6	438	100.0	5	1.1	1.42	Convergence criterion (GCONV=1E-8) satisfied.	0.45	4.50	0.005	Algorithm converged.	-0.011	0.020	1.41	Algorithm converged.	0.45	4.41	0.5550	0.71	Algorithm converged.	0.23	2.22

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_PERNGR35_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:33

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Serious Peripheral Neuropathy (sensory and/or motor)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-									
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk									
Name	Level	n	%	n	%	n	%	n	%	Odds Ratio		95% Lower CL	95% Upper CL	Absolute Risk	Convergence Reason	95% Lower CL	95% Upper CL	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL	p-value (Wald)	Relative Risk	Convergence Reason	95% Lower CL	95% Upper CL							
All	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01					Convergence criterion (GCONV=1E-8) satisfied.	0.06	16.15	0.000						Algorithm converged.	0.06	16.05	0.9961	0.99			Algorithm converged.	0.06	15.83

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_PERNs_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:34

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Serious Peripheral Neuropathy (sensory and/or motor) Grade 2-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

		Polatuzumab Vedotin + R-CHP				R-CHOP (N=438)				Polatuzumab Vedotin + R-CHP vs. R-CHOP														R-CHOP vs. Polatuzumab Vedotin + R-										
		Patients		Patients with		Patients		Patients with		Odds Ratio				Absolute Risk Difference				Relative Risk						Relative Risk										
Nam e	Leve l	n	%	n	%	n	%	n	%	Odds Rati o	Convergence Reason			95 Lowe r CL	95% Upper CL	Absolu te Risk	Convergence Reason			95% Lower CL	95% Upper CL	Relati ve Risk	Convergence Reason			95% Lowe r CL	95% Upper CL	p- value (Wald)	Relati ve Risk	Convergence Reason			95% Lowe r CL	95% Upper CL
All	n/a	435	100.0	1	0.2	438	100.0	1	0.2	1.01	Convergence criterion (GCONV=1E-8) satisfied.			0.06	16.15	0.000	Algorithm converged.			-0.006	0.006	1.01	Algorithm converged.			0.06	16.05	0.9961	0.99	Algorithm converged.			0.06	15.83

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_PERNSEGR25_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:22

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: STIAMP (suspected transmission of an infectious agent by the study drug)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Null Report: No results could be derived for this output.

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_STIA_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:18

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: STIAMP (suspected transmission of an infectious agent by the study drug) Grade 3-5
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Null Report: No results could be derived for this output.

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_STIAGR35_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:19

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: Serious STIAMP (suspected transmission of an infectious agent by the study drug)
MODEL: Unstratified analysis
STUDY: GO39942
Dichotomous Analysis (Safety)

Null Report: No results could be derived for this output.

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
* indicates convergence problem. Result is uninterpretable.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse_macros/current/prod/program/t_ae_raw.sas
Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/ACE_PRIMARY_CSR_Pooled/prod/output_global/t_ae_raw_STIAS_SE_GLOBAL_28JUN2021_39942.xls
08MAR2022 11:20

POPULATION: Global Population, Safety-Evaluable Population
ENDPOINT: All Patients
MODEL: descriptive
STUDY: G039942
Outcome of Adverse Events of Special Interest


	Polatuzumab Vedotin + R-CHP (N=435)														R-CHOP (N=438)													
	Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	Total	RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING
Category of Adverse Events	n	n	%	n	%	n	%	n	%	n	%	n	%	n	n	n	%	n	%	n	%	n	%	n	%	n	%	n
DILI (potential drug-induced liver injury)																												
All	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	2	1	50.0	0	0.0	0	0.0	1	50.0	0	0.0	0	0.0	0
Grade 3	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 5	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	1	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0
Serious DILI (potential drug-induced liver injury)																												
All	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	1	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0
Grade 5	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	1	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0
STIAMP (suspected transmission of an infectious agent by the study drug)																												
All	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Serious STIAMP (suspected transmission of an infectious agent by the study drug)																												
All	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Peripheral Neuropathy (sensory and/or motor)																												
All	301	191	63.5	4	1.3	94	31.2	0	0.0	12	4.0	0	0.0	0	292	199	68.2	2	0.7	82	28.1	0	0.0	8	2.7	1	0.3	0
Grade 1	234	160	68.4	4	1.7	59	25.2	0	0.0	11	4.7	0	0.0	0	214	144	67.3	1	0.5	64	29.9	0	0.0	5	2.3	0	0.0	0
Grade 2	59	28	47.5	0	0.0	30	50.8	0	0.0	1	1.7	0	0.0	0	73	54	74.0	1	1.4	15	20.5	0	0.0	3	4.1	0	0.0	0
Grade 3	8	3	37.5	0	0.0	5	62.5	0	0.0	0	0.0	0	0.0	0	5	1	20.0	0	0.0	3	60.0	0	0.0	0	0.0	1	20.0	0
Serious Peripheral Neuropathy (sensory and/or motor)																												
All	1	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 3	1	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Infections																												
All	409	376	91.9	4	1.0	20	4.9	5	1.2	4	1.0	0	0.0	0	343	308	89.8	1	0.3	21	6.1	6	1.7	3	0.9	4	1.2	0
Grade 1	103	92	89.3	0	0.0	8	7.8	0	0.0	3	2.9	0	0.0	0	77	67	87.0	0	0.0	9	11.7	0	0.0	1	1.3	0	0.0	0
Grade 2	211	199	94.3	2	0.9	9	4.3	0	0.0	1	0.5	0	0.0	0	187	174	93.0	0	0.0	11	5.9	0	0.0	2	1.1	0	0.0	0
Grade 3	82	77	93.9	2	2.4	3	3.7	0	0.0	0	0.0	0	0.0	0	60	55	91.7	1	1.7	1	1.7	0	0.0	0	0.0	3	5.0	0
Grade 4	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	12	11	91.7	0	0.0	0	0.0	0	0.0	0	0.0	1	8.3	0
Grade 5	5	0	0.0	0	0.0	0	0.0	5	100.0	0	0.0	0	0.0	0	6	0	0.0	0	0.0	0	0.0	6	100.0	0	0.0	0	0.0	0
Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Serious Infections																												
All	85	76	89.4	4	4.7	0	0.0	5	5.9	0	0.0	0	0.0	0	63	52	82.5	1	1.6	0	0.0	6	9.5	0	0.0	4	6.3	0
Grade 2	9	7	77.8	2	22.2	0	0.0	0	0.0	0	0.0	0	0.0	0	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 3	64	62	96.9	2	3.1	0	0.0	0	0.0	0	0.0	0	0.0	0	44	40	90.9	1	2.3	0	0.0	0	0.0	0	0.0	3	6.8	0
Grade 4	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	11	10	90.9	0	0.0	0	0.0	0	0.0	0	0.0	1	9.1	0
Grade 5	5	0	0.0	0	0.0	0	0.0	5	100.0	0	0.0	0	0.0	0	6	0	0.0	0	0.0	0	0.0	6	100.0	0	0.0	0	0.0	0
Neutropenia incl. Febrile Neutropenia																												
All	456	449	98.5	3	0.7	4	0.9	0	0.0	0	0.0	0	0.0	0	443	438	98.9	1	0.2	4	0.9	0	0.0	0	0.0	0	0.0	0
Grade 1	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	15	13	86.7	0	0.0	2	13.3	0	0.0	0	0.0	0	0.0	0
Grade 2	43	42	97.7	0	0.0	1	2.3	0	0.0	0	0.0	0	0.0	0	50	49	98.0	0	0.0	1	2.0	0	0.0	0	0.0	0	0.0	0
Grade 3	178	175	98.3	1	0.6	2	1.1	0	0.0	0	0.0	0	0.0	0	152	152	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 4	225	222	98.7	2	0.9	1	0.4	0	0.0	0	0.0	0	0.0	0	226	224	99.1	1	0.4	1	0.4	0	0.0	0	0.0	0	0.0	0
Serious Neutropenia incl. Febrile Neutropenia																												
All	71	70	98.6	1	1.4	0	0.0	0	0.0	0	0.0	0	0.0	0	47	47	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 1	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 2	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 3	45	44	97.8	1	2.2	0	0.0	0	0.0	0	0.0	0	0.0	0	24	24	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 4	24	24	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	23	23	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Hepatic Toxicity																												
All	74	66	89.2	0	0.0	7	9.5	0	0.0	1	1.4	0	0.0	0	61	52	85.2	0	0.0	7	11.5	0	0.0	2	3.3	0	0.0	0
Grade 1	46	42	91.3	0	0.0	3	6.5	0	0.0	1	2.2	0	0.0	0	43	37	86.0	0	0.0	4	9.3	0	0.0	2	4.7	0	0.0	0
Grade 2	18	15	83.3	0	0.0	3	16.7	0	0.0	0	0.0	0	0.0	0	14	12	85.7	0	0.0	2	14.3	0	0.0	0	0.0	0	0.0	0
Grade 3	10	9	90.0	0	0.0	1	10.0	0	0.0	0	0.0	0	0.0	0	4	3	75.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	0
Serious Hepatic Toxicity																												
All	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
Grade 3	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0
PT Diarrhoea																												
All	203	195	96.1	0	0.0	5	2.5	0	0.0	3	1.5	0	0.0	0	111	102	91.9	1	0.9	7	6.3	0	0.0	1	0.9	0	0.0	0
Grade 1	127	123	96.9	0	0.0	2	1.6	0	0.0	2	1.6	0	0.0	0	77	69	89.6	1	1.3	6	7.8	0	0.0	1	1.3	0	0.0	0
Grade 2	55	54	98.2	0	0.0	1	1.8	0	0.0	0	0.0	0	0.0	0	26	25	96.2	0	0.0	1	3.8	0	0.0	0	0.0	0	0.0	0
Grade 3	21	18	85.7	0	0.0	2	9.5	0	0.0	1	4.8	0	0.0	0	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0

Serious PT Diarrhoea																														
All	14	13	92.9	0	0.0	0	0.0	0	0.0	0	0.0	1	7.1	0	0.0	0	0.0	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 2	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 3	13	12	92.3	0	0.0	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0	0	0.0	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PT Febrile neutropenia																														
All	84	82	97.6	1	1.2	1	1.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	41	41	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 1	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 2	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 3	64	62	96.9	1	1.6	1	1.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	29	29	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 4	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Serious PT Febrile neutropenia																														
All	60	59	98.3	1	1.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	34	34	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 1	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 2	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 3	43	42	97.7	1	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	22	22	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 4	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PT Acute kidney injury																														
All	13	11	84.6	0	0.0	0	0.0	1	7.7	1	7.7	0	0.0	0	0.0	3	1	33.3	1	33.3	0	0.0	0	0.0	1	33.3	0	0.0	0	0.0
Grade 1	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 2	8	7	87.5	0	0.0	0	0.0	0	0.0	1	12.5	0	0.0	0	0.0	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 3	3	3	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 4	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0	0.0	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0
Grade 5	1	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Serious PT Acute kidney injury																														
All	4	3	75.0	0	0.0	0	0.0	1	25.0	0	0.0	0	0.0	0	0.0	1	0	0.0	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0
Grade 2	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 3	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 4	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0	0.0	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0
Grade 5	1	0	0.0	0	0.0	0	0.0	1	100.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PT Dry skin																														
All	25	14	56.0	0	0.0	11	44.0	0	0.0	0	0.0	0	0.0	0	0.0	9	5	55.6	0	0.0	3	33.3	0	0.0	1	11.1	0	0.0	0	0.0
Grade 1	20	10	50.0	0	0.0	10	50.0	0	0.0	0	0.0	0	0.0	0	0.0	7	5	71.4	0	0.0	2	28.6	0	0.0	0	0.0	0	0.0	0	0.0
Grade 2	5	4	80.0	0	0.0	1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0	0.0	0	0.0	1	50.0	0	0.0	1	50.0	0	0.0	0	0.0
Serious PT Dry skin																														
All	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SOC Infections & infestations																														
All	409	376	91.9	4	1.0	20	4.9	5	1.2	4	1.0	0	0.0	0	0.0	343	308	89.8	1	0.3	21	6.1	6	1.7	3	0.9	4	1.2	0	0.0
Grade 1	103	92	89.3	0	0.0	8	7.8	0	0.0	3	2.9	0	0.0	0	0.0	77	67	87.0	0	0.0	9	11.7	0	0.0	1	1.3	0	0.0	0	0.0
Grade 2	211	199	94.3	2	0.9	9	4.3	0	0.0	1	0.5	0	0.0	0	0.0	187	174	93.0	0	0.0	11	5.9	0	0.0	2	1.1	0	0.0	0	0.0
Grade 3	82	77	93.9	2	2.4	3	3.7	0	0.0	0	0.0	0	0.0	0	0.0	60	55	91.7	1	1.7	1	1.7	0	0.0	0	0.0	3	5.0	0	0.0
Grade 4	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	12	11	91.7	0	0.0	0	0.0	0	0.0	0	0.0	1	8.3	0	0.0
Grade 5	5	0	0.0	0	0.0	0	0.0	5	100.0	0	0.0	0	0.0	0	0.0	6	0	0.0	0	0.0	0	0.0	6	100.0	0	0.0	0	0.0	0	0.0
Missing	0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Serious SOC Infections & infestations																														
All	85	76	89.4	4	4.7	0	0.0	5	5.9	0	0.0	0	0.0	0	0.0	63	52	82.5	1	1.6	0	0.0	6	9.5	0	0.0	4	6.3	0	0.0
Grade 2	9	7	77.8	2	22.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	2	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Grade 3	64	62	96.9	2	3.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	44	40	90.9	1	2.3	0	0.0	0	0.0	0	0.0	3	6.8	0	0.0
Grade 4	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	11	10	90.9	0	0.0	0	0.0	0	0.0	0	0.0	1	9.1	0	0.0
Grade 5	5	0	0.0	0	0.0	0	0.0	5	100.0	0	0.0	0	0.0	0	0.0	6	0	0.0	0	0.0	0	0.0	6	100.0	0	0.0	0	0.0	0	0.0

Includes treatment-emergent AEs during AE reporting period only, which is defined as new or worsening AE from the first dose of any study drug through 90 days after the last dose of any study drug or prior to NALT, whichever is earlier.
Clinical cut-off: 28JUN2021

Program: root/global/globalshare/morse macros/current/prod/program/t ae resolved.sas
Output: root/clinical studies/RO5541077/CDPT7884/G039942/data analysis/ACE PRIMARY CSR Pooled/prod/output global/t ae resolved aesi SE GLOBAL 28JUN2021 39942.xls
08MAR2022 11:51

Kaplan-Meier Plot of OS, Intent-to-Treat Patients
Protocol: GO39942



R-CHOP	439	416	404	383	373	356	193	43	6
Pola+R-CHP	440	423	397	386	378	366	191	39	2

Stratified hazard ratio was displayed.
 CCOD: 25FEB2022 Data Extract Date: 05APR2022

Program: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/SuppR_FEB2022/prod/program/g_ef_km.sas
 Output: root/clinical_studies/RO5541077/CDPT7884/GO39942/data_analysis/SuppR_FEB2022/prod/output/g_ef_km_OS_IT_25FEB2022_39942.pdf
 06APR2022 20:34